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Abstract 
Formation of blood vessels at required number and time during bone regeneration 
represents a major challenge for tissue engineered constructs. Poor revascularization 
leads to scaffold failure and consequently, the loss of the implant. There are several 
problems associated with the use of growth factors in clinic such as low stability, 
controlled delivery to the site, and high price. Heparin is known to bind with 
angiogenic growth factors influencing the process of new blood vessels formation. The 
aim of the present study was to explore the potential of heparin to produce pro-
angiogenic bone regeneration materials. Heparin was electrostatically loaded onto 
composite materials from porous chitosan/hydroxyapatite scaffolds. Different 
concentrations of heparin were successfully loaded onto the scaffolds, and the release 
performance of the scaffold was analysed by toluidine blue assay showing that the 
scaffolds loaded with lowest concentration provide a sustained release. The angiogenic 
activity of the heparin loaded synthesized materials was evaluated by chorioallantoic 
membrane (CAM) assay.  After six day of materials implantation on CAM it was noted 
that overall low heparin concentrations exhibited a positive effect, with approximately 
28μg per scaffold showed a significant increment in blood vessels. The synthesized 
materials showed no cytotoxic effects when evaluated by using U2OS cell line. Also, 
as showed by the SEM images the scaffolds exhibited that interconnected porosity and 
a pore size able to support osteoblasts proliferation. 
This research provides information about the pro-angiogenic effect of heparin in 
potential bone regeneration materials.  
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Bone possesses the capacity to repair itself whenever an injury occurs. Successful bone 
healing depends on several factors that include, age, nutrition and, type of fracture 
among others 1,2. However, cases such as tumour removal, traumatic fractures, or 
injury infection, are highly prone to become critical size defects, where the loss of bone 
exceeds its self-healing ability. Bone grafting represents the main alternative for bone 
substitution. However, this technique presents some drawbacks that favour the 
investigation of more options for bone regeneration 3–6. Hence, materials research 
aiming to mimic bone tissue properties constitutes a major subject in tissue 
engineering. The developed scaffolds should fulfil three fundamental functions: (1) the 
scaffold must provide an optimal structure for bone formation process; (2) it should 
promote the regenerative capacity of the tissue; and, (3) it must match the mechanical 
properties of the implantation site 4,5,7. 
One of the challenges of current bone treatment strategies is how to stimulate blood 
vessel development 8,9. Revascularization during bone regeneration is key to a proper 
healing, as blood vessels provide nourishment, excretion pathways, and allow 
progenitor cells to reach from their niches to the injured site. Angiogenesis is the 
generation of blood vessels from pre-existing vasculature. Therefore, tissue 
engineering for bone has investigated a wide range of options to approach the 
limitation of enhancing angiogenesis during bone repair 9,10.  
Currently, delivery of growth factors has been favoured, as they highly influence the 
course of both processes: angiogenesis and osteogenesis. Vascular endothelial growth 
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factor (VEGF) and fibroblast growth factor (FGF) families have been preferred for these 
purposes. However, the direct use of these biomolecules has presented some 
drawbacks such as: high costs, unknown doses, contradictory results or possible 
tumour inducement, which have raised doubts concerning their applicability as a 
completely effective therapy for revascularization during bone regeneration 9–12. 
Heparin has been widely studied as an aid for the load and release of the 
aforementioned growth factors 13,14. This glycosaminoglycan binds to several 
angiogenic growth factors, thus, influencing their action 15. 
Regardless of the vast information available regarding the use of heparin to bind 
growth factors to scaffolds, not many studies regarding the angiogenic influence of 
heparin itself on the bone healing process have been reported. Therefore, the purpose 
of this study is to evaluate the angiogenic effect of heparin concentration present on 
bioactive scaffolds fabricated by employing chitosan and hydroxyapatite. 
1.1 Project Aim 
The aim of this project is to obtain a material capable of improving and promoting the 
process of angiogenesis during bone regeneration.  
1.2 Hypothesis 
Our hypothesis is based on the potential of heparin to bind with several angiogenic 
factors 15. Therefore, it is assumed that it will interact with the angiogenic growth 
factors from the surroundings and will induce a pro-angiogenic response. 
Additionally, the precise amount to achieve the purpose of promoting angiogenesis 
should be determined. 
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Figure 1.1 Schematic representation of the proposed heparinized scaffold. Ideally, the scaffold is to be 
inserted on the bone defect zone, heparin then will interact/bind with the angiogenic growth factors 
from the surrounding bio-environment, inducing an angiogenic response. 
 
1.3 Objectives 
− Production of freeze-gelled scaffolds 
Fabrication of stable scaffolds from chitosan and hydroxyapatite using freeze-
gelation method, suitable to be used as bone regeneration scaffold.  
− Heparin loading onto the scaffolds 
To obtain a material containing heparin, by forming a chitosan/hydroxyapatite 
and the heparin composite scaffold.  
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− Determine the presence of heparin in the scaffolds  
Using toluidine blue assay the amount and distribution of the heparin in the 
scaffold can be estimated. 
− Characterization of the morphology of the obtained scaffolds 
Determining the surface characteristics of the obtained materials by Scanning 
Electron Microscopy (SEM). Ideal scaffolds should exhibit an interconnected 
porous structure. 
− Characterization in simulated body fluid (SBF)  
Bioactivity is assessed by the observation of apatite formation in the scaffold 
after immersion in SBF. 
− Evaluation of cytotoxicity  
Using AlamarBlue® assay viability test in osteosarcoma cell line, to carry 
an assessment of any possible noxious effects by the combination of 
these compounds, prior the evaluation on CAM assay.  
− Evaluation of angiogenic potential  
To observe blood vessel formation and infiltration in the material implanted in 
the chick-embryonic membrane, by means of a CAM (chorioallantoic 
membrane) assay. 
1.4 Outline 
This work has been divided into four major chapters: literature review, materials and 
methodology, results and discussion, and conclusions. 
In general, the literature review includes relevant information regarding bone and 
bone healing, to present the ideal function of this tissue. Then, the common challenges 
in bone regeneration and revascularization, as well as the current alternatives for this 
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problem in tissue engineering are presented. Lastly, the available information 
regarding the use of heparin for revascularization techniques is also introduced in this 
chapter.  
The materials and methodology chapter describes the main materials used for scaffold 
preparation: chitosan, hydroxyapatite, and heparin; providing a complete description 
of their characteristics. Likewise, this chapter contains a stepwise description of the 
methodology followed to prepare the scaffolds as well as detailed information 
regarding the characterization methods used. This chapter also contains a full account 
of the procedure followed to define the final approach to produce the scaffold, 
justifying the use of our final methodology.  
Within the results and discussions chapter a detailed description of the results 
obtained by the characterization methods is provided. A comprehensive explanation 
on every result is included, for instance: explaining the reasons why a certain porosity 
and microstructure were observed on the SEM images. 
Finally, the conclusions chapter presents a summary of the findings and the main 
contributions produced from this work. This chapter also contains suggestions on how 
to improve this research project and what other perspectives could have been 
considered to improve the possibilities on bone revascularization. 
1.5 Summary  
Revascularization of bone has been widely investigated through several techniques 
and materials. As described in the following chapters, the challenges include the 
generation of a structure similar to functional bone tissue, as well as to generate the 
appropriate microenvironment to induce angiogenesis in the zone. Hence, the need for 
different approaches to achieve a successful revascularization of bone is required.   
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This chapter provides the significant background of the research that has been 
conducted in this study. Initially, a general description of bone and its composition, 
necessary information related to the research aim and healing process during bone 
regeneration is described. Therefore, after describing bone’s composition and how its 
healing process normally occurs, a general overview of abnormal healing and its 
consequences is mentioned. This leads to the current therapies that are being 
addressed and reported in literature to tackle this important aspect of bone repair and 
regeneration. Different approaches have been introduced and discussed in this chapter 
with the main emphasis on angiogenesis and the agents (i.e., growth factors, etc.) 
studied to stimulate angiogenesis. A number of agents have been used to encourage 
angiogenesis and one of them is heparin, which is the main focus point of this study. 
To understand it fully, finally, the heparin characteristics are outlined with the aim to 
explore its full potential for promoting bone repair and regeneration. 
 
2.1 Bone Tissue 
Bone is a specialized connective tissue that constitutes a main part of the skeletal 
system. 16–18. Due to bone’s complex composition, it is seen as a composite from the 
materials point of view 19.  Bone consists of mainly two matrices and water, altogether 
contributing to this important tissue its complex biomechanical behaviour. 18,19.  
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Osseous tissue also possesses an extraordinary remodelling capacity, which keeps this 
tissue fit according to the needs of the bone site and the individual’s activity 18,20. This 
healing ability allows bone to restore itself when an injury occurs, though this process 
can be limited by the size of the bone loss 21. 
The next sections will describe the most remarkable aspects of bone tissue, focusing on 
those that are more relevant to its auto-repairing activity and how tissue engineering 
aims to assist this process.   
 
2.1.1 Bone composition  
Bone consists of cells and extracellular matrix (ECM), in the same way like most 
connective tissues, however, ECM in bone is mineralized 16,17. From a material point of 
view, bone is considered an anisotropic composite which is mainly made of two 
matrices: an organic matrix and an inorganic matrix, as well as a water content 1,18–20,22. 
Bone matrices are responsible for the biomechanical properties of this tissue, the 
inorganic nature allows bone to be resistant, while the organic portion gives bone its 
characteristic tensile strength and elasticity 23,24. 
2.1.1.1. Organic Matrix 
During bone formation, osteoblasts secrete a material named osteoid which mainly 
consists of collagen, various proteoglycans, and glycoproteins 16,25. This material 
undergoes a mineralization process prompted by the mineralizing sacs, also released 
by osteoblasts 16,23.  
Majority of the organic matrix of bone is comprised of type I collagen (90% of its 
content) 18,23,25. The structure of collagen I is described as a triple helix, which is 
stabilized by hydrogen bonds among them. These triple helical fibres may also 
incorporate other types of collagen; such as type V in bone tissue 1,26. The characteristics 
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of bone collagen are defined by its posttranslational modifications and hydroxylation 
array. Likewise, bone collagen is affected by its mineralization pattern, which can be 
intrafibrillar (apatite crystals are deposited within the collagen fibrils) and interfibrillar 
(apatite crystals are between the collagen fibrils)  22,24,26. During bone formation, woven 
bone is formed mainly by haphazard collagen fibrils, which are mineralized 
subsequently by deposition of inorganic component among and within them. 
According to Olszta et al (2007), Ferreira et al. (2012) and Wang et al. (2012) collagen is 
able to activate, spread and orient the mineralization process in woven bone 22,27,28. 
Defects in collagen structure, fibre orientation, stability, and mineral distribution have 
a major impact on the mechanical properties finally achieved by bone tissue 29. 
Osteoblasts secrete several macromolecules other than collagen to form bone matrix. 
Among them: glycoproteins, proteoglycans, fibronectin, osteonectin, bone 
sialoprotein, osteopontin, and bone morphogenic proteins (BMPs). All of these 
molecules have important roles on signalling processes that impact mineralization, 
formation, and remodelling of bone 1,18,30. 
2.1.1.2 Inorganic Matrix 
Bon is comprised of approximately 70% of inorganic matrix 1,25. It consists of calcium 
phosphate crystals distributed orderly in the organic matrix 1,31. Chemical composition 
of this calcium phosphate resembles the structure of geological hydroxyapatite (HAp), 
Ca10(PO4)6(OH)2. Thus, it is constantly referred as ‘biological apatite’. However, it 
contains different ions which include magnesium, potassium, strontium, sodium, 
carbonate, and fluoride among others 1,32.  
The process by which bone mineral is formed, is still not well elucidated 16,30. However, 
it is known that osteoblasts secrete osteocalcin and mineralizing vesicles. Osteocalcin 
attracts calcium ions and the matrix vesicles release alkaline phosphatase, among other 
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enzymes. Therefore, the surrounding media acquires the necessary ion concentration 
and with the aid of several biomolecules, the formation and deposition of apatite 
crystals is possible 16,33. This mineralization process takes place along different sites of 
the collagen fibrils, thus, the mineral crystals can be considered as fillers on the organic 
matrix providing rigidity to this tissue 1,32,34. Due to findings of traces of different 
amorphous calcium phosphates in biological apatite, it is hypothesised that during 
mineralization process in vivo, the nucleation begins with an amorphous crystal 
growing. These amorphous crystals act as precursor of a more stable hydroxyapatite 
found in mineralized tissue such as bone 22,28,33.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
The mineral phase grants hardness to bone tissue, but its distribution and amount play 
a major role, since over-mineralized bone can be very brittle and prone to fracture 32. 
2.1.1.3 Bone Cells 
Though bone matrix is crucial and endows bone tissue with its main characteristics, 
bone cells are the organisms directing the how and when all of the decisive processes 
are going to take place in bone. The following main cells define the pathway to be 
followed, from formation and maintenance to remodelling of bone. 
2.1.1.3.1 Osteoblasts 
These marrow-derived cells are responsible for producing the material to build bone 
both during human growth and maturity 35. As aforementioned, osteoblasts secrete the 
osteoid, collagen, glycoproteins and other proteins, as well as the matrix sacs that 
finally will help to create the appropriate environment for the mineralization of bone 
1,18,35. Likewise, osteoblasts express cytokines and enzymes, like alkaline phosphatase, 
that influence critical events during bone repair and remodelling, such as bone 
resorption, mineralization and osteoprogenitor recruiting. Once their life cycle is 
completed, these cells can turn into osteocytes or die via apoptosis 35. 
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2.1.1.3.2 Osteocytes 
These branched cells distribute throughout the mineralized bone matrix. As 
mentioned before, osteocytes proceed from osteoblasts that ended up embedded in the 
bone matrix inside cavities named lacunae. While becoming osteocytes, the cell-
precursors developed dendrites which form a communication system among them 
known as canaliculi. These channels also allow cell nourishment and substance 
exchange 16,18,23,35. The well recognized function of osteocytes is to uphold the state of 
bone by receiving and transmitting signals. Osteocytes can detect several different 
hormones and allow bone adaptation to mechanical stimuli through remodelling 
process, that ultimately define its density and mechanical functionality 18. Likewise, 
these cells intervene in bone regeneration detecting the interruption communication 
when an injury takes place 35.  
Osteocyte survival depends on the vascularization of the zone they are allocated and 
they are able to live for years providing this state is preserved 23. 
2.1.1.3.3 Osteoclasts 
Osteoclasts are multinucleated cells of large size and are found on bone tissue surface. 
These cells are in charge of bone resorption by acidic degradation of its matrix 1,36. This 
process is triggered and regulated by a series of molecules among them: hormones, 
proteins and enzymes, such as RANK (receptor activator of nuclear factor κ), RANKL 
(receptor activator of nuclear factor κ ligand), parathyroid hormone (PTH), cathepsin 
K and calcitonin 18,23,36,37. Therefore, bone resorption is a process that helps to regulate 
calcium availability within the body. However, this process is very active during the 
first stages of bone remodelling and bone repair, in which old or damaged bone 
respectively, are removed to give rise to new bone formation 18,36. Thus, osteoclasts 
play a very important role in preserving functionality of bone, since a lack of resorption 
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or an excess of it may lead to serious diseases such as osteopetrosis or osteoporosis, 
respectively 16,37. 
2.1.1.3.4 Other bone cells 
Cell precursors, such as pre-osteblasts and pre-osteoclasts, are also found in bone. 
Likewise, bone lining cells are inactive osteoblasts located in the bone periphery and 
though their functions remain unclear, it is presumed that they are involved in the 
regulation of bone resorption 18,23,37. 
 
2.1.2 Bone structure and properties 
Bone function within the body can be summarized mainly in three types:  
− Metabolic: If necessary, diverse ions can be released from this tissue. Ions 
such as calcium and phosphate are essential for various biological 
processes 16,24. 
− Protector: Bones form the skeleton structure, which protects the internal 
organs, i. e. brain, heart, and lungs. Likewise, this tissue shelters bone 
marrow, which provides hematopoietic cells 16,19,20.  
− Mechanical: As important elements of the skeletal system, bones help to 
provide support and maintain the shape of the body, allowing 
displacement 16,18–21. 
Hierarchical models have been proposed to study bone’s architecture and function, 
while explaining the particular biomechanical properties of this tissue 22,33,38,39. A 
variety of models have been suggested, however they all share their focus on the 
different features exhibited from the nano- to the macro-organization of the bone 
components 22,33,38. Weinkamer & Fratzl (2010) explain the hierarchical structure of 
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bone tissue according to the distribution of its components at different scales: At a 
nanometric scale, bone is formed by collagen molecules with apatite mineral 
distributed among them (Figure 2.1 part 1). Mineralised collagen fibrils arrange 
themselves in patterns named bone lamellae, which in time form bone layers of the 
osteons and an intricate framework called trabeculae (Figure 2.1 parts 2 to 5). The 
micrometric sizes of these structures round between 10-6 and 10-4m. The macrometric 
scale represents the organization and distribution of trabecular and compact bone in a 
complete bone structure (Figure 2.1 part 6) 40.  
 
 
Figure 2.1.  Hierarchical structure of bone tissue: (1) Mineralized collagen fibres; (2 and 3) Microarray of 
mineralized collagen into lamellae; (4 and 5) Flat arrangement (trabecula) and cylindrical arrangement 
(osteon) of lamellae; (6) Complete bone structure (femur) formed by compact and trabecular bone. Picture 
taken from Weinkamer & Fratzl (2010) 40.   
 
2.1.2.1 Microstructure of bone tissue 
During bone formation, collagen fibres organize into flat layers once its mineralization 
is achieved. These layers, better known as lamellae, take part of the two different stages 
of bone configuration at a microscale level 38,39. On one side, woven bone is mainly 
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comprised by collagen fibres randomly organized and exhibiting poor mineralization 
patterns. This type of bone is mostly observed during embryo ossification, infant’s 
growth, and early stages of bone regeneration in adults, which later is replaced with 
lamellar bone 1,23. On the other side, lamellar bone consists on a well-structured array of 
the mineralized sheets (lamellae). Usually the lamellae organize in a cylindrical 
structure better known as osteon, though parallel arrangement is also found. The 
channel around which the osteon is built is called Haversian channel, therefore this 
structure is also identified as Haversian system 16,39. Figure 2.2 shows the structure of 
the Haversian system and its relation with the resultant macrostructure of bone 18. It is 
important to highlight how blood vessels and nerves travel axially through the 
Haversian channels and transversely through the Volkmann channels in this system 
16. Rho et al. (2016) emphasize the impact of the osteon’s inner arrangement on its 
biomechanical properties, as lamellae disposition defines the mechanical resistance 
achieved by the osteon, and ultimately influences the one reached by the tissue itself 
39.  
2.1.2.2 Macrostructure of bone tissue 
On a macroscopic level, bone is classified in two types: trabecular and cortical. Trabecular 
bone, also known as cancellous or spongy bone, is mainly formed by a complex porous 
framework of lamellae. This particular array named trabeculae, is not as randomly 
ordered as it may seem, since it has been proven to be strategically organized to 
support loads, providing the distribution of its pores and the lamellae orientation 18,39. 
On the other hand, cortical bone, also called compact bone, is mainly formed by 
mineralized sheets tightly packed and is generally identified to be formed by the 
Haversian system 18 described in section 2.1.2.1.  
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Majority of bones within the body are comprised by both types of bone, cortical and 
trabecular, and this composition is defined depending on their location and 
consequently their function 30. Long bones such as femur, humorous or clavicles exhibit 
a thick cortical component, surrounding the trabeculae portion that wraps the marrow 
canal 23,30. Whereas small bones such as vertebrae and those of the craniofacial skeleton, 
consist on a large section of trabecular bone enclosed by a slight fraction of cortical 
sheets 23,30. Figure 2.2 depicts the common disposition of these types within a large 
bone structure 18.  
Mechanical properties exhibited by cancellous and cortical bone depend on the 
distribution and content of inorganic and organic constituents, as well as on the 
arrangement of both osteons and trabeculae. Cortical bone possesses an anisotropic 
elastic modulus, being its mean value higher than that of cancellous bone, this is 
mainly attributed to the porosity of the latter 41. 
 
2.2 Bone repair 
The integrity of bone tissue depends on several factors, such as: the location of the 
bone, the individual’s gender, health, genetics, diet, and activity. Remodelling process 
deals with most of the damage of the bone structure throughout an individual’s life. 
However, sometimes the rate or efficiency at which the bone is replaced is lower than 
the loss of tissue and its mechanical properties turn defective, therefore fractures may 
ensue 1,2,21. 
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Figure 2.2. Structure of a large bone. Cortical and trabecular bone distribution with the vascular system 
running through them 18.  
 
Bone possesses the ability of repairing itself without scar formation whenever an injury 
occurs or an absence is produced, limited, however, by the size of the loss 6,21. Bone 
fractures can be produced by two main causes: 1) Acute damage, is when the applied 
load or the direction in which is inflicted to the tissue exceeds its limits. 2) Fatigue, if 
there is an accumulative microdamage on the osseous tissue the cracks are able to 
propagate, which leads to failure 2,42,43.  
Bueno et al. (2011) and Prendergast et al. (2001) coincide on describing bone repair by 
two main processes: primary and secondary healing. During primary restoration, 
ossification takes place through intramembranous formation. In this process, osteoclasts 
resorb the tissue at the edges of the fracture, followed by osteoblasts secreting osteoid.  
Thus, forming woven bone, which is later replace by lamellae, in a common 
remodelling pattern. This type of healing is observed if the fracture is perfectly fixed 
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and requires very stable conditions to occur, therefore, is less observed than secondary 
healing 1,6.  
Secondary repairing is a process of various steps which requires the synchronized 
interaction of several biological factors and routes to produce a proper bone 
restoration, achieved ultimately by endochondral ossification 1,6. When an injury 
occurs, there is an immediate interruption of communication through that specific part 
of the bone, as vascularity and tissue continuity are disturbed. As part of the healing 
process, this disruption causes necrosis and hypoxia at the bony edges. 1,9,10. This 
activates the hypoxia-inducible factor (HIF) which attempts to remediate this state by 
regulating gene activation and stimulating different pathways and growth factors, 
such as Vascular Endothelial Growth Factor (VEGF) 10,11,44. Likewise, the blood 
coagulation cascade responds forming a clot around the injured site, due to the platelet 
aggregation 10.  
From the resulting haematoma, platelet derived growth factor (PDGF) and other 
signalling carriers are liberated, and the inflammatory response ensues 10,11. On this 
stage, the fibrin mesh established by the haematoma allows inflammatory cells to 
arrive. Neutrophils are the first polymorphonuclear cells to reach the site, followed by 
the macrophage 11. Macrophage and osteoclasts deprive the injured site from debris 
and necrotic osseous tissue. Likewise, inflammatory cells release more signalling 
molecules to attract mesenchymal stem cells (MSC), fibroblasts and osteoprogenitor 
cells (OPC) 9–11.  
With the aid of the aforementioned growth factors, the transforming growth factor 
(TGF), the bone morphogenic proteins (BMP), and the fibroblast growth factor (FGF) 
mediate the differentiation process of the MSC and OPC into chondrocytes and 
osteoblasts. These cells then produce the extracellular matrix (ECM) 10,45,46. Thus, 
endochondral ossification takes place throughout the fracture breach ultimately 
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joining its edges. This soft callus (cartilage) is only provisional as it subsequently 
becomes mineralized by the osteoblast population (hard callus formation) 10,11. At the 
same time, intramembranous ossification advances from the inner periosteum 
assisting bone formation towards the fracture breach 1.  
During the hard callus formation, blood vessel ingrowth increases due to the 
coordinated action of various biochemical signals released mainly from the apoptosis 
of chondrocytes, thus improving blood flow for the healing to continue 11. Ultimately, 
once the cartilage becomes completely mineralized, it undergoes the normal 
remodelling process. This restores the anatomical composition of bone and 
consequently its mechanical stability and complete functionality 1,9–11.   
 
2.3 Angiogenesis in bone repair 
Angiogenesis is the process by which pre-existing blood vessels give rise to new ones 
15,47. Figure 2.2 clearly illustrates the distribution of blood vessels within the bone 
structure. It is possible to observe how vascularization travels from the surface 
(periosteum) to the interior of the trabeculae; spreading all over the osteon system 
throughout the Harversian channels and connecting from osteon to osteon through the 
Volksman’s channels 16. Therefore, angiogenesis is crucial during repairing and 
regeneration processes, not only for bone, but for mostly all the body tissues (except 
for cartilage, as it is not vascularized). The term ‘angiogenic-osteogenic coupling’ has been 
coined to refer to the fact that without a proper vascularization, osteogenesis is 
compromised. Similarly, key factors and processes during blood vessel formation are 
also determined and regulated by osteogenesis development 44,48. 
In bone, blood vessels provide nourishment, gas exchange, and waste product 
elimination 9,10. A vast variety of biomolecules circulate throughout the blood vessels. 
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Among them we can name growth factors, enzymes, vitamins, ions, proteins, and 
hormones. These biomolecules play key roles in the development and maintenance of 
this tissue 9–11,46. Likewise, blood vessels are the conduits by which OPCs and MSCs 
are transported from their niches to the fracture site, when they are needed for 
regeneration processes 44. Thus, vascularity helps to modify and maintain the 
metabolic microenvironment of bone, providing the angiogenic and osteogenic 
elements during its repair 10,44.  
In their reviews, Saran et al. (2014) and Hankenson et al. (2011) highlight the relevance 
of angiogenesis in bone repair. They reference examples of different studies where 
diminished or complete lack of blood supply in the injury lead to healing problems. 
Among them: fracture non-union (healing is not achieved) and delayed union (the 
injury takes a long time to heal). Furthermore, the failure of implanted scaffolds can be 
also attributed to the deficiency of blood vessel formation within the structures 9,10. 
Likewise, Lafage-Proust et al. (2010) emphasize the relationship between bone blood 
flow and bone mass. It has been observed that blood flow can decrease with the 
lowering of bone mass; in the same way, bone mineral density lessens in patients with 
peripheral artery disease. These and other examples point to a close, though non-
linear, relation between bone vascularization and bone’s maintenance and repair 49.  
 
As reviewed in section 2.2, there are several signalling molecules influencing bone 
repair. Moreover, many of these have shown an angiogenic effect as well. Table 2.1 
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Activation of genes and pathways involved in angiogenesis, 
erythropoiesis, increase VEGF expr. 
VEGF Both 
Recruitment of osteoblasts, MSC and EC. Influence in another 
GF 
TGF-β Both MSC recruitment, Differentiation of Osteoblasts 
PDGF Both Stimulation of osteoblasts 











Recruitment of bone cells and osteoclasts 
 
Table 2.1. Important Biomolecules in Bone Repair. Abbreviations: GF: Growth factor, EC: Endothelial 
Cells, MSC: Mesenchymal Stem Cells. Factors: HIF: Hypoxic Inducible Factor/ VEGF: Vascular 
Endothelial Growth Factor/ TGF-β: Transforming Growth Factor Beta/ PDGF: Platelet Derived Growth 
Factor/ FGF: Fibroblast Growth Factor/ BMPs: Bone Morphogenetic Proteins/ RANK: Receptor 
Activator of Nuclear Factor-Kappa B/ RANKL: Receptor Activator of Nuclear Factor-Kappa B Ligand. 
(Adapted from: Loi et al. (2016), Saran et al. (2014) and Maes & Clemens (2014)).  
 
2.4 Current approaches to improve vascularization during 
bone repair 
Bone tissue engineering research has investigated a wide range of strategies to 
overcome the limitation of enhancing neovascularization during bone repair. The use 
of one technique, or a combination of them, have been explored as means of improving 
vascularization during bone regeneration. Nevertheless, the search for the most 
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optimal combination of techniques and materials to achieve maximum regeneration is 
still in progress.  
The aim of the following subsections is to present general information regarding the 
current approaches to improve vascularization during bone repair. This, just to 
provide a general scenario of how tissue engineering is facing this issue, we are not 
using all these techniques in our research.  
2.4.1 Porous synthetic scaffolds 
Autografts represent the golden standard when it comes to bone tissue substitution. 
However, though autografts show exceptional biocompatibility and wound healing 
properties, their low availability, morbidity of donor site and long-term pain mean 
serious disadvantages for their use in bone tissue engineering 3,6. 
Therefore, the chance of using scaffolds made of biomaterials for bone substitution has 
been extensively studied. From the bone tissue engineering point of view, a scaffold 
can be defined as a three-dimensional structure that provides the needed healing 
environment allowing new bone formation 50. Ideally the scaffold should allow cells to 
grow, proliferate and differentiate; provide mechanical stability and strength; promote 
vascular infiltration and growth; and it should not unchain a cytotoxic response 10,50. 
To date, a variety of natural and synthetic polymers have been used in bone tissue 
engineering studies, for example, collagen, gellatin, fibrin, chitosan, PLA (polylactic 
acid), PGA (polyglycolic acid), PCL (polycaprolactone), among others. These 
materials, depending on the fabrication technique, have been able to produce porous 
scaffolds with interconnected matrices. However, natural polymers exhibit poor 
mechanical properties or inadequate degradation characteristics. On the other hand, 
synthetic polymers exhibit low bioactivity or unsatisfactory cell interaction 9,10,50. 
Moreover, most of the scaffolds produced are unable to meet the vascularization 
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requirements once implanted, i. e. vascular infiltration in situ is deficient which leads 
to the failure of the implant 9. 
Thus, the use of different materials polymers, ceramics, and their combination, is 
currently analysed. Furthermore, the combination of scaffolds and the addition of 
many biomolecules has improved the perspective in the use of biomaterials for 
improving vascularization in bone tissue engineering. 
2.4.2 Growth factor delivery 
As described in sections 2.2 and 2.3, bone healing is a series of coordinated events that 
culminate in the restoration of the bone tissue without leaving a scar. The final outcome 
of the healing process will be determined by the mechanical stimulus and the 
biological environment of the injured zone 10,11.  Growth factors are secreted molecules 
that affect (mediate) various processes of the cells. Depending on the range and 
receptors present, these biomolecules will finally aid to regulate the local environment 
in the fracture 50. It is not surprising that research aiming to understand their functions 
or to exploit their influence, has been very active. Among the growth factors used with 
therapeutic purposes in bone tissue engineering we can include: VEGF (Vascular 
Endothelial Growth Factor), FGF (Fibroblast Growth Factor), TGF-β (Transforming 
Growth Factor Beta) and PDGF (Platelet Derived Growth Factor), as well as BMPs 
(Bone Morphogenetic Proteins). These particular growth factors brought attention to 
research due to their action along the different stages of bone healing 9–11,51,52. 
Regarding their improvement of angiogenesis during bone regeneration, Hankenson 
et al. (2011), Saran et al. (2014) and Hu & Olsen (2016) reference various studies 
concerning the administration of the aforementioned growth factors (single growth 
factor or combination of growth factors), the results from the cited publications present 
contradictory conclusions, no matter the growth factor used. The use of exogenous 
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growth factor was able to provide positive angiogenic and healing effects, however, in 
some findings, the quality of the bone was not adequate. Moreover, even when blood 
vessel formation may be able to be induced, malformed vessels were present 9,10,46. This 
is mainly due to the effect of the in vivo environment (extracellular matrix, cell 
signalling, general health of the test subject) on the action of the growth factor.  
Yu et al. (2015) explain how the influence of the growth factors is naturally regulated 
through the cell secretion if needed, which explains why some of them intervene at 
different stages of the bone healing process. This undoubtedly represents a challenge 
for therapeutic growth factor delivery, since not only the carrier should be effective to 
reach the treated site, but also a maintained release needs to be achieved without 
exceeding the necessary dosage to its effectiveness, becoming toxic 51. Another 
drawback of this therapy is the order of application, since, biologically, the secretion 
of growth factors is a response of the stimulus sent to the cells during the healing 
process. However, in a therapeutic delivery, this is not yet adjustable and the outcomes 
of applying a growth factor when not needed can be unsuitable 9,51,52. Moreover, most 
of the information available regarding the effects of growth factors in bone healing 
resides in analysing the effects of the absence of the growth factors or blocking its 
receptors, rather than the application of the substance itself 53.  
Lastly, the incorporation of growth factors into a scaffold as its delivery system has 
represented another difficulty, mainly due to the abovementioned reasons: controlled 
and sustainable release. Inclusion of heparin or heparan sulphates have presented 
viable alternatives for growth factors such as VEGF and FGF 54–56, which increases the 
already expensive cost of the growth factor delivery therapy. Nonetheless, the research 
to improve growth factor delivery is ongoing in bone tissue engineering, aiming to 
improve delivery systems to achieve accuracy and regulation in growth factor release. 
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2.4.3 Cell scaffolds 
Bone tissue engineering has also focused its attention on the use of cells that can 
promote osteogenesis as well as angiogenesis. Primary studies show the use of 
Mesenchymal Stem Cells (MSCs) coming from the bone marrow, under the premise 
that they would stimulate both bone and vascular growth 9,57,58. On different in vitro 
studies MSCs have shown the ability to differentiate into osteoblasts or chondrocytes, 
moreover, MSCs can also be precursor for endothelial cells that ultimately will give 
rise to vascularity 9,57. According to García & García’s (2016) review in vivo 
experiments, MSCs show a positive effect on both processes when done separately, i. 
e. MSCs where able to differentiate into osteogenic line or to exhibit an endothelial 
potential to promote vascularization, the use of growth factors to stimulate the latter 
effect should be highlighted as the unknown dose and order of application of these 
give rise to other issues 57.  
The use of more than one cell line has also been tested, as some examples of these, we 
can mention co-cultures of: MSCs and endothelial progenitor cells (EPC), Osteoblasts 
and endothelial Cells (ECs), osteoblasts and human umbilical vein endothelial cells 
(HUVECs), among others. Results from most of these co-cultures in vitro show a good 
capacity of both cell lines to produce osteogenic and angiogenic effects. However, 
when translating to in vivo studies, mixed results are exhibited. Some researches show 
positive vascular infiltration and bone formation, compared to studies using only one 
cell type 57. On the other hand, studies like Koob et al. (2010) and Sharma et al (2018) 
using HUVECs and Bone Marrow Stromal Cells respectively show that though proper 
vascularization can be achieved, bone formation was not enhanced or defective 59,60.  
One of the main drawbacks for the use of any of the previously mentioned cell lines is 
their limited availability 10,61. Recent findings culturing MSCs from different sources, 
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such as adipose tissue, are ongoing with promising results. However, it has also been 
observed that the nature of the cell source determines its behaviour for regeneration 
potential. Moreover, factors such as cell culture protocols, culture media, number of 
cells used, animal model chosen, among others have been proven to highly influence 
the outcome of the study 57. In view of this discrepancy of results among different 
studies, it seems very obvious that further investigation is required before any 
definitive conclusions regarding the delivery of osteogenic and vasculogenic cells into 
bone defects. 
2.4.4 Gene therapy 
The main purpose of using gene therapy for bone and angiogenic regeneration is to 
modify the cells in order to have a stable expression of the target growth factor. Thus, 
having an expression of this molecule in response to the physiological needs, both 
vasculogenic and osteogenic 51,57,62. If successful, this would eliminate the use of 
external doses of growth factors 51.  
There are two main forms to deliver genes, using viral vectors or non-viral vectors. The 
use of viruses as a vehicle to transfer nucleic information to the target cells has 
presented the most efficient results, but their limitation for feasible clinical trials stems 
from their potential risks of immune responses in the hosts 10,51,57,62. On the other hand, 
non-viral vectors, consisting on a variety of options going from polymers, phosphates 
to liposomes 51,57. This type of delivery vehicle presents a low efficiency due to their 
non-specificity to the cells with which they interact 62.  
Regardless of the transfection method the major concern remain for the influence on 
the cell nucleus may have latent modifications in their DNA, which could lead to 
uncontrolled protein expression, unwanted effects or atypical tissue healing 10,51,57,62.  
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Current results from these type of therapy, however, show successful formation and 
differentiation of basic vascular structures, developing of microvasculature on 
implantation and improvement of bone healing process 10. It is important to highlight 
that most of the work has been performed on rats or mice models, with varied induced 
defects (calvarial, femoral, or muscular injection). Equally important is to mention that 
there have been some studies showing irregular cell expression prior re-implantation 
on the subject. These type of results keep this therapy from being feasible for clinical 
application yet 10. 
 
2.5 Heparin and revascularization improvement 
 
Heparin possesses an anionic nature due to the presence of sulphate ion groups on its 
structure (see section 3.1.4). Along with a variety of macromolecules, mainly with 
growth factor families, heparin influence in neovascularization processes has attracted 
a lot of attention. 
Chiodelli et al. (2015) published an extensive review on heparin and heparan sulphate 
proteoglycans molecular interactions related to neovascularization. In this review, the 
authors highlight heparin ability to bind with angiogenic growth factors (AGFs), 
which include both inhibitors and promoters. The balance between these two is the 
way heparin aids neovascularization regulation. Likewise, they present available 
information about the specific heparin sulphate groups that interact with angiogenic 
regulators 15, a summary is presented in Table 2.2.  
Furthermore, Bhakuni et al. (2016) and Rema et al. (2003) address the fact that 
molecular weight of heparin plays an important role on its angiogenic activity 63,64. 
According to Rema et al. (2003) and Collen et al. (2000), low molecular weight heparin 
(LMWH) has shown to inhibit angiogenesis when compared to high molecular weight 
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heparin (HMWH) on a chorioallantoic membrane assay (CAM assay) 64,65. In a similar 
way, Ito & Welsh’s (1999) study presented dual effects of heparin effect in the affinity 
of VEGF for its receptors, observing a difference in the action according to length of 
the polysaccharide unit 13. Nonetheless, this behaviour seems to be completely 
dependent on the angiogenic regulator’s affinity and molecular requirements.  
 
Heparin sulphate groups interaction with angiogenic regulators 
Angiogenic Regulator Sulphate groups 
VEGF-A  6-OSO3  
FGF2 2-OSO3  NSO3 
TGF-β   NSO3 
PDGF 2-OSO3 6-OSO3 NSO3 
FGFR1, FGFR4  6-OSO3  
Heparanase   NSO3 
 
Table 2.2. Specific Heparin sulphate groups interaction with angiogenic regulators. Abbreviations: VEGF-
A: Vascular Endothelial Growth Factor A/ FGF2: Fibroblast Growth Factor 2/ TGF-β: Transforming 
Growth Factor Beta/ PDGF: Platelet Derived Growth Factor/ FGFR1: Fibroblast Growth Factor Receptor 
1/ FGFR4: Fibroblast Growth Factor Receptor 4. (Adapted from: Chiodelli et al. (2015)). 
 
Though currently heparin is mostly used to bind with growth factors and aid its release 
in various systems 54,66–71, its action in wound healing and angiogenesis is still explored 
in the field of vascular tissue engineering 72–75.  
 
2.5.1 The use of heparin in bone healing techniques 
 
Although the use of heparin has been mainly for releasing growth factors from 
functionalized matrices, in this study the use of heparin alone inducing vascularization 
has been studied. Yar et al (2017) has reported heparin successfully loaded onto 
chitosan scaffolds to improve poorly vascularised wound beds 56. Similarly, Shahzadi 
et al. (2016) have bonded heparin to chitosan-PVA scaffolds to improve 
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neovascularization 76  and Gibliobianco et al (2015) reported layer by layer heparin 
coating to a PLA scaffold 77.  
Regarding the use of heparin for bone tissue engineering has been previously studied. 
Almodovar et al. (2013) reported the use of chitosan/heparin polyelectrolyte 
multilayers built on modified cortical bone pieces. Their main aim was to take 
advantage of the antibacterial properties of chitosan in bone healing. However, they 
also highlight the resultant sites to bind growth factors, ensuing from the inclusion of 
heparin into the scaffold, this helps with their release and availability to attract 
mesenchymal stem cells attachment, improving bone regeneration 75.  
Similarly, Yang et al. (2014) produced hydroxyapatite mineralized heparin/gelatin 
nanoparticles. They obtained a material enough stable to be used for growth factor 
release. The authors suggest their use with injectable hydrogels, so they can be 
delivered in situ during the bone healing 72.  
Similarly, Gümüșderelioǧlu & Aday (2011), functionalized freeze-dried chitosan 
scaffolds with heparin for bone tissue engineering. They tried two types of bonding: 
electrostatic interactions and covalent bonding. Their scaffold was able to release 
heparin for 20 days. Their findings focused mainly on bone growth, showing that 
covalent bonding presents better results in regards of in vitro osteoblast proliferation. 
This was explained that heparin was providing an enhancement of BMP activities. 
However, this team did not discuss concrete information regarding the ideal amount 
of heparin for promoting osteogenesis, nor effect on angiogenesis was mentioned 78.  
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2.6 Summary 
Bone is a complex skeletal tissue, which is bioactive and is changing all the time due 
to the impact of loading and unloading. The challenge is to find a biomaterial that can 
mimic its properties. The balance between its mineral and organic matrices provides a 
challenge for bone tissue engineering. In addition, as our understanding of the bone 
improves, researchers are appreciating the importance of having a good blood supply 
for bone repair and regeneration. Angiogenesis, and consequently, revascularization 
during bone repair endows bone with the ability to maintain its nourishment and its 
complete functioning. However, as it is described in the following chapter, natural 
materials, such as, chitosan and hydroxyapatite have proven to provide positive 
results in bone regeneration.  Similarly, the use of heparin rises the possibility of 
improving angiogenesis process during bone repair. 
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3 
Materials and Methods 
 
In this chapter, the materials used for the scaffold preparation are described in detail, 
including their main physicochemical characteristics and how they are expected to 
influence the outcome of this research project. At the end, a list of the particular 
materials, their sources and suppliers are provided.  
The development and/or optimization of the methodology used to prepare the 
proposed bioactive scaffold for improving bone angiogenesis is presented in detail in 
chapter 5, Section I. As a result of the experiments carried out during those trials, the 
following protocol was obtained. Stepwise descriptions of our freeze-gelation protocol 
are provided. Additionally, the process of loading heparin onto the scaffolds in order 
to functionalize them for vascular infiltration purposes, is described.  
 
3.1 Scaffold Materials 
The following sub-sections describe in detail the materials involved in the process of 
preparing the scaffolds. The description includes their main physicochemical 
characteristics, which finally influence on the expected the outcome of the project.  
3.1.1 Chitosan 
There are several reviews regarding chitosan and chitosan-derivatives and their 
biomedical applications due to its outstanding biocompatibility and biodegradability 
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characteristics 79,80,89–91,81–88. This section attempts to describe, in general terms, the most 
important characteristics of this material. 
Chitosan is a polysaccharide derived from the deacetylation of chitin. Its chemical 
structure, shown in Figure 3.1, is well described by Levengood & Zhang (2014) as a 
linear polysaccharide consisting of glucosamine and N-acetyl glucosamine units 




Figure 3.1 Chemical structure of chitosan. [Adapted from Mourya, V. K. et al (2008) 83] 
It is worth highlighting its naturally derived form, since chitosan is obtained from 
natural sources: the animal source consisting mainly in crustaceans and the vegetal 
source formed by certain fungi.   
In arthropods, chitin is part of their protection structures (cuticle) along with proteins 
and calcium carbonate 90. Being an important part of crustacean’s shells, chitosan 
production from this source is the most common since seafood industry provides a 
good source from its scrap 81,90. Croisier & Jérôme (2013) claim that chitosan obtained 
from vegetal sources presents a more consistent reproducibility and is favoured over 
crustacean chitosan for its use in healthcare 80.  Also research teams such as Kaya et al. 
(2015) and Mesa et al. (2015) have reported optimal biomedical-quality chitosan 
obtained from naturally abundant fungus 92,93. Despite all this, the main source of the 
available commercial chitosan remains to be crustaceans. 
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3.1.1.1 Fabrication of Chitosan 
The general process to obtain chitosan, whether the source is animal 90 or vegetal 93, 
can be summarized in the following five steps. The first step is the priming of the 
material, through homogenization in the case of fungi and decalcification of shells in 
the case of crustaceans. Secondly, a process of decomposition of proteins is followed, 
it is mainly performed using sodium hydroxide (NaOH) and heat. The next step is the 
treatment to remove the organic residues, regularly achieved through alkaline 
substances. However, according to Mesa et al. (2015), this is not required for fungi 
source. The fourth phase is pigment removal, and finally the last step is the 
deacetylation procedure 90,93. The deacetylation process modifies chitosan’s 
crystallinity, structure, and functionality endowing it the potential to be used in several 
applications when compared with chitin. Although chitin is naturally abundant, it is 
not soluble in many solvents, which complicates its handling and use. 
Thus, chitosan is generally obtained by the alkali treatment of chitin, which involves 
the hydrolysis of the amino acetated positions on chitin backbone. This is usually 
achieved using NaOH and a thermal treatment ca. 80- 120 °C for approximately 5h. 
However, Dash et al. (2011) also refer the use of potassium hydroxide, anhydrous 
hydrazine, and hydrazine sulphate for this phase 81. This process can also occur by 
enzymatic hydrolysis through the action of a chitin deacetylase 81. Likewise, Yaghobi 
& Hormozi (2010) and Domard (2011) describe deacetylation protocols consisting in 
treating chitin with the alkaline substance more than once, in order to obtain a 
maximum level of deacetylation 86,94. These authors also suggest that the hydroxide 
concentration plays a major role in this process. Most protocols show a degree of 
deacetylation of 70- 95%, while a 100% deacetylated chitosan can be achieved with 
their multistep processes 80,81,83,87.  
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3.1.1.2 Chemical, physical, and biological properties 
Besides its natural origin, the most remarkable features of chitosan noted among all 
the reviews are: biocompatibility, biodegradability, antibacterial nature, low-toxicity, 
haemostatic behaviour, the wide variety of chemical modifications it can undergo, and 
its ability to promote cell attachment and proliferation 79,80,89,90,81–88, such characteristics 
place on chitosan high expectations to be consider in various biomedical and 
pharmaceutical applications. 
Many authors coincide that, the degree of deacetylation (DD), the molecular weight 
(MW) and the number and position of amino groups present in its backbone confer to 
chitosan its properties and behaviour.  
For instance, Alves et al. (2008), Mourya et al. (2008), Pillai et al. (2009), and Dash et al. 
(2011) state that the number of cationic sites formed via protonation of amino groups 
by acids along the chitosan chain increases its solubility, giving rise to a water-soluble 
polyelectrolyte.  However, if the pH rises up to around 6 and 6.5, the amines lose their 
positive charge, becoming insoluble. Therefore, although this protonation of amino 
groups confers to chitosan one of its most remarkable capabilities (ionic charge) it can 
also limit its applications as it is only soluble in some acidic solutions 81–83,85,86. It is 
important to notice that the DD determines the number of amino groups available on 
the chitosan structure, modifying its crystallinity, which plays a major role in the 
solubility of any substance. 
The polycationic nature of chitosan also elucidates certain abilities that are very useful 
in bone tissue engineering. Chitosan is able to form stable ionic complexes with various 
water-soluble anionic molecules, which can improve its mechanical properties and 
enhance cell attachment. Park et al. (2013) and Resende et al. (2015) reported a positive 
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impact on chitosan flexibility and mechanical strength when combined with anionic 
biopolymers such as alginate or glycosaminoglycans (GAGs) 3,95. On Kim et al. (2008) 
and Levengood & Zhang’s (2014) reviews this last combination is especially remarked 
since GAGs help to regulate important processes in bone regeneration 79,89. On the 
other hand, Mourya et al. (2008) and Croisier & Jérôme (2013) consider that the cell 
permeation improvement of chitosan can be explained by its interaction with the 
negative portions of the membranes, which modifies their communication channels 
80,83. Similarly, Dash et al. (2011) and Usman et al. (2016) deem that the anionic adhesion 
of chitosan is also reflected on its haemostatic activity, since erythrocyte membranes 
are negatively charged 81,84.  
Biocompatibility is also affected for the DD, the aforementioned ability of chitosan to 
interact with cell membranes depends upon the ionic charge throughout the chitosan 
chain which is highly related to the DD. And as stated by Croisier & Jérôme (2013), as 
the number of positive charges augments, the interplay cell-chitosan increases, and this 
tends to enhance biocompatibility 80. Numerous studies have analysed the influence of 
chitosan in cell viability, proliferation and attachment. Though these properties are 
highly related to the chosen system, chitosan has demonstrated to provide an adequate 
environment for cell adhesion and growth, especially when combined with 
compounds that help the system to emulate cell matrix 79–83,85–89. 
Mainly, DD and MW affect the degradation rate of chitosan. Chitosan exhibits 
maximum levels of crystallinity when it reaches values near to 100 % of DD, this 
influences its biodegradation rate as low crystallinity implies a higher degradation rate 
and vice versa. On the other hand, MW shows the opposite effect as the higher the MW 
the lower degradation rate, due to the length of the chitosan chains. Biodegradation 
also depends upon the distribution of the acetyl residues throughout the chitosan 
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chain, for example, it has been found that the more alternated the position of these 
groups the lower the rate of enzymatic degradation 79–81,83,85. Regarding the 
degradation by-products of chitosan, they are non-toxic and can be integrated into 
different metabolic pathways 3,79. However, Svirshchevskaya et al. (2016) claim that a 
high hydrophobic substitution of chitosan can give rise to a toxicity growth 96, so 
attention must be paid when analysing such chitosan derivatives.  
Further noteworthy characteristics of chitosan include antifungal, antimicrobial, and 
antioxidant activity 80,83,89,97. Chitosan is also an FDA (US Food and Drug Administration) 
approved material for use in wound dressing and haemostasis treatments 98. 
3.1.1.3 Processing of Chitosan 
Chitosan can be processed to obtained a wide variety of forms such as porous scaffolds 
79–81,83,85,87–89, micro/nanoparticles or micro/nanospheres 79–81,85, micro and nanofibers 
79–82,87,88, hydrogels 79,80,90,81–83,85–89, films and membranes 80,81,85–89 and IPN 
(interpenetrating networks) 81. In order to achieve these structures different methods of 
processing can be employed, such as, freeze-gelation 79–81,85, freeze-drying 79–81,85,87–89, 
gas foaming 79, emulsion droplet 81, coacervation 81, ionotropic gelation 80,81,85, spray 
drying 81, phase separation 79, wet-spinning 79,80,82, electrospinning 79–82,88–90, layer-by-
layer deposition 80, wet casting 79,80, solution casting 79,89, chemical crosslinking 79–
81,83,85,86,89, and ionic and polyelectrolyte complexes formation 80–82,85–87,89. These are by 
no means an exhausted list of processing and new methods are being discovered as 
the understanding of the properties of chitosan is growing.  
Chitosan scaffolds are most commonly obtained by freeze-drying procedure. 
However, alternative methods like freeze gelation are gaining recognition within the 
biomaterials field.  
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The porosity achieved with these processes confers the structure its mechanical 
properties, i. e. size and shape of pores, along with their distribution regulate 
mechanical strength of the resultant scaffold. Likewise, these characteristics dictate the 
scaffold behaviour associated with angiogenesis and cell ingrowth and proliferation 
79,81,89. Most of the authors generally place emphasis on the ability of chitosan of 
forming structures with interconnected porosity; hence, it results propitious in bone 
tissue engineering applications. However, it has been observed that the larger the pore 
diameter and interconnectivity, the more fragile the resultant scaffold would be 79,89. 
None of the freeze-dried and freeze-gelled scaffolds developed to the date are suitable 
for load-bearing bone tissue regeneration, because the mechanical properties of these 
scaffolds are far from matching those of this type of bone, even though they show 
adequate characteristics for cell ingrowth. Ruiran et al. (2011) proposed freeze-gelled 
scaffolds made of chitosan and β-tricalcium phosphate (β-TCP). Likewise, Park et al. 
(2013) analysed freeze-dried apatite-coated scaffolds of chitosan and chondroitin 4-
sulfate. In both cases, though the mechanical properties of the scaffolds improved 
when compared to pure chitosan, they are far from matching the values exhibited by 
bone and show dependence on the concentration of their components 3,99. 
3.1.2 Hydroxyapatite 
As mentioned in section 2.1.1.2, the major component of inorganic matrix of bone is 
comprised by a calcium phosphate, better known as biological apatite. This material 
possesses a structure and a composition very similar to hydroxyapatite. Thus, 
hydroxyapatite has been a widely exploited material for bone substitution and 
regeneration, working under the premise that this calcium phosphate is able to 
emulate the characteristics of bone inorganic matrix. 
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The following segments attempt to describe the main characteristics found in the 
literature related to this ceramic, as well as its significance in bone restoration 
applications. 
3.1.2.1 Properties 
Hydroxyapatite is a calcium phosphate with the main composition Ca10(PO4)6(OH)2. 
Its stoichiometric ratio is 1.67, which means the molecular relation between Ca and P 
(Ca/P) is of this value 100. There are two main spatial distributions of hydroxyapatite 
identified: (1) monoclinic classified with a space group P21/b and (2) hexagonal with 
a space group P63/m. However, for biological purposes, only the latter is used due to 
its stability 101,102. Gruselle (2015) presents a depiction of the hydroxyapatite structure, 
showed in Figure 3.2. Calcium ions distribute among the phosphate groups within the 
structure bonding with its oxygen atoms, and the hydroxyl groups align in the c-axis 









Figure 3.2 Hydroxyapatite spatial distribution. [Adapted from: Gruselle (2015)] 
 
Gruselle (2015) also highlights the particular proneness of hydroxyapatite (and 
apatites in general) to establish ionic interactions, describing the main catalytic 
OH 
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behaviours derived from these charge exchanges. The presence of anionic groups such 
as OH- or PO4 and cationic groups like Ca2+ ion, within the hydroxyapatite structure 
allow this material to participate from a variety of surface and structural modifications, 
which ultimately bestow hydroxyapatite with its major qualities 100. 
Bioactivity describes the interaction (chemical bonding) between a material and the 
tissue where is implanted 103. This interaction would be mainly the result of a well-
orchestrated ion exchange between cell-biomolecules and material surface ions 100,103. 
Kokubo (1991) proposed the current standard evaluation of bioactivity in simulated 
body fluid (SBF) 104. After the evaluation of biomaterials for bone applications, it was 
observed that if a proper correlation between the tissue and the material occurs, apatite 
formation would be present in the implant. This is mainly a result of the proliferation 
of osteoblasts around the bioactive surface 105. Along with new apatite formation, 
bioactivity also implies a successful bonding between the existent biological apatite 
and the new apatite formed 104,105. Hydroxyapatite has proved to induce apatite 
formation when implanted, and this particular quality has been widely exploited as 
bone implant coating 106.  
Bioresorption refers to the ability of a material to dissolve within the biological 
environment 107. In the same way bone is naturally resorbed by the action of the 
osteoclasts, it is important for a material intended for bone regeneration aid to possess 
the ability of being resorbable. Thus, it will provide the mechanical support needed for 
the tissue to develop during the healing process just long enough for the new tissue to 
fulfil this task by itself, as a proper regeneration works 108. Solubility plays a major role 
for resorption rate of apatites and it can be modified with various ionic substitutions 
101. Among the available calcium phosphates used for bone defect treatment, 
hydroxyapatite possesses a low solubility in biological environment. However, several 
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ionic substitutions have been tested, which modify the lattice structure and ultimately, 
hydroxyapatite’s crystallinity and solubility 5,109. 
In addition, it is important to consider that once the material disintegrates, the by-
products generated should not have an adverse effect in the biological environment. 
Hydroxyapatite is well recognized for being biocompatible, as the ions liberated 
during its resorption (Ca2+, PO4- and OH-) are not harmful for the body 101,110. 
It is worth mentioning that these characteristics are mainly product of the different 
substitutions within the hydroxyapatite lattice structure and they may vary from one 
to another. Ionic substitution in hydroxyapatite will be discussed on subsequent 
sections.  
3.1.2.2 Synthesis of Hydroxyapatite 
There are several methodologies for the preparation of hydroxyapatite according to 
the targeted property to be modified, i.e. particle size, shape, and/or ionic substitution. 
For instance, some of the methods mentioned in the review by Sadat-Shojai et al. (2013) 
include chemical precipitation, solid-state synthesis, hydrothermal method, flow 
method and sol-gel method 111. Despite of the method chosen, the ratio Ca/P of the 
product must preserve the value of 1.67 in order to obtain a hydroxyapatite structure 
112.  
After critically appraising of the literature, it became apparent that flow method and 
sol-gel method are preferred synthesis methods to be employed in our studies. This is 
because they allow control over particle size, shape, and form of the resulting 
hydroxyapatite.  
As well described by Lakshmi et al. (1997), sol-gel synthesis implies the formation of a 
gel from the aggregation of suspended colloidal particles, which after heat treatment 
produces the entailed material 113. This method allows the obtainment of 
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hydroxyapatite of more uniform structures 111,112, process settlement is simple 114, and 
large surface area of the crystals obtained can be achieved 111. A range of shapes such 
as regular and irregular spheres, or filaments result from this process 111. 
On the other hand, hydrothermal method involves the reaction of the precursors at 
high temperature and pressure 111. Hydrothermal flow method consists in a system 
pumping the precursor solutions through separate pipes that eventually will meet in 
piece called “Tee” mixer. Afterwards, the blend keeps flowing through the pipe, which 
is now immerse in reactor with high temperature media. Ultimately, the obtained wet 
particles can be heat- or freeze-dried 115. This method not only allows to synthesize 
hydroxyapatite in a quick process, but also to have much control of properties like size 
and shape of the structure 111,115.  
3.1.2.3 Ionic Substitutions in Hydroxyapatite 
Though commonly described as hydroxyapatite, biological apatite differs from the 
synthetic form of this ceramic due to the presence of various different ionic 
substitutions 31,102. In their analysis of biological apatites from different sources, Liu et 
al. (2013) describe the most common natural substitutions found in biological apatites 
when compare to synthetic hydroxyapatite. Elements like Mg2+, Sr2+, K+ and Na+ are 
found in the cationic place of Ca2+. Instead of P, the presence of C, As and V can be 
observed. And regarding the hydroxyl (OH-) site, evidence of CO32-, F- and Cl- are 
reported 31. This explains why hydroxyapatite has been used as predecessor of several 
substituted-apatites, aiming to produce phosphates with a wide variety of properties 
and biological applications, from improving solubility 102,109 to providing antibacterial 
properties 116. 
The most common substitution observed in biological apatite is carbonate substitution. 
Carbonates distribute in two different sites within hydroxyapatite structure: (1) 
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substituting the hydroxyl group (A-type substitution) and (2) the so-called B-type 
substitution, taking position of the phosphate group 101. According to Ibrahim et al. 
(2010) the substitution can vary in an A/B ratio circa 0.8 109. This substitution influences 
significantly the solubility of hydroxyapatite due to lower bond energy between Ca2+ 
and the carbonate group (CO32-) 31,101.  
Hydroxyapatite chemical composition is Ca10(PO4)6OH, this means that within 
hydroxyapatite lattice structure there are 10 atoms of Ca2+ for unit cell. From Figure 
3.2, it is noticeable that these atoms arrange in two different sites, marked as Ca(I) and 
Ca(II). As explained on Šupová’s (2015) and Boanini’s et al. (2010) reviews, within Ca(I) 
sites four ions in total are harboured, aligned with c-axis of the hexagonal structure. 
Regarding the Ca(II) sites, six ions per unit cell are admitted in this position and they 
form a space known as anion channel, which can be occupied by monovalent as well 
as bivalent ions. Usually Ca(II) positions allocate cations bigger in size than those 
found in Ca(I) 101,102. As regards to the substitution in these sites, cations such as Na+ 
and Mg2+ have been incorporated in the lattice. Sodium has been explored to improve 
cell adhesion properties 101, whereas magnesium substitution is studied for cell 
proliferation promotion 101,117, though this latter can produce unstable hydroxyapatite 
101.  
3.1.3 Chitosan and Hydroxyapatite scaffolds 
As mentioned in the review by Levengood & Zhang (2014), chitosan and 
hydroxyapatite are among the most promising materials for bone tissue engineering. 
A wide variety of combinations between the two materials have been studied, as they 
can be physically mixed or co-precipitated 79. The reported combinations have showed 
favourable results in many respects: biological, mechanical, and physicochemical.  
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Tu et al. (2017) reported the fabrication an asymmetric nano-hydoxyapatite/chitosan 
composite membrane fabricated by solvent evaporating in vacuum with the ability to 
promote biomineralization by osteoblasts and accelerate bone regeneration 118.  
Likewise, Ruixuin et al. (2017) described the formation of porous nano-
hydroxyapatite/chitosan scaffolds and micro-hydroxyapatite/chitosan scaffolds 
prepared by compression moulding and particulate leaching method. The scaffolds 
exhibited remarkable porosity and pore interconnectivity which make them very 
suitable for guided bone regeneration. Similarly, the authors evaluated the enzymatic 
degradation behaviour by means of PBS (Phosphate Buffer Solution) and lysozyme, 
showing no noticeable degradation until week 8 of the experiment which can be 
translated into outstanding mechanical properties of the combination 119. 
These are just some examples of the prolific use of chitosan and hydroxyapatite, and 
most of the reviews of both materials provide many proved cases. The success of use 
of both materials lies in the fact that the combination of both materials promotes cell 
attachment and osteoinductivity, biomineralization, osteogenic response, structural 
stability, and notable degradation behaviour 79.  
3.1.4 Heparin 
Heparin is a sulphated glycosaminoglycan (GAG) discovered in the early 1900’s 120,121. 
The structure of this GAG is very complex. As described by Rabenstein (2002), heparin 
is formed by repeating subunits of uronic acid-(1→4)-D-glucosamine. The uronic acid 
substitutes may be the following: α-L-iduronic (IdoA) or β-D-glucuronic acid (GlcA), 
which may contain sulphate moieties. The β-D-glucosamine portion can be N-
acetylated or N-sulphated 120. Figure 3.3 shows the typical structure of heparin as 
depicted in Linhardt’s (2003) review, containing the aforementioned subunits. As 
observed in the first half of the repetitive structure, it can contain a highly sulphated 
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disaccharide. However, as shown in the other half, there is an under-sulphated part 
which can be substituted with X= sulphate or H, and Y=sulphate, Ac or H 121.  
 
 
Figure 3.3. Heparin structure. [Adapted from: Linhardt (2003)] 
 
Heparin is synthesized firstly as a proteoglycan which afterwards becomes a 
polydisperse blend of polysaccharides expressed and store in the mast cells (mostly in 
the surface) 120 with a relative molecular mass of around 5000 and 25000 121. 
3.1.4.1 Heparin sources 
Normally, heparin can be found in organs such as liver, intestines and lungs 121, and it 
can be synthesized from different animal tissues, such as porcine and bovine 120. This 
biosynthesis represents the current standard of fabrication of heparin; however, more 
synthesis methods are also under investigation 122. The pharmaceutically obtained 
heparin can be fractionated considering its degree of sulphation and chain length. But, 
isolation of discrete sequences is not possible, therefore, the obtained heparin is the 
result of the blend of similar chains and its characterization is the representative results 
for these common structures 120,121. Heparin obtained from different tissues, exhibit 
differences in their structures, it has been observed that porcine intestinal heparin is 
very similar to human heparin from mast cells 121. 
Among the alternatives currently analysed to produce heparin we can find the 
production from Chinese hamster ovary cells, which naturally produce heparin 
sulphates, like heparin in structure but without the anticoagulant properties of it. 
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These cells have a lower production rate, which requires the use of aid substances, such 
as cysteine, or gene modification techniques. Though there has been a great 
advancement in the use of mammalian cells for production of heparin, there is still 
much work to be done on the field122. 
3.1.4.2 Heparin properties 
Heparin is mostly recognized by its anticoagulant property 120,121, however, Chiodelli 
et al. (2015) also highlight mechanical functions as well as cell proliferation and 
differentiation influence 15. The main reason for this variety of activities is the 
interaction of heparin with a wide variety of biomolecules, such as cytokines, enzymes, 
and growth factors.  
Anticoagulant activity of heparin is elucidated mainly by its interaction with 
antithrombin and heparin cofactor II, serpins that regulate coagulation cascade by 
inhibiting thrombin and other enzymes 15,63,121. Therefore, it has been widely exploited 
for the treatment of thromboembolic diseases 120. 
Rabestein (2002) explains the interaction of heparin with various proteins through its 
anionic nature. This characteristic is mainly due to the sulphate groups allocated along 
its backbone 120. The ion exchange produced through this interaction allows heparin to 
bind with the positive domain of several macromolecules. Linhardt (2003) remarks the 
following: (1) Proteins like FGF family, VEGF family, chemokines, and serpins, 
influencing their activity in cell recruiting, proliferation, and development during 
processes like inflammation, coagulation or angiogenesis 63,121. (2) Enzymes such as 
prokaryotic heparin lyases (heparanase), which also influences its activity in tumour 
growth, tissue healing, and neovascularization 121. And (3) viruses like Dengue, 
interacting with the sulphate groups of the superficial heparin in cells, consequently 
being important for the evolvement of the disease 121.  
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Functionalization of heparin, in terms of its molecular weight, has been possible due 
to different depolymerization and purification methods, during its preparation. 
According to any or both of these, we can find low molecular weight heparin (LMWH), 
high molecular weight heparin (HMWH) and ultra-low molecular weight heparin 
(ULMWH). Their coagulation properties vary according to the interaction with 
antithrombin, due to the differences in their sulphated groups. It has been observed a 
better pharmacokinetic and dosage regulation with LMWH, while ULMWH show 
more sites that bind with antithrombin. These modification of weight and size in 
heparin also influence the way it interacts with other biomolecules such as growth 
factors and enzymes 123. 
 
3.1.5 List of Materials  
- Chitosan molecular weight 100,000-300,000, DD ≥90%. ACROS 
OrganicsTM, Lot: A0376581. 
- Hydroxyapatite sintered powder. Purchased from Captal S® Batch 
P220S. Particle size varied from 0.5± 0.2 μm to 12 ± 1 μm. 
- Heparin sodium salt, from porcine intestinal mucosa, unfractionated,  
IU>=100/mg. Alfa Aesar. Lot: A16198. 
- Acetic acid glacial ≥99.85%. ACROS OrganicsTM. Lot: A0375749. 
- Sodium hydroxide (NaOH) 98% pellets. ACROS OrganicsTM 
- Phosphate buffered Saline Tablets. OxoidTM  
- Ethanol absolute. AnalR NORMAPUR  
- Deionized water 
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3.2 Methodology for scaffold preparation 
A complete description of the methodology employed to prepare the proposed 
bioactive scaffold for improving bone angiogenesis is presented in the subsequent 
sections. The development and/or optimization of this process is presented in detail 
in chapter 5, Section I. As a result of the experiments carried out during this part, the 
following protocol was obtained. Two main phases can be considered: the preparation 
of the scaffold via freeze-gelation and the process of loading heparin onto the scaffolds 
to functionalize them for vascularization  infiltration purposes.  
3.2.1 Freeze-gelation 
As described in section 3.1.1.3 the most common method to produce chitosan scaffolds 
is using freeze drying techniques, however, Ho et al. (2004) hold the view that freeze-
drying can be replaced by freeze-gelation due to various advantages of the latter, such 
as less time and energy consuming, less remaining solvent and no surface skin 
formation 124. In the same way as in freeze-drying, during freeze gelation chitosan 
solution is frozen using a regular cooling rate to obtain the desired porosity. Pore 
dimension and interconnection are dependent mainly on thermal rates as well as 
chitosan amount; bigger pores can be obtained with lower freezing rates 79–81,125. Once 
chitosan solution is frozen, it is subsequently immersed in a precooled aqueous 
solution to induce its gelation. Since the gelation takes place below the freezing point, 
the chitosan frozen solution does not dissolve again, which prevent the structure of 
losing its shape and porosity while drying at room temperature 79,124,126,127.  
The methodology to prepare the scaffolds is based on Qasim S. B. et al (2015) 126  
methodology to produce porous membranes for periodontal regeneration, with slight 
modifications due to the addition of heparin sodium salt, and result from the trials 
described in chapter 5, section I. 
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3.2.1.1 Optimized freeze-gelation methodology 
 
Distilled water was warmed to 50°C in a 250 mL volumetric flask. 7.5 g of chitosan 
were added to this flask and the mixture was stirred for 1 hour. When this time had 
passed, heat was turned off and dropwise addition of glacial acetic acid began (at an 
approximate rate of 1mL/5min). To achieve a solution 0.3M, 4.3 mL of glacial acetic 
acid were used. Obtained chitosan solution was a golden colour viscous liquid. The 
magnet was removed, and the solution was diluted to 250 mL with deionized water 
while maintaining stirring for another 6 hours. 
Subsequently, 7.5 g of hydroxyapatite powder were added, and the mixture was 
stirred overnight (approximately 13 hours).  
On the following day, the solution was poured into plastic petri dishes, adding the 
necessary amount according to the required scaffold thickness. The containers were 
placed into the freezer at 4°C for 1.5 hour. After this period, the temperature was 
gradually decreased in -4°C per hour until a final temperature of -20°C. The frozen 
solution was kept at -20 °C for further 12 hours. 
On the next day, the frozen discs were carefully removed from the petri dishes by 
pressing the edges of the mould and gently applying pressure at the bottom of the dish. 
A 3M NaOH/ethanol solution was poured into glass petri dishes and the frozen discs 
were placed into them, more NaOH solution was poured into the glass petri dish to 
cover completely the frozen disc. All the immersed discs were place at –20°C for 12 
hours. 
After 12 hours of immersion in the gelling solution, the discs were taken out and 
washed as follows: 15 minutes with distilled water, 5 minutes with PBS, 15 minutes in 
80% ethanol solution and 15 minutes in absolute ethanol.   
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Finally, the obtained product was left to dry in the fume cupboard overnight 
(approximately 13 hours), until all moisture was removed. 
3.2.2 Heparin Coating 
Scaffolds were cut into cylinder shapes of approximately 5 mm of diameter using a 
hole puncher or a cork borer. 
50 mL of different aqueous solutions of heparin with concentrations of 0.5, 1, 2 and 5 
mg/mL were prepared by dissolving heparin sodium salt in the correspondent 
amount of deionized water (details of the amounts are presented in Table 3.1). With 
the purpose of all the material having undergone the same procedures, scaffolds 
without heparin, were put in distilled water alone, so they can be submitted to freeze-







0 0 50 
0.5 25 50 
1 50 50 
2 100 50 
5 250 50 
 
Table 3.1.  Amounts of heparin according to the loading concentrations. 
 
Subsequently, the scaffold cylinders were immersed in the heparin solution for 1.5 
hours at room temperature. 
After this time, the material was removed from the heparin solution and any excess of 
solution was blotted. Following by a removal of the moisture from the loading 
procedure by freeze drying the product at -25 °C, for 24 hours. 
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3.3 Summary 
The materials chosen in this study have demonstrated good proangiogenic potential, 
making them excellent materials for bone repair and regeneration. Chitosan provides 
outstanding biodegradable and biocompatible characteristics, enable them to act as a 
useful organic matrix. On the other hand, hydroxyapatite has been the material of 
choice for years to serve as the inorganic matrix of bone in tissue engineering scaffolds 
due to its similar composition with the one of real bone. The combination of these two 
materials has been amply studied and documented with positive results.  
Freeze-gelation was used to produce a good method to fabricate bioactive scaffolds for 
achieving the required structure characteristics, such as, interconnected porosity, pore 
size, bioactivity and hydroxyapatite particle distribution within the polymer matrices. 
The characterisation methods are described in the following chapter. 
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The following sections and sub-sections describe in detail the methodology employed 
to characterize the chitosan/hydroxyapatite/heparin scaffolds. 
The methods used for characterisation of the samples are outlined in detail. How each 
characterisation technique that was used as well as the procedures developed 
are described. Parameters that were used (finalised or altered according to 
requirements), such as time, settings, reagents amount, and general protocols 
are explained in detail, not only in this chapter but also addressed in the 
following chapter. Once the full chemical, biological, physical, and mechanical 
characterisation was achieved and the best materials identified, CAM assay was 
used and this has been explained fully, as this is a critical aspect of this thesis 
to assess angiogenesis in relation to natural materials on their own and in 
combination with heparin.   
 
4.1 Structural characterisation 
4.1.1 Scanning Electron Microscopy (SEM) 
The morphology of the scaffolds was analysed by scanning electron microscopy (SEM). 
Using a Jeol JSM 7800F microscope. Another set of images were obtained with a Vega3 
Tescan, under the same conditions. The cylindrical samples were observed from top, 
bottom, and side faces as pointed in Figure 4.1. Each sample holder was prepared with 
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3 samples of the same heparin concentration: one sample is placed with the top face 
facing up (chitosan side), another scaffold with its bottom face facing up 
(hydroxyapatite side) and the third scaffold was transversally cut in a half to place the 





Figure 4.1 Scaffold orientation and faces. 
 















From the obtained images, porosity of the samples was determined by measuring the 
pore diameters of selected pores in the image using ImageJ®. Figure 4.3 shows an 
example of this process, though less pores are presented in this image with the purpose 
of allowing to see the measures. 
Upper face 
(chitosan side) Lateral edges 
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Figure 4.3 Example of representative porosity measurement using ImageJ® (less pores than usually 
measured are showed to provide an example). Scale bar is 200 µm. 
 
4.1.2 EDX analysis  
Additionally, Energy Dispersive X-Ray (EDX) spectroscopy was performed on the 
scaffolds. This technique allows the acquisition of a compositional analysis of the 
sample. The purpose was to verify the presence of the sulphate on the scaffold. This 
was performed by using a Jeol JSM 7800F microscope. 
4.1.3 In-vitro degradation study 
The procedure for the in-vitro degradation study was based on Qasim S. (2017) 128. 
Four time-intervals were evaluated: 1 day (T1), 7 days (T2), 14 days (T3), and 21 days 
(T4). 
The media solution used for this in- vitro degradation study was prepared by 
dissolving 500 mg of lysozyme powder (Alfa Aesar) into 500 mL of a sterile PBS 
solution. This solution was kept in the fridge at 10 °C. 
The study consisted of 3 experiments with 3 replicates per each sample.  
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Every sample (and replicate) was individually weighted, and its weight was recorded 
as Wi. Once the samples were weighted, pictures of the first sample of each group next 
to a ruler were taken as a reference of their initial appearance. 
Every test tube was labelled with the composition of the scaffold (indicating the 
heparin content), experiment number and the number of sample and/or replicate. The 
samples were placed individually into the test tubes followed by the addition of 3 mL 
of the media solution. All the tubes were placed into an oven at 37° C. 
Individual set of samples was set for each designed interval, i. e. 45 samples were 
placed for T1 interval, 45 samples for T2 interval, etcetera.  
Samples were taken out of the oven according to the designed intervals. The pH of the 
media for the first sample of each group was measured (while waiting for the pH 
measurement to take place, the samples were kept on a hot plate adjusted to 37 °C).  
The rest of the samples from each group were taken out of the oven one by one and 
washed three times with 1 mL of deionized water each time. Next, each sample was 
placed on a two-layer tissue, labelled with its identification. Every sample was left on 
the tissue for 30 seconds for each side to remove most water from its surface.  
After, every sample was transferred to an individual clean vial for a 24 hour-drying in 
an oven at 37 °C. 
Once the samples were dried, they were taken out of the oven and individually placed 
on a tissue paper, applying gentle pressure 2 times on each sample to remove the 
surface water. 
Finally, the samples were weighted, recording this data as Wf. After the weight 
measurements, pictures of the first sample of each group were taken for comparison.  
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The following equation was applied using the data from the weight measurements. 
This equation determines the degradation, which is expressed as % Dry weight: 
% 𝐷𝑟𝑦 𝑤𝑒𝑖𝑔ℎ𝑡 𝑟𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 =  (
𝑊𝑓
𝑊𝑖
) × 100 
NOTES: 
1) All the test tubes with samples in lysozyme media, were swirled 1 time 
a day manually. 
2) The lysozyme solution was replaced with fresh solution every week. 
4.2 Physicochemical characterisation 
4.2.1 FTIR-ATR 
FTIR characterisation was performed using a Nicolet iS50 FT-IR spectrometer, in 
conjunction with the Attenuated Total Reflectance (ATR) sampling accessory 
equipped with a diamond crystal, which allows to analyse surface of the sample. 
Spectra from the top and bottom surfaces of the scaffolds were obtained for 
comparison. Spectra were obtained at 4cm-1 resolution by accumulating 128 number of 
scans using Omnic™ 9 software. 
4.2.2 Heparin determination 
Toluidine Blue assay is a method based on the process developed by Smith P. K. et al 
(1980) 129. The assay is based on the change from blue to purple produced when 
Toluidine Blue interacts with a heparin solution. A heparin-dye complex is formed 
which can be removed by adsorption in an immiscible organic solvent, the absorbance 
of the remaining dye is then read in a spectrophotometer. The purple shade and the 
amount of heparin-dye complex produced depend on the concentration of heparin, 
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thus the presence of heparin is not only visibly determined, but it also can be quantified 
by comparing with a calibration curve. 
4.2.2.1 Calibration Curve 
The calibration curve is necessary to compare the results of the absorbance of the 
samples against the absorbance of known concentrations.  
A solution 0.05% of toluidine blue was prepared. For this purpose, 0.2 g of NaCl were 
dissolved in a 100 mL flask using deionized water. Once the NaCl was dissolved, 1 mL 
of HCl 1 N was added and let to stir for at least 10 minutes. Finally, 5 mg of toluidine 
blue (TB) dye were added and kept under stirring for another 15 minutes. The solution 
was diluted to 100 mL with deionized water.  
A set of 12 concentrations of heparin solution, from 0 to 140 µg/mL, were used for the 
preparation of the calibration curve. To prepare these solutions, 8 mg of heparin 
sodium salt were dissolved in 8 mL deionized water, stirring at room temperature. To 
prepare 50 mL of a solution with a concentration 160 µg/mL, the 1 mg/mL heparin 
solution was dissolved in a 50 mL volumetric flask. Next, a series of dilutions from this 
solution were prepared by adding the necessary amount of the 160 mg/mL solution 
and deionized water, as shown in Table 4.1. 
A set of clean 5 mL bijou container labelled according to the heparin concentration 
were prepared. 750 µL of TB solution were added to each tube. Subsequently, 250 µL 
of heparin solution were added to the corresponding concentration container and the 
mixture was swirled. These mixtures were left to rest for 30 minutes. Next, 750 µL of 
n-Hexane were added into each container, followed by a vigorous shake of the 
container for at least 30 seconds. The aqueous part of this mixture (bottom liquid) was 
taken out and placed it in a 96 well plate to be read. At least 2 replicates of each 
concentration were taken. 
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0 0.00 5.00 
10 0.3 4.7 
20 0.6 4.4 
30 0.9 4.1 
40 1.3 3.8 
50 1.6 3.4 
60 1.9 3.1 
70 2.2 2.8 
80 2.5 2.5 
100 3.1 1.9 
120 3.8 1.3 
140 4.4 0.6 
 
Table 4.1. Dilutions performed to prepare calibration curve. 
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Along with the calibration curve, the equation for the tendency line was obtained, this 





4.2.2.2 Quantitative Heparin determination protocol 
The study consisted of 3 sets of experiments with 2 replicates per each sample 
concentration. 
For this evaluation, a 0.05% toluidine blue solution was used. This solution was 
prepared in 100 mL volumetric flask by dissolving 5 mg of toluidine blue dye in an 
aqueous solution containing 0.2 g of NaCl and 1 mL of HCl 1 N. 
Seven time-intervals were tested according to the data show in Table 4.2. The same set 
of samples (which includes all the heparin concentrations) was evaluated on each 
designed interval. 
Interval ID Time 
T1 30 minutes 
T2 60 minutes 
T3 90 minutes 
T4 150 minutes 
T5 210 minutes 
T6 24 hours 
T7 48 hours 
T8 5 days 
 
Table 4.2. Intervals for toluidine blue assay. 
 
The cylindrical scaffolds were individually placed into test tubes adding 1 mL of 
deionized water into each tube, followed by incubation at 37 °C according to the test 
intervals mentioned before. 
The samples were taken out of the oven when the first time-interval was concluded. 
As soon as every time interval was finished, 250 µL of the incubation water were 
extracted from every sample tube ** and added into correspondent tubes containing 
Eq. 4.1 
Chapter 4: Characterisation 
82 
Griselda Valeria Nájera Romero ― June 2021 
750 µL of Toluidine Blue solution. Every tube was carefully swirled, so the incubation 
water is completely mixed with the Toluidine Blue solution. This process was followed 
by a 30-minute rest, after which 750 µL of n-Hexane were added into every tube and 
the mixtures were vigorously shaken for at least 30 seconds. The aqueous phase 
(bottom liquid) was removed and transferred into a clean 96 well plate for its reading. 
The absorbance of this phase was measured at 630 nm using a plate reader, the 
readings were compared to the results of a calibration curved previously elaborated. 
To obtain the correspondent amount of heparin Equation 4.1 was solved for x. The 
results for the scaffolds without heparin were considered as background, therefore, 
they were subtracted from the result. 
 
**NOTE: Once the 250 µL of incubation water were extracted, the samples were 
changed to new testing tubes with clean deionized water and taken back to the oven 
to complete the following time interval of the experiment until it is concluded, and the 
process was repeated.  
4.2.2.3 Qualitative Heparin determination protocol 
Another set of scaffolds, two per each heparin concentration, was separately immersed 
in 1.5mL of the 0.05% toluidine blue solution. The scaffolds were left to rest for 5 
minutes, followed by a wash with deionized water until no rests of the dye are 
observed in the washing water. The scaffolds were carefully dried using a tissue paper. 
Pictures of each scaffold were taken to verify the presence and distribution of the 
heparin on the scaffold by observing the purple shade. 
4.2.3 pH determination 
pH was measured using a Mettler Toledo GmbH, Analytical, FiveEasy PlusTM bench 
meter. The electrode was rinsed with distilled water, blotting the excess between every 
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use.  Subsequently the electrode is introduced in the solution until the pH value 
appears on the bench meter screen. 
4.3 Biological characterisation 
4.3.1 Cell viability 
Cell viability was evaluated through Alamar Blue assay. This method tests cell health 
and viability under the premise that living cells reduce the non-toxic reagent resazurin 
(blue and non-fluorescent) to resorufin (red and fluorescent). Therefore, an estimation 
of the living cells on time is performed by measuring the absorbance of their media. 
The cylindrical scaffolds were disinfected using 70% ethanol and 1 hour under UV 
light.  
Resazurin 1mM solution was prepared by dissolving 57.3 mg of Resazurin in 250 mL 
of sterilized PBS. 
 After disinfection, 30,000 cells of the line U2OS were seeded onto the scaffolds in a 24-
well plate. On days 1st, 4th, 9th and 14th  an Alamar blue ® assay was performed by 
changing the media where the scaffolds were suspended and adding the reagent (10% 
of the sample volume). By using a plate reader, the absorbance of each sample was 
obtained reading at 570 nm. Viability percentage was estimated considering the 
resultant absorbance for the cells growing in the well-plate without heparinized 
scaffold as the 100% of metabolic activity and the result for the media alone as the 0% 
of metabolic activity. 
Once the assay was performed, the solution was removed from all the wells of the well-
plate. Each scaffold was carefully washed three times with PBS to remove the colour 
from the Alamar Blue® assay. New cell media was added into each well and the well 
plate was returned to incubation.  
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During the test, media was weekly changed and after every cell viability evaluation, 
being replaced for fresh cell media. 
4.3.1.1 Cell culture 
The methodology to preserve the U2OS cells used for this evaluation was as described 
next. All these procedures must be performed inside a cell culture cabinet and using 
all the protective equipment, as well as performing the applicable disinfection 
protocols. 
4.3.1.1.1 Medium preparation 
For this particular methodology of cell culture, we use the DMEM (Dulbecco’s 
Modified Eagle Medium) with 10% of additives. 
 50 mL of the DMEM are taken out of the bottle. Subsequently the following additives 
are incorporated.  
- 50 mL of FCS (foetal calf serum) previously unfrozen. 
- PS (penicillin-streptomycin, 5 mL vial) 
- Glu (glutamine, 5 mL vial) 
The media should be gently mixed and kept stored in the fridge until use. 
4.3.1.1.2 Cell passage 
The media was completely removed from the T75 flask containing the cells. 
Subsequently, the T75 flask was washed twice using 5 mL of PBS each washing.  
Afterwards, Trypsin- EDTA solution was added into the flask and taken back to the 
incubator for 5 min. The purpose of this step is to remove the adhered cells. 
The flask was taken out of the incubator and observed under the light microscope, it is 
possible to gently shake the flask, if necessary, to help the detachment of the cells from 
the flask surface. 
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The cell containing Trypsin-EDTA is taken out of the T75 flaks and poured into a 
universal tube containing 5 mL of DMEM. Then, this tube was centrifuge at 1000 rpm 
for 5 min. During this process, a cell pellet should be formed at the bottom of the 
universal tube.  
The DME was carefully removed from above the cell pellet. Later, 5 mL of DMEM were 
added to softly resuspend the pellet, at this point, attention must be paid to avoid the 
creation of bubbles or foam during this process. 
10 mL of DMEM were poured into a new and clean T75 flask. Put the necessary volume 
of cell solution (according to the cell counting). The T75 flask was incubated at 37.5 °C. 
4.3.2 Angiogenic response ex-ovo  
During ex-ovo CAM assay (CAM stands for chorioallantoic membrane) the scaffolds 
were implanted on live chicken embryo. This assay provides an overview of the 
performance of the material in a live environment. The followed procedure was based 
on Mangir et al (2019) and Eke G. et al (2017), 130,131.  
Fertilized chicken eggs were carefully cleaned with 20% IMS solution prior its 
incubation at 37.5°C in a humidified chicken incubator. On the third day of incubation, 
the eggs were carefully cracked, the embryo was transferred into a sterilized petri dish 
containing 2mL of penicillin- streptomycin and kept in a humidified cell incubator at 
37.5°C (no carbon dioxide or any other gas was used in the cell incubator).   
The survival of the embryos as well as the consistency of the parameters (temperature, 
humidity) were daily checked and registered during the experiment.  
On the 6th day, the scaffolds were sterilized using 70% ethanol and 1 h under UV light. 
The implantation of the sterile scaffolds within the CAM of the embryo was performed 
on the 7th day by taking each egg one by one out of the incubator and placing individual 
scaffolds on the CAM space of the embryo as mentioned by Mangir et al. (2019).  
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Sample pictures were obtained on the 10th day and on the sacrifice day (13th day), using 
an electronic PC microscope.  
4.3.3 Histology 
To retrieve the samples, it was necessary to carefully cut the CAM tissue surrounding 
the scaffold. This has to be done as fast as possible to avoid the scaffold to be bled. 
Immediately afterwards the chicken embryo was sacrificed.  
Subsequently, the scaffolds were immersed in a bijou container with 5 mL of 3.7 % 
Formaldehyde solution for at least 12 hours. The fixed scaffolds were then slice-cut by 
using cryo-embedding technique (Leica), obtaining 10 μm slices. The slices were then 
stained using a regular haematoxylin & eosin protocol.  
Observation under light microscope was performed to examine vascular infiltration.  
4.4 Summary 
All the characterisation methods are focused on highlighting and evaluating the main 
characteristics of our system to ensure it is a suitable structure for bone regeneration. 
For instance, SEM provides useful information regarding the structure of the scaffolds, 
such as pore size and distribution. Likewise, toluidine blue assay offers a remarkable 
tool to quantify the net amount of heparin loaded during the study, which represents 
one of the main findings of this research. Finally, CAM assay allows to test the material 
in a living environment, which ultimately translates to a preliminary in vivo 
performance of the scaffolds.  
The next chapters contain the results obtained from these evaluations. 
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5 
Results and Discussion 
Section I:  
Exploring methodologies for fabrication of 
hydroxyapatite/chitosan composites enabling 
vascular infiltration 
 
Chitosan-hydroxyapatite composites have been reported in literature, however, to 
fabricate the architecture of the scaffold that would enable vascular infiltration and 
bone growth, it was important to test different methodologies and adapt them to 
satisfy our current requirements.  
Detailed descriptions of the methodologies are described and alluded to as 'Trials', 
under the different approaches attempted.  The first 5 'Trials' relate to the inclusion of 
carboxymethyl cellulose and the influence of pH, whilst 'Trials 6-9' describe and 
discuss the effect of freeze drying and freeze gelation methods and the suitability of 
these systems for incorporation of heparin.  
The final method used to fabricate the scaffolds was selected based on the results from 
these different trials, and it has been fully described in Chapter 3, section 3.2. 
 
5.1 Defining solution content: trials with carboxymethyl cellulose 
The use of carboxymethyl cellulose in combination with chitosan has been previously 
reported with successful results 132–136. The purpose of mixing the two polymers is 
mainly to improve mechanical properties of chitosan structures. Liuyun et al. (2009) 
reported scaffolds from nano-hydroxyapatite/chitosan/carboxymethyl cellulose for 
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bone tissue engineering. Their results show interconnected porosity, good mechanical 
strength and they allowed cell attachment and proliferation.  
Additionally, Chen et al. (2015) described the preparation of a biodegradable scaffold 
made from bioactive glass/chitosan/carboxymethyl cellulose for bone haemostasis 
and bone regeneration, exhibiting successful results for reconstruction of bone defects.  
For their part, Jiang et al. (2010) presented an option for preparation of a polyelectrolyte 
complex from chitosan/carboxymethyl cellulose/nano-hydroxyapatite for guided 
bone reconstruction with successful preparation results.  
In the following trials the results obtained from reproducing some reported 
methodologies are described, in order to adapt them to the purpose of creating a good 
scaffold for bone regeneration and incorporation of heparin to improve angiogenic 
performance. It is important to highlight that, since freeze-drying and freeze-gelation 
methodologies were considered for the preparation of the scaffolds, the formation of a 
solution that was completely homogeneous in appearance was crucial in these trials. 
Therefore, any result that did not appear homogeneous, was immediately discarded.  
5.1.1 Trial 1 
Scaffold preparation based on Liuyun, J. et al., J. Biom. Sci. (2009) 132 
A hydroxyapatite (HA) slurry was prepared by adding 4 g of HA into 146 mL of 
distilled water. It was left under stirring approximately for 1 hour. Meanwhile, 3 g of 
chitosan and 3 g of carboxymethyl cellulose powders were weighed and mixed in a 
flask. 
 Once the powders were evenly mixed and the slurry was homogenous in appareance, 
the powders mixture was carefully added into the slurry keeping the stirring. A big 
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lump was immediately produced from the addition of the polysaccharide powders 
(Figure 5.1). 
The mixture was kept under stirring for approximately 3 hours, until the lump was 
finally dissolved, and a homogeneous mixture was achieved. 
Subsequently, 3 mL of glacial acetic acid were added. Formation of small lumps was 







5.1.2 Trial 2 
The purpose of this study was to use freeze-drying or freeze-gelation methodology to 
prepare a porous scaffold. Therefore, a homogenous slurry is necessary to assure that 
the same composition can be found in any part of the scaffold. From the first trial, it 
was not possible to obtain a homogeneous slurry, due to the formation of lumps after 
the addition of acetic acid to the mixture of chitosan, hydroxyapatite and 
carboxymethyl cellulose. It was considered that the addition of acetic acid might have 
been very abrupt, therefore, for this trial this process was modified. 
Figure 5.1.  Slurry preparation of chitosan, 
hydroxyapatite and carboxymethyl cellulose. 
Figure 5.2.  Formation of small lumps within the 
slurry, after acetic acid addition. 
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This trial is based on scaffold preparation following Liuyun procedure. Liuyun, J. et al., 
J. Biom. Sci. (2009) 132 
To prepare a HA slurry, 1 g of HA was slowly added into 36.5 mL of distilled water. 
The solution was left to stir for approximately 2.5 hours. In another beaker, 1 g of 
carboxymethyl cellulose was dissolved in 34.5 mL of distilled water, by the gradual 
addition of the polysaccharide. After the carboxymethyl cellulose was dissolved, 1 g 
of chitosan powder was slowly added to this solution with a spatula. Once the chitosan 
was completely and homogeneously distributed in the carboxymethyl cellulose 
solution (approximately 1 hour of stirring), this solution was carefully added into the 








After adding all the carboxymethyl cellulose/chitosan solution in the HA 
slurry, this mixture was let under stirring for approximately 1 hour, until a 
completely homogenous solution was obtained. Then 1 mL of glacial acetic acid 
was slowly added, with the aid of a burette, keeping the stirring (Figure 5.4).  
Figure 5.3.  Addition of chitosan and 
carboxymethyl cellulose solution to 
the hydroxyapatite slurry. 
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5.1.3 Trial 3 
Despite the slow addition of acetic acid, clumps were formed in trial 2. To avoid an 
abrupt change of pH due to the addition of glacial acetic acid, it was decided to reduce 
its concentration by preparing an aqueous solution. Therefore, a 2% acetic acid 
aqueous solution was prepared. Additionally, chitosan was previously dissolved in 
this 2% acetic acid aqueous solution prior its mixing with carboxymethyl cellulose.  
This trial is based on Liuyun, J. et al., J Mater Sci: Mater Med (2009). 137 
Using 50 mL of an acetic acid solution 2%, 1 g of chitosan was dissolved under constant 
stirring. At the same time, 1 g of carboxyethyl cellulose was dissolved in 50 mL of 
distilled water at room temperature, by slowly adding the powder to the water. 
Figure 5.4.  Addition of acetic acid to the slurry. Figure 5.5.  Final slurry full of lumps. 
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Once the carboxymethyl cellulose was completely dissolved in the water, 1 g of HA 
was gradually added into this solution, keeping the stirring for approximately 1.5 
hour, to obtain a homogeneous distribution of the HA. 
When the HA was completely distributed in the carboxymethyl cellulose solution, the 
addition of the chitosan solution was started using a dropping funnel. 
Once the chitosan solution became in contact with the carboxymethyl cellulose 
solution, beads of chitosan were formed from the drops that have fallen into the 









5.1.4 Trial 4 
It was observed that the interaction between the carboxymethyl cellulose was strongly 
abrupt, causing the formation of the beads instead of a uniform mixture. Therefore, 
another method, based on Jiang, H. et al., J Mater Sci: Mater Med (2011) 133, was 
considered. 
Figure 5.6.  Bead formation when chitosan solution is added to the 
carboxymethyl cellulose and hydroxyapatite solution. 
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For this, 1 g of carboxymethyl cellulose was dissolved in 100 mL of distilled water, by 
slow addition and constant stirring. In the meantime, 50 mL of HA slurry were 
prepared by pouring 2 g of HA in distilled water. Once the slurry was homogeneous, 
1 g of chitosan was carefully added into it and the mixture was left under stirring for 
approximately 1 hour). When a homogeneous solution was obtained, the 
carboxymethyl cellulose solution was gradually added with the aid of a dropping 
funnel and was left to stir for 2.5 hours. Jiang, H. et al. stated that to prepare this 
solution, pH should be kept between 5 – 5.2. Therefore, with the aid of a burette, the 
addition of 2% acetic acid solution was carefully started, keeping this mixture under 
vigorous stirring and the temperature between 26 and 27 °C. The pH was constantly 
measured, when a pH of 5.87 was reached, a thicker mixture was observed. After 10.3 
mL of the 2% acetic acid aqueous solution was added, the pH reached a value of 5.18 
and the addition was stopped. The mixture was kept under stirring for 15 more 
minutes more until the solution was poured into a plate. The consistency of the mixture 










Figure 5.7.  The addition of acetic acid causes the appearance of lumps and a 
heterogeneous mixture when the pH reached 5.18. 
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5.1.5 Trial 5, the influence of pH 
During trial 4 a homogenous solution was not observed. Therefore, to verify the 
influence of the pH on the homogeneity of the resultant mixture, different variations 
of the amount of acetic acid added to the solution, and consequently variations on the 
pH were tested. 
This trial is based on Jiang, H. et al., J Mater Sci: Mater Med (2011). 133. 
1 g of carboxymethyl cellulose was dissolved in 500 mL of distilled water by slow 
addition and constant stirring. In the meantime, 50 mL of HA slurry were prepared 
using 1 g of HA in distilled water. Once the slurry was homogeneous, 1 g of chitosan 
was carefully added into it. When a homogeneous solution was obtained 
(approximately 2 hours of stirring), the carboxymethyl cellulose solution was 
gradually added with the aid of a dropping funnel and was left to stir for 3 hours.  
A pH value of 7.834 was measured to this slurry. Subsequently, with the aid of a 
burette, 2% acetic acid solution was added at a rate of 1 mL/3 min to this mixture 
under vigorous stirring and keeping the temperature between 27 and 28 °C.  
The paper mentions that pH should be kept between 5 and 5.2, therefore acetic acid 
solution was added to control the pH in the slurries, until 4 different pH were 
observed: 5.641 (before the threshold mentioned in the paper), 4.897, 4.843 (just below 
the threshold) and 4.290 (more acidic media). These slurries were used to compare the 
results with our previous sample of this method which has a pH of 5.185 (Figure 5.8). 
The most homogeneous gel was found between a pH of 5 - 4.85. Though undissolved 
powder remained in the solution. 
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5.1.6 Conclusions from the trials using carboxymethyl cellulose 
After these trials it was decided to avoid the use of carboxymethyl cellulose in the 
fabrication of the composites. The aim of using of carboxymethyl cellulose was to 
improve the mechanical properties of the scaffold. However, the electrostatic 
interaction between chitosan and carboxymethyl cellulose is strong, producing 
precipitation and/or irregular mixtures. The homogeneity of the mixture was an 
important parameter because this mixture is going to be used with freeze-gelation and 
freeze-drying for scaffold formation.  
In previous works, Jiang et al. (2011) compared the use of different methodologies to 
prepare chitosan/carboxymethyl cellulose/nano-hydroxyapatite membranes. They 
studied gradual electrostatic assembling (GEA), solution blending method and layered 
casting method. Ultimately GEA gave the most successful results, providing 
homogenous membranes, unlike the other two methods in which the electrostatic 
interactions between chitosan and carboxymethyl cellulose did not allow the formation 
of uniform structures 133. Therefore, choosing the appropriate method to produce the 
scaffolds is crucial when working with these two polymers.  
(a) (b) (c) (d) (e) 
Figure 5.8.  The effect of pH in forming carboxymethyl cellulose + chitosan + HA composites. 
5 different pH values were tested (a) 5.641, (b) 5.185, (c) 4.897, (d) 4.843 and (e) 4.290. 
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During the trials, variations of the pH provided the targeted response to eliminate 
precipitation formation. However, pH interval is short, and depends on several 
variables. Furthermore, the pH interval that provided a more homogeneous solution 
is a value for hydroxyapatite’s dissolution in acidic media (pH <5) 138. Therefore, if 
hydroxyapatite were added to the solution, it would probably become unstable, due 
to an excessive protonation of its lattice. 
Another drawback is that precipitation and particle aggregation add one step to the 
process. Because, even when the lumps and clusters can be filtered and processed, it is 
ideal to provide a process as simple as possible (thinking about future 
industrialization). 
Additionally, and most importantly, this strong force interaction would be a setback 
to add the heparin. Heparin possesses a negative charge, which, coming to this 
interplay of strong charge interactions, would have hindered its integration to the 
system. Therefore, for further protocols, carboxymethyl cellulose was not tested nor 
considered in this work.  
 
5.2 The effect of chitosan: hydroxyapatite ratio in 
fabricating scaffolds using freeze-drying  
One important aspect to consider for the fabrication of the scaffold was the ratio of 
chitosan and hydroxyapatite, which ultimately defines all the interactions within the 
composite. The following trials describe the methodologies compared to define the 
best chitosan: hydroxyapatite ratio to work for the bioactive scaffold’s fabrication. Two 
main phases can be considered: the preparation of the scaffold via freeze-drying and 
the process of loading heparin onto the scaffolds to functionalize them for 
revascularization purposes.  
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One important factor considered during these trials was the malleability of the 
resultant scaffolds. This was important since the fabrication involves cutting the 
material into small pieces for the implantation purposes. Therefore, it was key that the 
obtained composite material allowed an easily cutting process. 
5.2.1 Trial 6 
This trial is based on methodology followed from Koç, A. et al., J. of Biom. Appl. (2014) 
139 to prepare freeze-dried scaffolds.  
50 mL of a mixture 80:20 of chitosan: hydroxyapatite was obtained by dissolving 2 g of 
chitosan and 0.5 g of hydroxyapatite in 47.5 mL of 2% acetic acid solution. 
A second solution, with a ratio of 50:50 chitosan: hydroxyapatite, was also prepared 
by dissolving 1.25 g of chitosan and 1.25 g of hydroxyapatite in 47.5 mL of acetic acid 
solution 2%.  
To prepare the previously mentioned solutions, chitosan was slowly added to the 
acetic acid solution 2%. Once it was completely dissolved, the solution was left to stir 
for approximately 2 hours. Then, the hydroxyapatite powder was slowly poured to the 
solution and left to stir overnight for full incorporation. Obtaining the mixtures 








Figure 5.9.  Chitosan/Hydroxyapatite solutions. Chitosan: hydroxyapatite 80:20 ratio is observed on the 
left, while 50:50 ratio is presented on the right. The appearance of a homogenous slurry can be observed. 
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Both solutions were frozen at -30° C for 12 hours. Subsequently, these solutions 
were freeze-dried at -15 °C with a pressure of 0.520 mbar for 29 hours. And 
finally, left on aeration for 40 hours.  
The scaffolds shown in Figure 5.10 were obtained by this methodology. It is 
important to notice that the scaffold with higher hydroxyapatite content was 








Figure 5.10. Scaffolds prepared using the methodology described in Trial 6. In the image on the right 
chitosan: hydroxyapatite 80:20 ratio is observed, while 50:50 ratio is presented on the right. Both 




Treatment 1: Immersion in a 1M NaOH solution for 5 h 
The following treatment for these materials was to immerse them into a 1M 
NaOH in absolute ethanol solution for 5 hours to remove acetic acid residues 
(Figure 5.11).  
Afterwards, the scaffolds were washed with distilled water for approximately 
3 minutes and underwent freeze drying again, to remove the remaining 
moisture. 
For the moisture removing process, the scaffolds were frozen for -25 °C for 5 hours. 
Later, the drying began at -10 °C and a pressure of 0.520 m bar for 13 hours.  
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Figure 5.11.  Scaffolds obtained by methodology of Trial 6 during immersion in 1M NaOH. In 
the image on the right chitosan: hydroxyapatite 80:20 ratio is observed, while 50:50 ratio is 
presented on the right. 
 
As a result of these treatments, the scaffolds became hardened in appearance (Figure 








Figure 5.12.  Appearance of the scaffolds obtained from Trial 6 methodology after following a 
1M NaOH immersion treatment. Scaffolds shown on the right have a chitosan: hydroxyapatite 
80:20 ratio, while 50:50 ratio is presented on the right. Image on the top present the top sides, 
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5.2.2 Trial 7 
The scaffold should have a malleable structure because they are to be cut into smaller 
pieces using a cork borer for the subsequent heparin loading and biological 
characterization. The methodology followed in Trial 6 indicated that the treatment of 
the freeze-gelled chitosan: hydroxyapatite scaffolds with sodium hydroxide solution 
affected the scaffold's structure. Hence the trial 7 experiments were aimed to determine 
the effect of the concentration of sodium hydroxide solution, the number of washing 
cycles and freeze-drying on the obtained scaffolds.  
This trial is based on work reported by Koç, A. et al., J. of Biom. Appl. (2014) 139. 
A 200 mL of 2 % acetic acid solution was prepared by drop-wise adding 4 mL of glacial 
acetic acid in 20 mL of distilled water. Once acetic acid was completely added, the 
solution was diluted with enough distilled water to make a 200 mL solution. 
A solution of chitosan and hydroxyapatite, ratio 80:20, was prepared by dissolving 4 g 
of chitosan and 1 g of hydroxyapatite in 95 mL of the acetic acid solution 2%. 
Similarly, a solution of chitosan and hydroxyapatite, ratio 50:50, was prepared by 
dissolving 2.5 g of chitosan and 2.5 g of hydroxyapatite in 95 mL of the acetic acid 
solution 2%. 
For the preparation of the abovementioned mixtures, the chitosan was lowly added to 
the acetic acid solution. Once the powder was completely dissolved, the solution was 
left to stir for 3.5 hours. The resultant mixture turned into a clear-gold viscous liquid 
(Figure 5.13). Then, hydroxyapatite was slowly added and left to stir overnight to be 
fully incorporated (Figure 5.14). 
Subsequently, the mixtures were poured into petri dishes (Figure 3.18) and frozen at -
30 °C for approximately 12 hours. 
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The freeze-drying process was started at -15 °C and 0.520 mbar for 37 hours. After the 
main drying process was turned off, aeration was allowed for 24 hours. The obtained 
sponge-like scaffolds are shown in Figure 5.16. For both chitosan: hydroxyapatite 
ratios, the appearance is of multiple sheets joined together to form the scaffold. 
 








Figure 5.13.  Proper dissolution of chitosan in 
acetic acid solution 2% shows a clear-gold 
appearance. 
Figure 5.14.  Chitosan solution after 
adding the hydroxyapatite, turns into a 
white solution. 
Figure 5.15.  Chitosan and hydroxyapatite homogeneous solutions with ratios 80:20 
(top dishes) and 50:50 (bottom dishes). 
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Additionally, these scaffolds were submitted for one of the following of treatments. 
No treatment 
One scaffold of each chitosan: hydroxyapatite (CS: HA) ratio was stored without any 
treatment. 
Treatment 2: Washing scaffolds with distilled water 
One scaffold of each ratio was washed with distilled water (running water) for around 
3 minutes. It was not possible to continue washing the scaffolds longer because they 
started to dissolve and lost mechanical stability. pH was measured as described in 
section 4.2.3. pH did not change much after washing Table 5.1). The scaffolds were 
frozen at -20 °C for approximately 2 hours. After this time, they were freeze-dried at -












Figure 5.16.  Chitosan/ hydroxyapatite sponge-like scaffolds. Ratio 
80:20 is shown on the left and 50:50 on the right. 
 
Table 5.1.  Treatment 1, pH changes after washing the scaffolds with distilled water. 
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Treatment 3: Immersion in a 0.1M NaOH solution for 1.5 h 
One scaffold of each CS: HA ratio were immersed (separately) in 0.1 M NaOH/ethanol 
solution for 1.5 hours. The pH of the NaOH/ethanol solution was 13.095. At the end 
of the immersion, shrinkage on the scaffolds was observed. The scaffolds were taken 
out of the solution and washed with distilled water until the water reaches a neutral 












Subsequently, the scaffolds from both treatments were frozen at -25 °C for 5 hours. 
Followed by the drying process at -10 °C and 0.520 mbar for 13:33 hours. 
It is important to mention that all the treated scaffolds turned stiff (Figure 5.17). All 




Images of the dried scaffolds were taken though a magnifying glass to observe their 
macroscopic structure. The images are presented in Figures 5.18 to 5.21, with view 
from the top (A) and a view from their lateral side (B).  
Table 5.2.  Treatment 3, pH changes after washing the scaffolds with distilled water. 
 
Figure 5.17. Resultant scaffolds from the following treatments: (A) scaffolds washed with distilled 
water and (B) scaffolds immersed in a 0.1 M NaOH solution. Scaffolds of chitosan: hydroxyapatite 
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Figure 5.18. Macroscopic structure of the resultant scaffolds from trial 7 after treatment 1: Immersed in 
NaOH 1M, for 5 hours, washed with distilled water. A sheet-like arrangement is observed on the top 
faces of the scaffold. Chitosan: hydroxyapatite ratio of 80:20 can be observed on the left, while the 50:50 









Figure 5.19. Macroscopic structure of the resultant scaffolds from trial 7 after treatment 2: Washed with 
distilled water for 3 minutes. It is possible to notice a sponge-like structure on the top faces of the 
scaffold. Chitosan: hydroxyapatite ratio of 80:20 can be observed on the left, while the 50:50 ratio is 







Figure 5.20. Macroscopic structure of the resultant scaffolds from trial 7 after treatment 3: Immersed in 
NaOH 0.1M, for 1.5 hours. Smaller ordained sheets can be seen on the top faces of the scaffolds, lateral 
faces present porosity. Chitosan: hydroxyapatite ratio of 80:20 can be observed on the left, while the 
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Figure 5.21. Macroscopic structure of the resultant scaffolds from trial 7 without any posterior treatment. 
Longer and less tighten sheets are observed from this treatment. Chitosan: hydroxyapatite ratio of 80:20 
can be observed on the left, while the 50:50 ratio is presented on the right. 
 
The appearance of stacked small sheets can be observed throughout all the images 
from Figures 5.18- 5.21. The rapid freezing during the beginning of the freeze-drying 
process causes the chitosan/hydroxyapatite solution to arrange in sheets. It is possible 
to observe that these sheets arrange and pack differently according to the NaOH 
treatment received. The purpose of the NaOH treatment is to neutralize the scaffold 
by deprotonating chitosan, which makes it less soluble in aqueous solutions. The 
presence of positive charges along the chitosan matrix, repelling each other, causes an 
effect on the arrangement of the chitosan/hydroxyapatite sheets. Due to this effect, a 
longer exposure to NaOH results in closely packed sheet, compared to those without 
treatment that appeared more loosely packed. 
 
SEM images of scaffolds that were immersed in a 1M NaOH solution for 5 h and 
scaffolds without treatment were obtained to compare the effect of the NaOH/ethanol 
solution on the scaffold structure. Figure 5.22 shows a comparison of the distribution 
of hydroxyapatite along the chitosan matrix for the two chitosan: hydroxyapatite 
ratios.  
NaOH did not appear to have an effect on hydroxyapatite distribution along the 
chitosan matrix. In general, regardless of the NaOH treatment, the appearance of the 
80:20 50:50 
Top Lateral Top Lateral  
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scaffolds was as represented in Figure 5.22, i. e. the distribution of hydroxyapatite 
particles was similar to all the scaffolds no matter the NaOH treatment, with 
hydroxyapatite particles consistently distributed throughout the entire chitosan 
matrix. It is possible to observe a denser presence of the hydroxyapatite in the 50:50 










Figure 5.22. Hydroxyapatite distribution on the scaffold matrix for chitosan: hydroxyapatite ratios (A) 
80:20 and (B) 50:50. Scale bars are 10 μm. Arrows point at HA particles. These two images are for the 
scaffolds treated with 1 M NaOH for 5 h, but are representative of the HA distribution for all the NaOH 
treatments. It is possible to observe the presence of hydroxyapatite particles distributed throughout the 
entire chitosan matrix.  
  
Additionally, Figure 5.23 shows the impact of the NaOH/ethanol solution on the 
chitosan/hydroxyapatite structure, which was previously mentioned before. It is 
possible to observe that porosity on the laterals was conserved. However, for the 
scaffolds with longer exposure to NaOH, the sheet-like appearance closed down and 
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Figure 5.23. Impact of the NaOH/ethanol treatment on the scaffold’s structure for both component 
ratios. Images of the top surfaces of the scaffold show the appearance of packed sheets, with a tighten 
packaging in the scaffolds with longer exposure to NaOH. The side views provide a general idea of the 
porosity changes with the NaOH treatment, were a closed and disorganised porosity is observed for 
scaffolds with longer exposure to NaOH and higher HA content. Bottom surfaces show less porosity 
than the rest of the scaffold surfaces. All scale bars represent 100 µm. White arrows point at HA 
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Following the treatments, the scaffolds were cut in small cubes of approximately 3 mm 
per side, to be loaded with heparin. Afterwards, two heparin solutions were prepared, 
one with the concentration of 1mg/mL by dissolving 120 mg of sodium heparin salt in 
120 mL of distilled water and the other one with 3 mg/mL by dissolving 360 mg of 
sodium heparin salt in 120 mL of distilled water. The solutions were left to stir for 
approximately 2 hours at room temperature. 
From every treatment, two groups of the cut scaffolds were separated, one was 
completely immersed in the heparin solutions of 1mg/mL for 1 hour and the other of 
3 mg/mL for 3 hours. Once the immersion time was concluded, the solution excess 
was blotted, and the scaffolds were freeze-dried at -30 °C overnight.  
The resultant scaffolds were analysed by FTIR- ATR to analyse the chemical 
composition and the presence of heparin. Since there are several combination from the 






Immersed in a 1M NaOH solution for 5 h + 
Immersed in heparin solution (1mg/mL)for 1 h 
CHHE11 
50:50 
Immersed in a 1M NaOH solution for 5 h + 
Immersed in heparin solution (1mg/mL)for 1 h 
CHHE12 
80:20 
Immersed in a 0.1M NaOH solution for 1.5 h + 
Immersed in heparin solution (1mg/mL)for 1 h 
CHHE13 
50:50 
Immersed in a 0.1M NaOH solution for 1.5 h + 
Immersed in heparin solution (1mg/mL)for 1 h 
CHHE14 
80:20 
Washed with distilled water for 3 min + 
Immersed in heparin solution (1mg/mL)for 1 h 
CHHE15 
50:50 
Washed with distilled water for 3 min + 
Immersed in heparin solution (1mg/mL)for 1 h 
CHHE16 
80:20 
None + Immersed in heparin solution 
(1mg/mL)for 1 h 
CHHE17 
50:50 
None + Immersed in heparin solution 
(1mg/mL)for 1 h 
CHHE18 
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80:20 
Immersed in a 1M NaOH solution for 5 h + 
Immersed in heparin solution (3mg/mL)for 3 h 
CHHE31 
50:50 
Immersed in a 1M NaOH solution for 5 h + 
Immersed in heparin solution (3mg/mL)for 3 h 
CHHE32 
80:20 
Immersed in a 0.1M NaOH solution for 1.5 h + 
Immersed in heparin solution (3mg/mL)for 3 h 
CHHE33 
50:50 
Immersed in a 0.1M NaOH solution for 1.5 h + 
Immersed in heparin solution (3mg/mL)for 3 h 
CHHE34 
80:20 
Washed with distilled water for 3 min + 
Immersed in heparin solution (3mg/mL)for 3 h 
CHHE35 
50:50 
Washed with distilled water for 3 min + 
Immersed in heparin solution (3mg/mL)for 3 h 
CHHE36 
80:20 
None + Immersed in heparin solution 
(3mg/mL)for 3 h 
CHHE37 
50:50 
None + Immersed in heparin solution 
(3mg/mL)for 3 h 
CHHE38 
 
Table 5.3. Identification of the samples according to their treatment and heparin loading concentration. 
 
Heparin presents peaks at around 1230-1220 cm-1 corresponding to the asymmetric 
stretching of sulphate groups (SO3- asymmetric stretching). Another characteristic 
sulphate peak has been reported at around 1040-1020 cm-1 corresponding to the 
symmetric stretching of sulphate groups. However, in our chitosan: hydroxyapatite 
scaffolds this last peak may be hindered by the presence of the phosphate υ3 peak of 
hydroxyapatite, present at 1190-976 cm-1.  
The FTIR spectra of the scaffolds loaded with 1 mg/mL of heparin concentration are 
presented in figures 5.24-5.27. Each figure shows a comparison between the spectra of 
the two chitosan: hydroxyapatite ratios tested 80:20 and 50:50. The main peaks 
associated with the presence of heparin were not observed for the 1 mg/mL heparin 
loading concentration. 
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Figure 5.24. FTIR-ATR spectra of the scaffolds immersed in the NaOH 1M and loaded in the heparin 










Figure 5.25 FTIR-ATR spectra of the scaffolds immersed in the NaOH 0.1M and loaded in the heparin 
sodium salt solution (1mg/mL) for 1 h. Ratios 80:20 and 50:50, respectively. 
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Figure 5.26 FTIR-ATR spectra of the scaffolds washed with distilled water and loaded in the heparin 













Figure  5.27 FTIR-ATR spectra of the scaffolds without a treatment and loaded in the heparin sodium 
salt solution (1mg/mL) for 1 h. Ratios 80:20 and 50:50, respectively. 
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The FTIR spectra of the scaffolds that were loaded with a higher concentration of 
3mg/mL of heparin are shown in Figures 5.28-5.31. A low intensity peak was observed 
at 1225 cm-1 in these spectra, associated with the sulphate asymmetric stretching 




Figure 5.28. FTIR-ATR spectra of the scaffolds immersed in the NaOH 1M and loaded in the heparin 
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Figure 5.29. FTIR-ATR spectra of the scaffolds immersed in the NaOH 0.1M and loaded in the heparin 













Figure 5.30. FTIR-ATR spectra of the scaffolds washed with distilled water and loaded in the heparin 
sodium salt solution (3mg/mL) for 3 h. Ratios 80:20 and 50:50, respectively. 
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Figure 5.31. FTIR-ATR spectra of the scaffolds without treatment and loaded in the heparin sodium salt 
solution (3mg/mL) for 3 h. Ratios 80:20 and 50:50, respectively. 
 
5.2.3 Conclusions from trials using different chitosan: 
hydroxyapatite ratio using freeze-drying methodology 
Freeze-drying method is a procedure that removes moisture from a frozen solution. 
Sublimation of the ice crystals of the solution produces a porous solid structure.  
According to Levengood & Zhang (2014) and O’Brien et al (2004), porosity during 
freeze-drying depends on the cooling rate used to freeze the solution. The faster the 
rate and the lower the temperature, the smaller the porosity achieved. This is mainly 
due to the nucleation and growth of the ice crystals not being uniform during 
quenching (fast cooling) 79,140.  
Images from the macrostructure of the scaffold, Figures 5.18-5.21, show the appearance 
of a laminated matrix with pores in the top and lateral views of the scaffold. SEM 
images shown in Figure 5.23 show that for the lateral surface of freeze-dried scaffolds 
of 80:20 CS:HA ratio, a very small  porosity was achieved, with pore size of between 
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9.39 and 29.21 µm, with an average of 17.55 µm. On the other hand, the sheets observed 
from the top surface of the scaffold presented a separation between 27.47 and 85.12 
µm, with an average of 44.82 µm. This is the result of the rapid cooling rate.  
Another important aspect to highlight, is the influence of hydroxyapatite in the 
resultant structure. Firstly, the distribution of the hydroxyapatite was not even along 
the chitosan matrix. As observed in Figure 5.23, the materials with 80:20 chitosan: 
hydroxyapatite ratio presented aggregation of hydroxyapatite in different parts of the 
chitosan matrix. However, the distribution of the phosphate for the 50:50 ratio was 
more uniform, and the phosphate was present throughout the matrix, without forming 
clusters. On the other hand, hydroxyapatite considerably reduced the porosity of the 
scaffolds. In the images showed in Figure 5.23, it is notable that for scaffolds with a CS: 
HA ratio of 50:50 there is an almost null porosity in the bottom surfaces, the appearance 
of a smooth surface is noteworthy. It is possible to observe the matrix arrangement as 
sheets, however the space between them is short, with a separation range of 6.48 to 
37.65 µm, with an average of 16.58 µm if any space was observable.  
This was mainly caused by the presence of the charge interaction: negative from 
hydroxyapatite and positive from chitosan, that helps to distribute the phosphate on 
the polymer matrix. However, increasing the amount of the hydroxyapatite creates a 
stronger interaction which closes down the already tight porosity from the quenching 
process.  
Current research is still on going to look for the importance of porosity in bone tissue 
engineering scaffolds. The result has shown that both microporosity and 
macroporosity play an important role for the best performance of the scaffolds. 
Microporosity has been defined as the presence of pores of size <10 μm, while 
macroporosity includes the presence of pores >100 μm 141. The importance of 
macroporosity lays on the fact that macropores provide the necessary pore size for cells 
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to migrate, infiltrate, organize and proliferate without space restrictions 142,143. On the 
other hand, microporosity has proven to provide several factors for cell maintenance. 
Among them we can count the presence of different proteins that are necessary to 
stimulate different osteogenic functions of cells such as attachment, proliferation, and 
mineralization. Microporosity provides enough surface area to allow the presence of 
more protein adsorptions sites. However, it has been observed that an excess of 
micropores can have an unbeneficial effect in bone-cells development 141,144. Therefore, 
a synergistic presence of both pore sizes should be present for a successful bone tissue 
engineering scaffold. Thus, regardless of providing good stimulation for cell 
maintenance, the resultant scaffolds from these procedures, may not offer an optimal 
structure for cell migration and development.  
Furthermore, the neutralization with NaOH is usually performed to improve the 
degradation characteristics of the material. Neutralization process deprotonates 
chitosan reducing its charge and making it less prone to solubility in an aqueous 
media, therefore, delaying its degradation. In these trials, the treatment with NaOH 
affected mainly two features: porosity and heparin detection. 
Firstly, from Figure 5.23 it is remarkable that the porosity from the top surfaces of the 
scaffolds appeared more closed after the NaOH treatment, this is also attributed to the 
charge interaction that occurs with NaOH, where the strong interaction of OH- with 
protonated NH3+, closes down the porosity. 
On the other hand, the treatment with NaOH defined the heparin detection with FTIR. 
As previously mentioned, this treatment reduces chitosan’s protonation produced 
during its solubilization. In the FTIR spectra presented in Figures 5.24-5.30, the 
presence of peaks from both compounds can be observed: the phosphate groups from 
hydroxyapatite and the amino and alkyl groups from chitosan. However, the presence 
and intensity of the sulphate group was decided by the NaOH treatment.  
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Thus, it is possible to observe that for the scaffolds immersed for a long period in the 
NaOH solution with higher molarity (1 M), the peaks related to the sulphate groups 
have a very low intensity, if any can be observed. The very low concentration of 
heparin loaded onto theses scaffolds fails to show any discernible peaks. On the other 
hand, the scaffolds treated with the NaOH solution of lower molarity (0.1 M), exhibited 
sulphate peaks of the highest absorbance. This can be explained by the reduction in 
concentration and time of exposure to NaOH solutions reduced the deprotonation of 
chitosan, allowing to provide enough groups for the heparin to bind, therefore 
providing higher intensity peaks associated with the presence of heparin.  
Regarding the scaffolds that were not neutralized with the NaOH treatment, the 
intensity of the sulphate peak related to heparin depended on the time of immersion 
in the heparin solution. For these scaffolds, it was possible to observe a relatively 
higher intensity in the sulphate groups for the scaffolds immersed in the 3mg/mL 
heparin solution for 3 hours comparing to the intensity of the peaks for the scaffolds 
immersed in the 1mg/mL heparin solution, which do not show any noticeable 
sulphate peaks. 
5.3 The effect of using freeze-gelation method for 
fabricating chitosan/hydroxyapatite scaffolds  
The following trials describe the methodologies compared to consider the use of 
freeze-gelation methodology to prepare the scaffolds. Two main phases can be 
considered: the preparation of the scaffold via freeze-gelation and the process of 
loading heparin onto the scaffolds to functionalize them for vascularization promotion 
purposes.  
Chapter 5: Results and Discussions. Section I 
 
118 
Griselda Valeria Nájera Romero ― June 2021 
5.3.1 Trial 8: Preparation of chitosan/hydroxyapatite scaffolds via 
a known freeze-gelation methodology 126. 
Previous trials explore the effects of using freeze-drying in the fabrication of the 
scaffolds, showing that the resultant scaffolds may provide unsuitable porosity for the 
purpose of this project. Therefore, it was considered that the use of freeze-gelation 
since, as mentioned in section 3.2.1, the porosity can be controlled during the freezing 
process, besides this methodology presents some advantages over freeze-drying such 
as energy consumption and absence of skin formation.  
The following procedure was followed to prepared freeze-gelled scaffolds. 
150 mL of a 1.5 % chitosan solution were prepared using 0.2 M acetic acid solution, 150 
mL chitosan solution was prepared by adding the 2.25 g chitosan powder to the 
distilled water at 50°C. The solution was left to stir for 1 h, after which the heat was 
turned off. Subsequently, a 1.72 mL of acetic acid was added drop-wise to form a 0.2 
M acetic acid solution. The mixture was left under stirring for approximately 20 h.  
A second solution was prepared by adding the chitosan in the distilled water at 50°C. 
The solution was left to stir for 1 h after which the heat was turned off. Then the 1.7 
mL of acetic acid was added drop-wise to form a 0.2M solution. The solution was left 
under stirring for 6h. After this time, 4.5 g of hydroxyapatite were added, and the new 
mixture was left under stirring overnight (approximately 13h). 
Once both solutions were prepared, the solution of just chitosan was poured in a petri 
dish and left in the freezer at -4 °C for 1 h. Following this time, the temperature was 
decreased another 4°C (reaching a temperature of -8°C) and the solution was left in the 
freezer for another hour. 
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Subsequently, the slow addition of the solution of chitosan and hydroxyapatite was 
started. And both solutions were kept at -8°C for another hour (Figure 5.32). Following 
this time, the temperature was decreased by -4 °C each hour until a temperature of -







Figure 5.32. Mixture formed after the addition of the chitosan and chitosan/hydroxyapatite solutions. 
 
The frozen solutions were removed from the plastic petri dishes by gently pressing the 
edges, a frozen disc was formed. Subsequently, the frozen disc was immersed in a 3 M 
NaOH/ethanol solution and was kept at -20°C for 12 h. 
After removing the disc from the NaOH/ethanol solution, it was subjected to series of 
washing using the following protocol: 
a) 15 minutes with distilled water. 
b) 15 minutes with PBS. 
c) 15 minutes with 80% ethanol solution. 
d) 15 minutes with 100% ethanol. 
Finally, the product was left uncovered in the hood overnight to dry. 
The resultant scaffold turned mechanically stiff, i. e. not malleable to be but into 
smaller scaffolds. 
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5.3.2 Trial 9: Modification of the freeze-gelation methodology to 
allow heparin addition  
From the previous trial, it was observed that resultant scaffolds were not easy to 
manipulate, as they were very stiff (as previously mentioned, stiffness is not a desirable 
feature for our further ends). The purpose of this trial was to observe the influence of 
the washings on the mechanical properties of the scaffolds, as differences were noticed 
during the washes with NaOH in trials 6 and 7. This trial was based on Qasim, S. B. et 
al (2015) 126, with some modification to observe the effect on the heparin loading. 
A 1.5 g of chitosan was poured into distilled water warmed at 50°C and stirred during 
1h, followed by the addition of 1.14 mL of acetic acid to form a solution 0.2 M (Figure 
5.33 section A). The mixture was left to stir for 6 h at room temperature. After this time, 
1.5 g of hydroxyapatite were added, and the solution was left under constant stirring 
overnight (approximately 13 h) for complete distribution of the hydroxyapatite.  
On the following day, the solution was poured in plastic petri dishes. The appearance 
of the solution was homogeneously white (Figure 5.33 sections B and C). The solution 














Figure 5.33. (A) Addition of acetic acid to the chitosan mixture. (B) Chitosan/hydroxyapatite slurry 
being poured into plastic petri dishes. 
A B 
C 
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Subsequently, the temperature was decreased by 4 °C every 1.5 h until the fridge shelf 
reached -20°C. The solution was kept under these conditions for 25 h. 
During this interval, the NaOH/ethanol 3 M solution was prepared. To prepare 500 
mL of this solution, first, 60 g of NaOH were poured into 250 mL of ethanol in a beaker 
until saturation. Followed by the addition of 200 mL of ethanol under constant stirring. 
Once the remaining pearls of the NaOH were completely dissolved the solution was 
diluted to 500 mL with more ethanol. This solution was kept at -20°C until its use.   
The frozen chitosan/hydroxyapatite solution was carefully removed from the petri 
dishes by gently pressing the edges of the dish. The frozen discs were transferred to a 
bigger glass petri dish (Figure 5.34 section A), and the precooled NaOH/ ethanol 
solution was slowly added until completely cover the discs (Figure 5.34 section B). 
The frozen discs were removed from the NaOH/ethanol solution and two treatments 
were performed on the material, one to each disc: 
 
Treatment 1 (Qasim, et al (2105) 126) Treatment 2 (Modification) 
The disc was washed with deionized water 
for 5 min 
The disc was washed with deionized water 
during 20 min. 
Put in PBS solution for 15 min Put in PBS solution for 5 min 
Washed several times with different 
concentration of ethanol (15 min per 
concentration wash): 
70%, 80%, 90%, 95%, 100% 
Washed with ethanol (15 min per 
concentration wash): 
80% and 90% 
Finally, the disc was immersed in a 1:10 
glycerol solution for 15 min 
 
 
Table 5.4.  Treatments performed on the resultant material. 
 
Following the treatments, both discs were placed uncovered in the fume hood to dry 
at room temperature, to allow the evaporation of the solvents and washing solutions. 
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Figure 5.34. (A) The frozen discs were transferred to glass petri dishes. (B) The discs were completely 
covered with NaOH/ethanol solution 3M. 
 
 
After 8 h of drying, the disc with treatment 1 turned hard and its edges bended 












Figure 5.35. Resultant scaffolds after drying. Scaffold with treatment 1 is observed on the left of the 





Two heparin solutions with concentrations of 3 mg/mL and 5 mg/mL were prepared 
by dissolving sodium heparin in distilled water at room temperature. Each scaffold 
was divided into 4 parts considering the heparin concentration was loaded onto it, 
according to Table 5.5. Each part of the disc was cut into cubes of approximately 3mm 
per side. Each correspondent quarter of the disc was fully immersed into 20 mL of the 
heparin solution and kept under these conditions for 24 h (Figure 5.36 section A). 
Precipitation was observed on disc 1 (Figure 5.36 section B).  
 
A B 
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Disc 1 
Washed with deionized water, PBS 
(15min), 5 washes of ethanol, immersed in 
glycerol 
Disc 2 
Washed with deionized water, PBS (5min), 







FGAW No heparin CHFG No heparin 
FGAW3 3mg/mL CHFG3 3mg/mL 
FGAW5 5mg/mL CHFG5 5mg/mL 
 




Figure 5.36. (A) Heparin loading process by immersion of the scaffolds into the heparin solution 
concentration 3 mg/mL, for scaffolds of both treatments. (B) Heparin precipitation was observed at the 
end of the loading process of scaffolds from disc 1 (FGAW, FGAW3 and FGAW5).  
 
 
Finally, the scaffolds were removed from the heparin solution and placed them in open 
petri dishes, followed by an uncovered drying proceed at room temperature during 
12h, approximately. 
 
SEM images of the scaffolds without heparin and of the scaffolds with the highest 
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Figure 5.37. SEM images of FGAW scaffold without heparin (Scaffold washed with deionized water, 
PBS (15min), 5 washes of ethanol, immersed in glycerol, not loaded with heparin). Bars are 100 µm and 












Figure 5.38. SEM images of CHFG scaffold without heparin (scaffold washed with deionized water, PBS 
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Figure 5.39. SEM images of FGAW scaffold immersed in the solution of 5 mg/mL (scaffold washed with 
deionized water, PBS (15min), 5 washes of ethanol, immersed in glycerol, loaded into the 5mg/mL 












Figure 5.40. SEM images of CHFG scaffold immersed in the solution of 5 mg/mL (scaffolds washed 
with deionized water, PBS (5min), 2 washes of ethanol, loaded into the 5 mg/mL heparin solution). Bars 
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Additionally, the FTIR-ATR spectra of the scaffolds were obtained. Results for the 








Figure 5.41. FTIR-ATR spectra of the scaffolds with all the washes (Treatment 1) and no heparin loaded 
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Figure 5.42. FTIR-ATR spectra of the scaffolds with all the washes (Treatment 1) and loaded in the 
3mg/mL heparin solution (A, B and C refer to the position where the spectra were taken bottom, top or 
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Figure 5.43. FTIR-ATR spectra of the scaffolds with all the washes (Treatment 1) and loaded in the 
5mg/mL heparin solution (A, B and C refer to the position where the spectra were taken bottom, top or 
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Secondly the spectra of the scaffolds with treatment 2 (CHFG) and the different 
heparin concentrations are presented (A, B and C refer to the position where the 






Figure 5.44. FTIR-ATR spectra of the scaffolds with the washing modification (Treatment 2) and no 
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Figure 5.45. FTIR-ATR spectra of the scaffolds with the washing modification (Treatment 2) and loaded 
in the 3mg/mL heparin solution (A, B and C refer to the position where the spectrum was taken: 
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Figure 5.46. FTIR-ATR spectra of the scaffolds with the washing modification (Treatment 2) and loaded 
in the 5mg/mL heparin solution (A, B and C refer to the position where the spectrum was taken bottom, 




5.3.3 Conclusions from using freeze-gelation to fabricate 
chitosan/ hydroxyapatite scaffolds 
Freeze-gelation of chitosan is based on the fact that chitosan gels under alkaline 
conditions. During this process, the homogeneous polymer solution is frozen, 
following by an immersion in a basic-precooled coagulating solution. Therefore, the 
solvent is removed during the freezing stage keeping the shape and structure of the 
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frozen solution. The spaces left by the solvent removal, become the pores of the scaffold 
124. The freeze-gelation process upon which this work is based, followed a series of 
washes after the gelation process to remove the presence of NaOH and it included a 
washing with glycerol to improve stability of the scaffold. However, following the 
complete procedure resulted on obtaining rigid scaffolds, and decreasing the 
availability of cation sites in the scaffold structure, which is necessary for the 
interaction with heparin.  
This is noted in the FTIR spectra of the scaffold with all the washes (FGAW) showed 
in Figures 5.41 to 5.44, where the low absorbance of the NH2 peaks at 1589 cm-1 show 
the decrease of the available amino sites. Comparing the spectra of the scaffolds with 
the washing modification (CHFG) in Figures 5.44 to 5.46 it is notable the presence of 
the amino sites around 1580 cm-1. These amino sites represented more available site for 
the heparin to bind. This is also notable for the heparin loading, since the scaffolds with 
the washing modification exhibited higher absorbance for sulphate peaks, around 1242 
cm-1. Whereas the same peak for the scaffolds with all the washings, was only 
observable with the higher loading concentration (5 mg/mL). Which explains the 
precipitation during the loading of the FGAW scaffolds since heparin could not bind 
properly to the scaffolds.  
Regarding the scaffold structure, scaffolds with high porosity were obtained. 
Differences among their porosity were observed from Figures 5.37 to 5.40. Scaffolds 
with all the washes exhibited a pore size from 51 to 260 µm, with an average of 109.2 
µm. These results were preserved regardless of the heparin loading. These scaffolds 
showed the presence of a spike-shaped material covering the surface, which is 
presumable the glycerol from the plasticizing process. The hydroxyapatite can be seen 
uniformly distributed throughout the chitosan matrix. On the other hand, the scaffolds 
with the washing modification, showed the presence of hydroxyapatite evenly 
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distributed on the chitosan matrix. The porosity revealed on these scaffolds goes from 
120 to 460 µm, with an average size of 243 µm, regardless of the presence of heparin.  
The difference in porosity is also attributed to extensive washing with PBS and the 
plasticizing at the end, since this modifies chitosan structure and therefore, its 
interactions providing a tighter matrix. 
 
5.4 The effect of the fabrication method on the 
bioactivity of chitosan/hydroxyapatite scaffolds 
Bioactivity is defined as the ability of triggering a response or effect in the living tissue 
145, in bone tissue engineering this translates to the ability to promote bone growing 
and the formation of a tight bond between tissue and implant, and it is very much 
dependent on the chemical composition of the material and the biological environment 
106.    
The apatite forming ability has been widely used as bioactivity evaluation. According 
to Kokubo & Takadama (2006) the reason is the assumption that the apatite produced 
by the osteoblasts should form a strong bond with the apatite layer formed on the 
surface of the implant, as long as its composition and structure simulates the one of 
bone.  Hence, it is a key requirement for a material to form bonelike apatite on its 
surface, which can be evaluated in a solution with ion concentration similar to those in 
blood plasma, which they called simulated body fluid (SBF) 104.  
The following trial compares the bioactivity results for the scaffolds prepared by 
freeze-drying and freeze-gelation methodologies. Additionally, the results according 
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Fabrication method Freeze Gelation Freeze Drying 
CS:HA ratio 50:50 80:20 50:50 80:20 
Short identification FG50 FG80 FD50 FD80 
 
Table 5.6. Identification of the chitosan: hydroxyapatite ratios tested during the bioactivity evaluation. 
 
 
5.4.1 Bioactivity methodology 
5.4.1.1 Solution preparation 
The solution for the scaffolds was prepared as described below using the amounts 
shown in Table 5.7. 
First, deionized water was warmed to 50 °C and chitosan was added, this mixture was 
left under stirring for 1h. Subsequently, heat was turned off and slow addition of acetic 
acid was started. Once enough amount of acetic acid to achieve 0.2 M was added, the 
solution was diluted to 250 mL and left under constant stirring for 6 h. Then, 
hydroxyapatite was slowly added, and the resultant mix was left under stirring 
overnight (approximately 12 h). 
CS : HA Reagent Amount 
80:20 
Chitosan 12 g 
Hydroxyapatite 3 g 
Acetic acid 2.87 mL 
50:50 
Chitosan 7.5 g 
Hydroxyapatite 7.5 g 
Acetic acid 4.3 mL 
 
Table 5.7. Reagent amounts to prepare 250 mL of the chitosan/hydroxyapatite solution. 
 
To prepare 1 L of the 3M NaOH/ethanol solution, i. e. the gelation solution, 120 g of 
NaOH were completely diluted in 90 mL of distilled water. Next, the solution was 
diluted to 1L by the slow addition of ethanol. The solution was kept at -20 °C until 
used.  
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5.4.1.2 Freeze-drying protocol 
The chitosan/hydroxyapatite solution was poured into glass petri dishes, adding the 
necessary amount according to the desired thickness of the scaffold. The solution was 
placed at 4 °C for 1 h, following by a decrease in the temperature by 4 °C hourly until 
it reached -30°C. The solution was left for freezing overnight. On the following day, 
the frozen solution was freeze-dried at -25 °C at 0.520 mbar for 30 hours. 
 
5.4.1.3 Freeze-gelation protocol 
The chitosan/hydroxyapatite solution was poured into plastic petri dishes, adding the 
necessary amount according to the thickness of the scaffold. The solution was placed 
at 4°C for 1 h, following by the decrease of the temperature by 4 °C hourly until it 
reached -20 °C. At -20 °C, the solution was left to freeze overnight. The frozen solution 
was removed from the petri dishes by gently pressing the edges and the frozen discs 
were immersed into 3M NaOH/ethanol solution (precooled at -20 °C). The frozen discs 
were kept in the gelation solution at -20 °C for 12 h.  
Following this time, the frozen scaffolds were carefully removed from the gelation 
solution and the next series of washes were performed: 15 min in deionized water, 5 
min in PBS, 15 min in 80% ethanol and 15 min in 100% ethanol.  
The scaffolds were left uncovered in the fume hood for at least 8 h before being placed 
in a desiccator.  
5.4.1.4 Description of bioactivity protocol 
For this evaluation, the SBF composition and recipe was taken from the paper by 
Kokubo & Takadama (2006). A basic comparison of the nominal concentrations of 
Kokubo’s SBF and the ones of human blood plasma is presented in Table 5.8 104. 
Excluding the values for chloride ion and carbonate, the values are very close.  
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The bioactivity was evaluated as part of the process of selecting the best chitosan and 
hydroxyapatite concentration and to define the best methodology to prepare the 
scaffolds: freeze-gelation or freeze-dryer (Ong B., 2017) 146. 
Ion 
Ion concentration (mM) 
Blood plasma SBF 
Na+ 142.0 142.0 
K+ 5.0 5.0 
Mg2+ 1.5 1.5 
Ca2+ 2.5 2.5 
Cl- 103.0 147.8 
HCO3- 27.0 4.2 
HPO42- 1.0 1.0 
SO42- 0.5 0.5 
pH 7.2 -7.4 7.4 
 
Table 5.8. Comparison of ion concentrations of SBF and human blood plasma 104. 
 
 
The scaffolds were cut into rectangles of 1.5 cm2, weighed and this weight was 
registered as Wi. After preparing SBF solution following the methodology described 
by Kokubo & Takadama’s (2006), scaffolds of each chitosan: hydroxyapatite ratio and 
fabrication method were individually placed into clean vials with 10 mL of SBF. The 
SBF solution was weekly replaced with afresh solution. The study lasted 8 weeks.  
Three scaffolds of each variant were weekly retrieved from the SBF solution, carefully 
washed with distilled water and oven-dried at 50°C for 24 hours to remove all 
moisture.  
The scaffolds were then weighed, registering this weight as Wf.  The retrieved scaffolds 
were characterized using FTIR-ATR technique, SEM and EDX analysis. 
For FTIR-ATR, the conditions and equipment were the ones described in chapter 4, 
section 4.2.1. 
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For SEM observation a Hitachi TM3030Plus was used, while the EDX analysis was 
performed by a Quantax 70 EDS accessory for this SEM equipment. For this 
equipment, no coating was required, and the samples were simply adhered to a 
specimen holder. 
 
5.4.2 Conclusions on the study of the effect of the fabrication 
method on the bioactivity of chitosan/hydroxyapatite scaffolds 
The resultant chitosan/hydroxyapatite scaffolds prepared by freeze- drying method 
are shown on the left in Figure 5.47, while the scaffolds prepared via freeze- gelation 
are shown on the right in Figure 5.47. The formation of surface skin (circled in red) on 
the surface of the scaffolds prepared by freeze-drying method was observed. Scaffolds 
prepared by freeze-gelation method, did not present surface skin. 
As discussed by Levengood & Zhang (2014), the presence of surface skin is not 
desirable when fabricating tissue engineering scaffolds: Since surface skin is not 
porous, it may impede the ingress of nutrients and oxygen to the scaffold structure, 
also hindering the egress of wastes from it 79, which would lead to scaffold malfunction 
and failure. 
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Figure 5.47. (a) and (c) Scaffold prepared by freeze-drying method, top and bottom surfaces, 
respectively. (b) and (d) Scaffold prepared by freeze-gelation method, top and bottom surfaces, 
respectively. 
 
The scaffolds prepared by freeze drying exhibited a tight porosity, more on the top 
surface of the scaffold. The top surface had the appearance of a structure formed by 
stacked sheets. Table 5.9 presents the pore size (in µm) according to the fabrication 
method and the chitosan: hydroxyapatite ratio. As described in section 4.1.1, from the 
obtained SEM images, porosity of the samples was determined by measuring every 





Chapter 5: Results and Discussions. Section I 
 
139 



















Average 39.20 33.53 47.74 71.20 15.56 72.98 28.22 127.58 
Minimum 21.05 20.12 16.72 30.68 10.09 24.30 16.67 77.19 
Maximum 55.95 47.23 100.29 127.93 29.16 118.38 52.63 177.05 
 
 
Table 5.9. Pore size according to the fabrication method (on week 0). All measurements are given in 
µm.  FD50 and FD80 are the scaffolds prepared by freeze-drying with chitosan: hydroxyapatite ratio of 
50:50 and 80:20 respectively. FG50 and FG80 are the scaffolds prepared by freeze-gelation with chitosan: 
hydroxyapatite ratio of 50:50 and 80:20 respectively. 
 
 
SEM images of the scaffolds showing the effect of SBF on the scaffolds structure with 
time can be observed in Figures 5.47 (top surfaces) and 5.48 (bottom surfaces). 
Firstly, the differences from the fabrication methods, are shown on the images of week 
0, i. e. before undergoing any treatment.  
It is possible to observe that, with a longer exposure to the SBF, pore size and shape 
changes. For scaffolds prepared by freeze-drying, the pores are completely covered by 
week 8, presumably with the apatite layer. On the other hand, for the scaffolds 
prepared via freeze-gelation it is possible to observe a reduction on the pore size as 
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Figure 5.48. Comparison on the effect of SBF on the scaffold structure. Top surfaces of the scaffolds. 
FD50 and FD80 are the scaffolds prepared by freeze-drying with chitosan: hydroxyapatite ratio of 50:50 
and 80:20 respectively. FG50 and FG80 are the scaffolds prepared by freeze-gelation with chitosan: 
hydroxyapatite ratio of 50:50 and 80:20 respectively. WK0= week 0, WK4= week 4, and WK8= week 8 of 
exposure to SBF. Images are 300X, all bars represent 300 µm. 
 
 
The same effect is observed for the bottom surface of the scaffolds in Figure 5.49. This 
surface is already apatite rich due to the preparation methodology, however, a higher 
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Figure 5.49. Comparison on the effect of SBF on the scaffold structure. Bottom surfaces of the 
scaffolds. FD50 and FD80 are the scaffolds prepared by freeze-drying with chitosan: hydroxyapatite 
ratio of 50:50 and 80:20 respectively. FG50 and FG80 are the scaffolds prepared by freeze-gelation with 
chitosan: hydroxyapatite ratio of 50:50 and 80:20 respectively. WK0= week 0, WK4= week 4, and WK8= 
week 8 of exposure to SBF. All scale bars represent 300 μm.  
 
 
It is possible to observe from Table 5.9, that the presence of hydroxyapatite tightens 
the porosity, since the pore size is lower for the scaffold of 50:50 ratio. This is mainly 
due to the interaction among hydroxyapatite lattice ions, i.e. Ca2+, OH- and PO43-, and 
the positively charged amino groups from of chitosan.  This interaction diminishes 
with a lower amount of hydroxyapatite, causing that the 80:20 ratio exhibited a more 
relaxed structure.  
In previous trials, showed in section 5.2, freeze-drying also exhibited very small pore 
size due to the quenching. However, for this study the solution preparation, as well as 
the freezing rate was the same for both processes, showing that the phase separation 
FD50  WK0 
FD50  WK4 
FD50  WK8 
FD80  WK0 
FD80  WK4 
FD80  WK8 
FG50  WK0 
FG50  WK4 
FG50  WK8 
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FG80  WK4 
FG80  WK8 
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also plays an important part on the pore formation. Most of the articles suggest that 
freezing rate and temperature, and solution concentration are the defining parameters 
in pore size definition.  During this trial, the only change is the process for the removal 
of the solvent: sublimation in freeze-drying and gelation of a homogeneous solution 
during freeze-gelation. The most important parameters during freeze-drying are 
temperature and pressure. Transforming ice into vapor requires energy since the 
product needs to be heated to facilitate the removal of water. However, if during this 
warming process the temperature goes higher that the eutectic point, changes in the 
structure of the frozen solution can occur 147. The eutectic point for a 60% acetic 
acid/water solution  is -26.5 °C 148. The freeze-drying process was conducted at -25°C 
which probably allowed changes on the frozen solution that lead to a reduced porosity.  
Regarding the effect of SBF on the structure of the scaffolds, changes on the pore size 
are notable regardless of the fabrication method. For freeze dried scaffolds it is possible 
to observe that during the bioactivity test the entire surface appears with a decreased 
porosity and cover with phosphate. On the other hand, for freeze gelation, though it is 
possible to observe formation of an apatite layer in the SEM images, the structure 
yielded in time, with a wider averaged porosity. 
Figures 5.50 to 5.57 show the FTIR spectra of the scaffolds throughout the bioactivity 
study. The spectra show characteristic peaks from both chitosan and hydroxyapatite, 
demonstrating the phosphate dispersed through the polymer matrix.  
The high absorbance for phosphate groups and carbonate peaks can be highlighted. 
There has been an increase in the intensity of hydroxyl peaks at around 3340cm-1 over 
8 weeks in each sample spectrum, except for 80FG. This can be attributed to the water 
present in the structure with the increased amount of time immersed in the SBF. It is 
also highly likely due to the presence of calcium phosphate. 
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Figure 5.50. Comparison on the effect of SBF on the chemical structure through the 8 weeks of study. 













Figure 5.51. Comparison on the effect of SBF on the chemical structure through the 8 weeks of study. 
FD50 Top surfaces. 
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Figure 5.52. Comparison on the effect of SBF on the chemical structure through the 8 weeks of study. 













Figure 5.53. Comparison on the effect of SBF on the chemical structure through the 8 weeks of study. 
FD80 Top surfaces. 
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Figure 5.54. Comparison on the effect of SBF on the chemical structure through the 8 weeks of study. 












Figure 5.55. Comparison on the effect of SBF on the chemical structure through the 8 weeks of study. 
FG50 Top surfaces. 
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Figure 5.56. Comparison on the effect of SBF on the chemical structure through the 8 weeks of study. 













Figure 5.57. Comparison on the effect of SBF on the chemical structure through the 8 weeks of study. 
FG80 Top surfaces 
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The increase in the hydroxyl peak is mostly attributed to the formation of calcium 
phosphate that relies on the concentration of HA present in the scaffold. This can be 
confirmed by the gradual increase in phosphate peaks too. Which indicates that a layer 
of calcium phosphate apatite has been formed. 
From the EDS analysis, Ca/P ratio was calculated. The resultant Ca/P ratios for the 
scaffolds before and after bioactivity study are presented in Table 5.10.  
 




Carbon 29.46 28.86 
Oxygen 55.35 52.90 
Calcium 10.33 11.77 
Phosphorus 4.87 6.47 
Chlorine  -  - 
  





Carbon 40.13 51.66 
Oxygen 50.42 38.73 
Calcium 0.97 3.27 
Phosphorus 0.62 1.53 
Chlorine  - 2.60 
Sodium 7.87 2.20 
  
Ca/P ratio 1.56 2.13 
(A) FD50 
  Element 
Wk0 Wk8 
[norm. at.%] 
Carbon 46.02 62.22 
Oxygen 41.29 28.91 
Calcium 8.52 2.86 
Phosphorus 4.18 1.46 
Chlorine  - 4.56 
  





Carbon 53.63 51.93 
Oxygen 43.23 36.48 
Calcium 2.13 2.21 
Phosphorus 1.01 1.80 
Chlorine  - 4.23 
Sodium  - 3.35 
  
Ca/P ratio 2.11 1.23 
Table 5.10. Results from EDX analysis for each scaffold in the beginning and at the end of the 
bioactivity study. 
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For scaffolds with 80:20 ratio, the presence of sodium and chloride on the surface of the 
sample can be observed. As SBF has very high content of these two elements present, it is 
very likely that formation of NaCl crystals occurred. This is most likely caused by 
insufficient washing of the samples which was carried out to remove the minerals present 
on the surface 149. It can be seen that all fabricated samples, except 80FG scaffold, have a 
Ca/P ratio higher than the stoichiometric ratio of hydroxyapatite. Additionally, that the 
Ca/P ratio has decreased after 8 weeks of immersion in SBF. This suggests that calcium 
phosphate apatite layer has been formed which causes the percentage of phosphate ions 
(PO43-) present in 50FG, 50FD and 80FD to increase. On the other hand, from the Ca/P ratio 
of 80FG, it is suggested that there is decrease in the percentage of PO43- . However, the Ca/P 
ratio is not an accurate representation of the nature of the calcium phosphate phase, as the 
bone apatite is usually nonstoichiometric. The formation of bone apatite implies the 
electrostatic interaction of the positive Ca+ ions and the negative charged ions available in 
the surface and the microenvironment. Furthermore, the process of apatite formation is a 
slow one 150, which explains the differences in the Ca/P ratios among the tested scaffolds.  
Finally, even when SBF immersion provides an insight of the way the scaffold can 
chemically interact with the surroundings, it has been suggested by Drouet (2013) that this 
process should not be taken as a conclusive proof of the bioactive properties of a material. 
This is mainly due to fact that SBF immersion only considers the interaction of the scaffold 
with a mineral rich environment, it is necessary to contemplate the cellular behaviour as 
well 149. 
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5.5 Final conclusions from exploring methodologies for 
fabrication of hydroxyapatite/chitosan composites enabling 
vascular infiltration 
After finalizing the trials to study various protocols to develop our material we can conclude 
as follows: 
• Composites elaborated with carboxymethyl cellulose require careful 
treatment, since the interaction with chitosan is very strong it produces non-
homogenous solutions. 
• Chitosan: hydroxyapatite ratio plays a major role in the final behaviour of the 
produced scaffolds. All electrostatic interactions depend on the presence of 
the phosphate. Therefore, characteristics such as the porosity and the heparin 
attraction will be defined by the phosphate distribution throughout the 
matrix.  
• Freeze-drying methodology provides a simple process to obtain porous 
scaffolds. However, attention must be paid in the cooling rates in order to 
achieve a desired or required porosity. 
• Freeze-gelation provides a simple, yet efficient procedure to produce porous 
scaffolds. The characteristics achieved with the chitosan/hydroxyapatite 
mixture offer a possibility to explore further to produce bone tissue 
engineering scaffolds. 
• Bioactivity is an important characteristic of tissue engineering scaffolds. 
Scaffolds prepared with chitosan/hydroxyapatite mixture, preliminarily 
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proved to be bioactive since formation of apatite layer was observed on their 
surface, regardless of the fabrication method or the phosphate concentration. 
5.6 Summary 
The complete development of the process for fabrication of a hybrid bioactive scaffold to 
promote bone angiogenesis was presented in this chapter. Firstly, the content was defined, 
always aiming to allow the addition of heparin, since our hypothesis is that the presence of 
heparin will induce and promote bone angiogenesis. Therefore, different compositions and 
protocols were tested in order to obtain the best option that allows us to test our hypothesis. 
Finally, the best option to continue the study of heparin influence in bone angiogenesis is 
the scaffold produced with freeze-gelation with a chitosan: hydroxyapatite ratio of 50:50. 
Since it is endowed with the required characteristics in terms of porosity, chemical 
characteristics, and bioactivity performance, providing a suitable scaffold for bone tissue 
engineering purposes. 
The following chapter contains the results of the characterisation of the scaffolds obtained 
by this selected protocol.
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6 
Results and Discussion 
Section II.  
Optimized freeze-gelled heparinized 
chitosan/ hydroxyapatite scaffolds  
 
The previous section explored two methodologies for chitosan/hydroxyapatite 
scaffold preparation. Two CS:HA ratios were studied, as well as different 
modifications in the freeze-gelation methodology, analysing the impact of these 
variations on the scaffold’s structure, bioactivity, and heparin interaction in general. 
Therefore, as mentioned in the conclusions from the previous section, based on the 
results from these trials an optimized freeze-gelation methodology was developed, 
since it is expected they will provide an appropriate structure for vascular infiltration. 
The optimized freeze-gelation methodology has been described in detail in chapter 3, 
section 3.2. 
Hence, the present chapter describes and reports all the results obtained from 
characterising the scaffolds prepared with the optimized freeze-gelation methodology, 
working only with a 50:50 chitosan/hydroxyapatite ratio. The characterisation 
methods employed to analyse these scaffolds have been described in chapter 4. These 
results are discussed in detail in this chapter to provide a comprehensive conclusion 
form this study. 
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6.1 Structural characterization 
The scaffolds obtained by freeze-gelation method had a sponge-like appearance. They 
looked white in colour due to the presence of hydroxyapatite. After cutting them with 
the cork borer they were shaped into cylindrical scaffolds of cylindrical of 5mm of 







Figure 6.1 Appearance of the produced scaffolds. Scale bars are 2.5 mm. 
 
The following table shows the abbreviations used to name the samples obtained, 
according to the concentration of heparin loading solution they were immersed in 





Heparin loading concentration 
(mg/mL) 
MMW 
Scaffold prepared of pure chitosan medium molecular weight for 
comparison purposes 
M0 
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6.1.1 Scanning Electron Microscopy (SEM) 
 
The morphology of the freeze-gelled scaffolds was analysed using SEM. As shown in 
Figure 6.2, embedded hydroxyapatite crystals can be observed completely distributed 









Figure 6.2. Structure of chitosan/hydroxyapatite scaffolds without heparin. The presence of embedded 
hydroxyapatite crystals can be observed throughout the chitosan matrix (yellow arrows). Dispersion of 
hydroxyapatite was similar in all the scaffolds regardless of the heparin loading concentration, therefore 
only this concentration was shown as representative. Scale bars are 50µm and 10µm, respectively. 
 
One significant difference that can be spotted on the porosity and hydroxyapatite 
distribution according to the side of the cylinder-shaped scaffold. A chitosan-rich side 
was found on the top face of the scaffold. A surface with scattered hydroxyapatite 
particles and irregular porosity can be seen in Figure 6.3 (A). Lateral views of the 
scaffold, Figure 6.3 (B), show consistent porosity and hydroxyapatite is evenly 
embedded throughout the chitosan matrix on this side. The bottom face of the scaffold 
exhibited the hydroxyapatite-rich side, Figure 6.3 (C), where a surface rough in 
appearance and with little or no porosity can be observed.  
Figures 6.4 to 6.6 show a more detailed view of the structure of the scaffold according 
to its different faces (top face, bottom face, edges). These images show that heparin 
loading did not affect pore distribution on the scaffolds, as mentioned before, since 
porosity was similar in size and distribution among the different concentrations.  To 
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compare the effect of adding hydroxyapatite on the chitosan matrix we have included 


















Figure 6.3. Differences in porosity and hydroxyapatite distribution according to scaffold’s view. The 
scaffold presented in these image as a representation of the hydroxyapatite distribution is the scaffold 
M0.5 (immersed in a 0.5 mg/mL heparin solution), however the same phosphate distribution was 
observed in all of the scaffold prepared. HA particles shown with yellow arrows. (A) correspond to the 
top face of the scaffold where random porosity can be seen, less hydroxyapatite crystals are observed. 
(B) are the side views of the scaffold, bigger interconnected pores can be found. (C) correspond to the 
bottom face of the scaffold. A dense concentration of hydroxyapatite particles is seen, causing the 
reduction of porosity observed, instead, a lot of cracks can be notices. Scales bars are 2mm, 100 µm, 100 
µm, and 100 µm, respectively. 
 
Figure 6.4 shows in detail the top surface of the scaffolds. In this image all the heparin 
concentration are compared. Pore distribution on this face was between 42.59 µm and 
264.52 µm, with and average pore size of 118.29 µm as showed in Histogram 6.1. Pore 
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Figure 6.4. Top surface of the scaffolds. Elongated pores can be observed in the scaffold without HA 
and/or heparin, though this length and consequently the pore size is slightly reduced in most of the 
pores with the addition of HA (yellow arrows). Pore size distribution is ample, finding pores from 
around 40 µm to 200 µm. Heparin content did appear to have any visible effect in the porosity of the 
scaffolds, since pore size distribution was similar in all the samples, regardless of the heparin 
concentration. (A) chitosan MMW without hydroxyapatite. (B) M0 scaffold without heparin. (C) M0.5 
scaffold loaded in the 0.5 mg/mL heparin solution. (D) M1 scaffold loaded in the 1 mg/mL heparin 
solution. (E) M2 scaffold loaded in the 2 mg/mL heparin solution. (F) M5 scaffold loaded in the 5 










As observed in Figure 6.4 the porosity in the top face varies in size. It is also notable 
that the pore size and shape changed in the chitosan matrix with the addition of 
A B C 















































Probability Plot of Chitosan side
Normal 
Histogram 6.1. Distribution of pore sizes in 
the top surface of the scaffold, also called 
chitosan-side. The majority of the pores have 
sizes between 100-130 µm.  
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hydroxyapatite. Since pores in the image of the scaffold made of only chitosan (i.e 
without any hydroxyapatite or heparin), present long pores. Even, when this pore 
shape was observed in the rest of the samples, the length of the pores was shorter in 
the presence of hydroxyapatite.  
Figure 6.5 shows the side views of the cylindrical scaffolds. This side of the scaffolds 
exhibited the bigger pore size, with a wide size distribution from 53.56 µm to 392.63 













Figure 6.5. Side views of the scaffolds. Higher porosity and bigger pores can be observed on this face of 
the scaffold. The pore size and distribution are similar in all the scaffolds including the scaffold without 
HA and/or heparin. Pore size distribution is ample too , finding pores from around 50 µm to nearly 300 
µm. Heparin content did appear to have any visible effect in the porosity of the scaffolds, since pore size 
distribution was similar in all the samples, regardless of the heparin concentration. (A) chitosan MMW 
without hydroxyapatite. (B) M0 scaffold without heparin. (C) M0.5 scaffold loaded in the 0.5 mg/mL 
heparin solution. (D) M1 scaffold loaded in the 1 mg/mL heparin solution. (E) M2 scaffold loaded in the 
2 mg/mL heparin solution. (F) M5 scaffold loaded in the 5 mg/mL heparin solution. Scale bars are 100 
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Histogram 6.2. Distribution of pore sizes in the lateral surface of the scaffold, also called edges. The 
majority of the pores have sizes between 120-150 µm. 
 
As observed in Figure 6.5 the porosity in the side views of the scaffolds also varies in 
size. In this parts of the scaffolds the pore size and shape did not appear to be changed 
with the addition of hydroxyapatite to the chitosan matrix, since pores in the images 
of the scaffold made of only chitosan (i.e without any hydroxyapatite or heparin), 
present similar size and shape to those of the rest of the samples. 
Lastly, Figure 6.6 presents the bottom side of the scaffolds. This side was found to be 
characterized for a porosity ranging from 16.21 μm to 168.19 μm, with an average of 
60.23 μm (see Histogram 6.3). The entire surface of the polymer matrix appears to be 
covered by the hydroxyapatite particles, which gives it the appearance of a very rough 
surface when compared to the surface of the scaffold made of only chitosan (i.e without 
any hydroxyapatite or heparin). Though some porosity can be observed in this side, 
the presence of cracks along these surfaces was characteristic, revealing inner porosity 

















































Probability Plot of Edges
N rmal 
Chapter 6: Results and Discussion. Section II 
 
158 














Figure 6.6. Bottom surface of the scaffolds. Lower porosity and smaller pores can be observed on this 
face of the scaffold. The presence of cracks is noticeable (yellow arrows). The pore size and distribution 
are similar in all the scaffolds with HA, appearing denser than the scaffold without HA and/or heparin. 
Inner porosity is shown with red arrows. Pore size distribution goes from around 16 µm to nearly 160 
µm. Heparin content did appear to have any visible effect in the porosity of the scaffolds, since pore size 
distribution was similar in all the samples, regardless of the heparin concentration. (A) chitosan MMW 
without hydroxyapatite. (B) M0 scaffold without heparin. (C) M0.5 scaffold loaded in the 0.5 mg/mL 
heparin solution. (D) M1 scaffold loaded in the 1 mg/mL heparin solution. (E) M2 scaffold loaded in the 
2 mg/mL heparin solution. (F) M5 scaffold loaded in the 5 mg/mL heparin solution. Scale bars are 100 
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Probability Plot of Hydroxyapatite side
Normal 
Histogram 6.3. Distribution of pore sizes in the bottom surface of the scaffold, also called 
hydroxyapatite-side. The majority of the pores have sizes between 40-70 µm. 
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6.1.1.1 EDX analysis 
Energy Dispersive X-Ray Spectroscopy (EDX) is a characterization method based on 
the discrimination of the X-Ray energies by a detector, knowing that each energy is 
characteristic of the orbital transition of some electrons in each element, during the X-
Ray interaction with the sample. Therefore, this technique allows the acquisition of a 
compositional analysis of the sample.  
The results from EDX analysis allowed to detect the sulphate on the sample. The 
sulphate confirms the presence of the heparin on the scaffold. There is a low presence 
of sulphate, around 0.7 to 1.3 Wt%. 
The elements detected on the samples are shown in Table 6.2. Figures 6.7 to 6.11 show 









Table 6.2. EDX results for all the samples. 
 







M0 M0.5 M1 M2 M5 
C 36.9 30.4 49.9 34.3 46.0 
O 25.5 17.8 12.6 12.6 10.7 
Ca 6.4 2.1 0.5 8.4 4.4 
P 4.6 1.0 - 2.8 1.2 
N 6.8 3.7 - 3.2 8.2 
S - 1.0 0.7 1.3 1.0 
Na 2.0 7.4 7.1 4.1 3.2 
Cl 0.2 0.4 0.8 1.0 0.6 
Mg 0.2 0.1 0.4 0.2 0.2 
Au 17.5 36.0 27.9 32.1 24.6 
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Figure 6.8. EDX spectrum for M0.5 (scaffold loaded in the 0.5 mg/mL heparin solution). 
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Figure 6.11. EDX spectrum for M5 (scaffold loaded in the 5 mg/mL heparin solution). 
 
6.1.1.2 Discussion of SEM results 
Images of the scaffold show that a scaffold with interconnected porosity was obtained 
(Figures 6.2 – 6.6). 
The addition of heparin onto the scaffold by immersion in aqueous solution, did not 
affect the structure scaffolds regardless of the heparin concentration. The addition of 
hydroxyapatite, however, did change the porosity when comparing to scaffolds 
without hydroxyapatite, since the porosity appear to be closed in those with the 
phosphate.  
 According to Hsieh et al. (2007) porosity in chitosan scaffolds prepared via freeze-
gelation depends mainly on two factors: a) freezing rate and temperature and b) acetic 
acid concentration.  
During the freezing stage of the freeze-gelation process, the lower the temperatures 
and the faster freezing rates, the smaller pores were obtained. This is because these two 
variables control the ice crystals sizes and their formation process.  
Chapter 6: Results and Discussion. Section II 
 
163 
Griselda Valeria Nájera Romero – June 2021 
The acetic acid concentration influences the heat release during neutralization with the 
3M sodium hydroxide solution of the gelation phase. In this part of the process, some 
of the frozen chitosan solution slightly melt, creating zones of different concentration. 
From Hsieh et al. (2007) it can be concluded that a more acidic the solution, produces 
a higher exothermic rate of the neutralization process, leading to an excessive 
remelting of the frozen solution, forming denser and more compact zones 151.  
Moreover, hydroxyapatite surface charge usually is slightly negative, according to the 
concentration of the ions present on the lattice surface, being in decreasing order Ca2+ 
(4.5 ions /nm2), PO3-4 (3.02 ions/nm2) and OH- (2.57 ions/nm2) 138. Therefore, the 
presence of hydroxide and phosphate groups on its lattice surface determine the nature 
of its charge. However, this charge can change with pH152. When hydroxyapatite 
becomes in contact with an acidic solution, there is a change on its surface charge due 
to the adsorption of H+ onto the hydroxide ions and the protonation of the phosphate 
groups of the surface 138. This protonation is what ultimately leads to hydroxyapatite 
dissolution in acidic media (pH <5). Even when chitosan was dissolved in a solution 
of acetic acid for the freeze-gelation process, the solution is not strong enough to 
dissolve hydroxyapatite and despite this change on its surface charge, it is still 
attracted to chitosan positive charges sufficiently to not precipitate and keep mostly 
dispersed into the matrix chitosan provides. Therefore, this chitosan solution was used 
to form a matrix in which the phosphate would be suspended.  
The dispersion of hydroxyapatite along the chitosan matrix ultimately affects it 
density, and its concentration produces differences on the frozen zones, affecting the 
porosity size and distribution.  
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Figures 6.3 to 6.6 also present a difference between the surfaces of the scaffold. This 
gradient of hydroxyapatite from top to bottom was originated during freezing part of 
the freeze-gelation process. During the process of freeze-gelation, the porous are 
formed by removing the solvent while the frozen shape is retained. As mentioned 
before, the freezing rate is decisive for pore size determination. The freezing rate used 
during this process was at a relatively slow rate to carefully form the crystals which 
formed the pores in the chitosan matrix. Therefore, during this process, an amount of 
the suspended hydroxyapatite settled at the bottom of the container. However, 
majority of the hydroxyapatite was kept in suspension due to the surface charge 
interplay mentioned above and it could be observed homogeneously dispersed in the 
rest of the scaffold, as shown in Figure 6.3. Having a hydroxyapatite-rich side of the 
scaffold will allow to provide better bioactive properties to our scaffold. Since 
hydroxyapatite is often used as coating to induce bioactivity on orthopaedic implants, 
mainly because of the interaction of the osteoblasts around the bioactive surface, which 
promotes the formation of new mineralised bone matrix.  
Lastly, the pore size represents a very important parameter for designing any scaffold 
in tissue engineering. It influences the cellular activity in terms of attachment, matrix 
deposition and differentiation. It seems to exist a general agreement within the field of 
bone tissue engineering to consider that the optimal pore size for bone tissue scaffolds 
is between 100 and 500 μm, to have good cell adhesion and proliferation, and vascular 
ingrowth 50,142. Therefore, considering the porosity of the scaffolds as shown in 
histograms 6.1- 6.3, they are able provide an optimum environment for new bone 
growth and support for micro-vascularity to distribute blood across the entire scaffold. 
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6.1.2 In-vitro degradation study 
A study of the in-vitro degradation of the prepared scaffolds was performed using a 
solution containing chicken egg white lysozyme.  
Firstly, the results showing the changes on the scaffold structure are shown. The 
following figures present the SEM images obtained over time from the different faces 
of the cylindrical scaffolds. For comparative purposes only images of the scaffold 
without hydroxyapatite (MMW), the scaffold without heparin (M0), and the scaffold 












Figure 6.12. SEM images (200X) of the top surfaces of the scaffolds over time immersed in PBS and 
lysozyme. A ripped surface is observable for MMW sample, showing signs of degradation (yellow 
arrows). Mineral precipitation on the scaffolds with HA is pointed with red arrows. MMW: scaffold 
without hydroxyapatite. M0: scaffold without heparin. M5: scaffold loaded in the 5 mg/mL heparin 
solution. All scale bars are 100 µm. 
 
 
MMW  MMW  MMW T3 MMW T4 
M0 T0 M0 T2 M0 T3 M0 T4 
M5 T0 M5 T2 M5 T3 M5 T4 
Day 7 Day 14 Day 21 Day 0 
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Figure 6.13. . SEM images (200X) of the side views of the scaffolds over time immersed in PBS and 
lysozyme. No visible changes were observed in this side on the scaffold. MMW: scaffold without 
hydroxyapatite. M0: scaffold without heparin. M5: scaffold loaded in the 5 mg/mL heparin solution. All 
scale bars are 100 µm. 
 
From Figures 6.12 it is possible to observe that the structure of the scaffolds was less 
affected by the exposure to the lysozyme solution for the scaffolds with hydroxyapatite 
content. On the contrary, the scaffold without hydroxyapatite (MMW), showed signs 
of degradation of its walls all throughout the experiment. Formation of mineral 
deposits precipitation of salts on the scaffold surface is observable in the top surface.  
The SEM images indicates that by day 14 and 21, the structure of the scaffold prepared 
only with chitosan (MMW) is highly decayed, with walls that appeared to be ripped, 
moreover on the top surface (Figure 6.12, MMW, Day 21). 
MMW  MMW  MMW  MMW  
M0  M0  M0  M0 T4 
M5  M5  M5  M5  
Day 7 Day 14 Day 21 Day 0 
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In Figure 6.13, the side views of the scaffolds are presented. There were no visible 
changes on the structure on the lateral sides of the scaffolds. Showing similar porosity 
and pore size, throughout the study. A similar case can be observed in Figure 6.14, 
where the bottom surfaces of the scaffold are presented. In this figure, however, the 
scaffold prepared of only chitosan (i. e. without hydroxyapatite or heparin), exhibited 
a loss of porosity throughout the experiment (yellow arrows), with a loss of stability 























Figure 6.14. SEM images (200X) of the  bottom surfaces of the scaffolds over time immersed in PBS and 
lysozyme. No visible changes were observed in this side on the scaffold for the scaffold with HA content. 
For the scaffolds without HA and/or heparin a reduction on porosity (yellow arrows) and a structure 
decay (red arrows) are observed. MMW: scaffold without hydroxyapatite. M0: scaffold without heparin. 
M5: scaffold loaded in the 5 mg/mL heparin solution. All scale bars are 100 µm. 
 
 
MMW  MMW  MMW  MMW  
M0 M0 M0 M0  
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Figure 6.15 shows the variations of the scaffolds weight percentage over time. It is 
possible to note that the scaffold prepared with pure chitosan (MMW) lost nearly 7% 
of its weight by day one of exposure to the PBS/lysozyme solution and on the last day 
of the experiment, day 21, it had lost at least  16% of its weight. 
The behaviour for the scaffolds with hydroxyapatite is, however, the opposite. They 
gained closely between 5 – 8% of weight on the first day. Nonetheless, on the following 
days, these scaffolds started to lose this weight, ending up the experiment with 
approximately the 99% of their weight remaining. The complete description of the in-
vitro degradation study, including how these weights were determined is included in 
Chapter 4, part 4.1.3. 
 
 
Figure 6.15. Dry weight remaining ratio (%) and pH change from scaffolds exposed to PBS and 
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Figure 6.16. Changes in the appearance of the scaffolds exposed to PBS and lysozyme solution.  
 
 
It was notable from Figure 6.15 that the higher the heparin concentration, the more 
gain weight for the scaffold during the first week of the study. By day 14th, as stated 
before, these scaffolds started to lose weight. Behaviour of the pH was consistent with 
these trends. For the MMW scaffold there was an increment of the pH up to 7.9 on the 
first two weeks of the study, following by a descend of the pH value to 7.2 on the last 
week of the experiment. Scaffolds with hydroxyapatite and heparin followed the same 
trend, with pH up to 7.6 on the first two weeks and finalizing the experiment with a 
pH of 7.2. 
In addition, Figure 6.16 shows the changes in the appearance and size of the scaffolds 
during the exposure to PBS and lysozyme solution. It is possible to observe that the 
most significant changes in the diameter of the scaffolds, from 1 to 2 mm smaller, are 
seen on the last day of the experiment due to the degradation of the scaffold.  
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Figure 6.17. FTIR-ATR spectra from MMW (scaffold of just chitosan, i.e. without HA and/or heparin) 

























Figure 6.18. FTIR-ATR spectra from the Top Face of M0 (scaffold without heparin) exposed to PBS and 
lysozyme over time. 
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Figure 6.19. FTIR-ATR spectra from the Bottom Face of M0 (scaffold without heparin )exposed to PBS 






















Figure 6.20. FTIR-ATR spectra from the Top Face of M1 (scaffold loaded in a 1mg/mL heparin solution) 
exposed to PBS and lysozyme over time. 
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Figure 6.21. FTIR-ATR spectra from the Bottom Face of M1 (scaffold loaded in a 1mg/mL heparin 






















Figure 6.22. FTIR-ATR spectra from the Top Face of M2 (scaffold loaded in a 2mg/mL heparin solution) 
exposed to PBS and lysozyme over time. 
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Figure 6.23. FTIR-ATR spectra from the Bottom Face of M2 (scaffold loaded in a 2mg/mL heparin 























Figure 6.24. FTIR-ATR spectra from the Top Face of M5 (scaffold loaded in a 1mg/mL heparin solution) 
exposed to PBS and lysozyme over time. 
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Figure 6.25. FTIR-ATR spectra from the Bottom Face of M5 (scaffold loaded in a 1mg/mL heparin 
solution) exposed to PBS and lysozyme over time. 
 
 
Regarding the macrostructure of the scaffolds (Figure 6.16), MMW exhibits the major 
changes on its size over time losing over 2mm in diameter. However, the rest of the 
scaffolds reduced their diameter only by 1 mm at the end of the experiment. 
FTIR spectra show consistent results for all the scaffolds. The following Table 6.3 lists 
the peaks that show a sharper figure and higher absorbance over time. It is possible to 
observe that consistently for all the scaffolds with hydroxyapatite, the phosphate peaks 
as well as the NH2 bending and stretching bands sharpened over time. Finally, the 
peaks of the OH band separated during the in vitro degradation study, clearly showing 
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Peak 
Assignment 
Scaffold over time/ Wavelength 
MMW M0 T M0 B M1 T M1 B M2 T M2 B M5 T M5 B 
Phosphate υ4 - 567 562 562 562 562 562 562 562 
Phosphate υ4 - 600 600 600 600 600 600 600 600 
Phosphate υ3 - 1017 1017 1021 1017 1021 1022 1026 1017 
SO3 stretching - - - - - - - 1242 1242 
CH2 bending 1366  - 1371 1376 - 1380 - 1380 - 








1648 1645 - 1649 - 1649 1654 1649 1649 
CH2 stretching 2880 2882 2876 2875 2872 2890 2876 2880 2880 
CH3 stretching 2904 - - - 2910 - 2919 2923 2909 
NH2 bending - 3284 3292 3287 3288 3292 3288 3287 3288 
OH stretching 
chitosan 
3350 3366 3350 3359 3356 3354 3360 3359 - 
OH stretching 
hydroxyapatite 
- - 3441 3435 3442 3435 3441 3426 - 
 
Table 6.3. FTIR peak assignment for the changes on the chemical structure of the scaffold over time in 
the in-vitro degradation study. NOTES: Peaks in red decreased their absorbance. T: Before 
biodegradation study. B: At the end of degradation study. Phosphate appear in MMW due to PBS 
exposure. 
 
6.1.2.1 Discussion of in-vitro degradation study results 
The purpose of exposing the material to the action of an enzyme was to mimic the 
degradation it undergoes during implantation, since lysozyme is present in various 
human fluids in varied concentrations 153. For comparison purposes, scaffolds of just 
chitosan medium molecular weight (MMW) were prepared via freeze- gelation 
methodology, to observe the effect of adding hydroxyapatite into the chitosan matrix. 
Figures 6.12 – 6.14 showed the variations of the scaffolds structure over time under the 
immersion in the PBS + Lysozyme. The SEM images only compare the effect of the 
degradation media on the structure of the scaffold of pure chitosan (MMW), scaffolds 
of chitosan and hydroxyapatite without heparin (M0) and scaffolds made of 
chitosan/hydroxyapatite/heparin in the highest loading concentration (M5).  It is 
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possible to observe that for day 7 there is precipitation of salts all over the scaffolds 
with hydroxyapatite, particularly for the scaffold with heparin (Figure 6.12). By day 14 
and 21 we can observe a similar trend with all the scaffolds, salts precipitation on 
hydroxyapatite/scaffolds-surface, but all of them present slightly opening porosity, 
due to the degradation of chitosan matrix (Figure 6.12). This can also be confirmed 
with graph presented in Figure 6.15, which shows the percentage of dry weigh 
remaining after degradation protocol and Figure 6.16, which shows the changes in the 
size of the scaffolds overtime.  
Commonly, immediately after immersion in liquids, chitosan hydrogels tend to swell 
and retain water, which can explain little or non-existent weight loss on the first day 
of immersion 153. However, as time goes by the swelled structure provides a higher 
porosity and surface area that favours lysozyme degradation of the structure and loss 
of the weight and integrity of the scaffold. This is notable for scaffold MMW, the 
weight loss was immediate since lysozyme degrades chitosan by hydrolysing its 
glucosamine bonds. This also shows that chitosan degradation is dependent on the 
degree of deacetylation (DD). As mentioned before, lysozyme degrades chitosan by 
acting on the NH2 groups, the availability of these groups increases, of course, with the 
DD. For the scaffold’s matrix, chitosan with a DD ≥90% was used, providing an ample 
source of NH2 groups for lysozyme to hydrolyse during its interaction with the 
scaffold. 
For the scaffolds with phosphate, however, matrix degradation is affected by the 
presence of hydroxyapatite, which hampers lysozyme interaction with chitosan. 
Lysozyme is able to be adsorbed onto hydroxyapatite surfaces, favoured by the 
interactions of lysozyme functional groups and hydroxyapatite phosphate groups 154. 
This is also reflected on the FTIR spectra (Figures 6.17 -6.25) with the phosphate, NH2 
and CO peaks being sharper and with an increased absorbance. Furthermore, chitosan 
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matrix degradation depends on pH, and the presence of heparin decreases protonation 
of chitosan amino groups due to its complexation with the negative charged heparin-
functional groups, neutralizing pH with time 155, as observed in Figure 6.15.   
The degradation behaviour of the scaffolds is mainly a result of the deposition of 
lysozyme on hydroxyapatite and the presence of heparin holding up chitosan 
degradation. However, pore size and distribution, and interconnectivity of the matrix 
provided enough surface for the interaction of all the components, being determining 
factors for the degradation process. As a result, it is notable the degradation process 
from surface to bulk of the scaffold by the light beginning of weight loss and a slight 
yielding of chitosan structure by the 21 day of exposure. 
6.2 Physicochemical characterization 
6.2.1 FTIR-ATR 
Top and bottom surfaces of the cylinder-shaped scaffolds were analysed by ATR-FTIR 
spectroscopy.  
Figure 6.26 shows the resulting spectra comparing top and bottom surfaces of the 
scaffold M0 and the precursors used for its fabrication (chitosan and hydroxyapatite). 
FTIR spectra confirmed the composition of the scaffold and, in accordance with the 
SEM results, they show the clear difference between the two surfaces. For comparison 
purposes hydroxyapatite spectrum (C) was placed right below the bottom surface 
spectrum (D), the same case with chitosan (A) and the top surface (B). 
Regarding the presence of heparin, Figures 6.27 and 6.28 show the scaffolds top and 
bottom surface spectra. Besides sharing the matrix characteristic peaks, indicated in 
Figure 4.26, it is notable the band at 1230 cm-1 corresponding to the SO3 asymmetric 
stretching. 
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Figure 6.26. FTIR results in the spectral region 4000-400 cm-1 for (A) Chitosan, (B) Top surface of scaffold 
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Figure 6.27. FTIR results in the spectral region 4000-400 cm-1 for top surfaces of the scaffolds M0, M0.5, 














Figure 6.28. FTIR results in the spectral region 4000-400 cm-1 for bottom surfaces of the scaffolds M0, 
M0.5, M1, M2 and M5. 
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Peak assignment is shown in Table 6.3, for the scaffolds T, which represents the results 
before undergoing biodegradation. 
6.2.1.1 Discussion of FTIR results 
Chemical interaction between the components of the matrices (M0 scaffold) was 
characterised by ATR-FTIR spectroscopy. From the spectra of Figure 6.26 it is possible 
to observe that a functionalized scaffold was achieved, with a chitosan-rich surface and 
a hydroxyapatite-rich surface, as explained in section 6.1.1.1.  
 Spectra from hydroxyapatite and the bottom surface showed well-defined phosphate 
(PO4) peaks at 564 cm-1 and 1018 cm-1, corresponding to PO4 4 and PO4 3 stretching 
modes, respectively. Likewise, hydroxyl (OH) stretch peak was observed at 3571cm-1 
for both spectra 156.  
Regarding chitosan and the top surface, their spectra showed a band for alkyl (CH2, 
CH3) bending at 1375-1415 cm-1, a small hump between 1586 and 1650 cm-1 corresponds 
to the CO stretching from Amide I, and, the peaks of CH2, CH3 stretch near 2850-2915 
cm-1 157,158. These spectra also show a band assigned to C-O-C stretching between 1025-
1060 cm-1 and a broad peak of OH and NH2, NH3 stretching vibrations at 3555 cm-1 
157,158.  
On the other hand, the presence of the heparin was not evident for the lower 
concentration loads, due to the small amount present on the scaffold. However, for M2 
and M5 we can observe the presence of a band between 1230 – 1258 cm-1 which can be 
attributable to the SO3 asymmetrical stretching according to Kim & Urban (1998). A 
broaden around the 1020-1040 cm-1 band can also be due to the presence of the SO3 
symmetrical stretching of the heparin. It also remarkable that the presence of these 
heparin peaks is higher in the chitosan-rich side than in the hydroxyapatite side, where 
the heparin peaks are only notable for the M5 scaffold. This is mainly due the fact that 
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chitosan, a polycation, attracts a higher amount of the negatively charged heparin 
compared to hydroxyapatite (being slightly negative on its surface as described in 
section 6.1.1.1).  
  
6.2.2 Heparin determination 
6.2.2.1 Qualitative determination of heparin  
The objective of the qualitative determination of heparin onto the scaffolds, performed 
with a 0.05% Toluidine Blue solution, was to observe the presence and distribution of 
heparin on the scaffold. The solution changed from blue to purple almost immediately 
after the immersion of the scaffolds in the Toluidine Blue solution. As showed in Figure 
6.29, the purple shade is also an indication of the amount of heparin present in the 


















Figure 6.29. Toluidine Blue solutions after the immersion of the scaffolds. 
 
The purple shade also helped to observe of the distribution of heparin throughout the 
scaffold. Figure 6.30-A presents samples of M5 scaffold, showing its top and bottom 
surface, and its core obtained with a transversal cut of the scaffold body. It is possible 
to observe the presence of heparin even within the scaffold. Figure 6.30-B shows one 
M0 M0.5 M1 M2 M5 
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part the well-plate used for the qualitative heparin determination. The scaffolds within 








Figure 6.30. Scaffolds tainted with Toluidine Blue. The change from blue to purple denotes the presence 
and distribution of heparin. 
 
Closer images of the scaffolds (20X) were taken on the purple shade zone on every 
scaffold to observe if the shade could give an indication of the amount of heparin 
present in each concentration. From Figure 6.31 (A to E), it is possible to notice the 
difference between the sample without heparin which exhibits a completely blue 
surface, and the rest of the samples with heparin, which can be seen as purple surfaces 




Figure 6.31. Scaffolds stained with Toluidine blue (20X); it is possible to observe the change from blue to 
purple in the presence of heparin. Loading concentrations: (A) M0, (B) M0.5, (C) M1, (D) M2, (E) M5. 
 
6.2.2.2 Quantitative determination of heparin  
At the end of the Toluidine Blue assay for heparin quantification it was observable that 
total amount of heparin detected on every scaffold, varied according to the loading 
concentration where they were immersed. Figure 6.32 shows an image of the vials at 
Top surface Bottom 
surface 
Core 
M0 M0.5 M1 M2 M5 A B 
A B C D E 
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the end of the Toluidine Blue assay. It is notable how, after the n-hexane extracts the 
heparin-Toluidine Blue complex (purple liquid), the rests of the dye in aqueous phase 
are significantly lower when the heparin concentration is higher (blue liquid). This 
allowed to visually determine which scaffolds present more heparin amount. 
By using the data of the amount of heparin the scaffolds release over time, the total 
sum of all the results was obtained, providing an estimated total concentration of 
heparin per scaffold, showed in Table 6.4. Average concentrations go from 28.14 μg to 
315.89 μg per scaffold. Considering that the scaffolds weighed an average of 6.47 ± 









Figure 6.32. Vials during Toluidine Blue assay, showing how higher heparin concentrations create a 















% of total 
scaffold weight 
% release within 
the first 1.5 h 
0.5 28.14 0.435  44.68 
1 50.14 0.775 57.06 
2 138.85 2.146 82 
5 315.89 4.882 90.38 
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Regarding the quantification of the heparin, Figure 6.33 presents a graph showing the 
percentage of heparin released throughout the different time intervals. 
It is interesting to highlight that higher loading concentrations (M2 and M5) showed a 
faster heparin release, losing more than 80% of the heparin content within the first 1.5 
hours of the experiment.  
The lower loading concentrations (M0.5 and M1), however, kept a steady release over 




Figure 6.33. Percentage of heparin released from the scaffolds over time. 
 
 
6.2.2.3 Discussion of heparin determination 
Toluidine Blue assay allowed the quantitative determination of the heparin content as 
well as its qualitative distribution on the scaffold.  
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The distribution of heparin throughout the scaffold was confirmed by showing the 
change of colour from blue to purple along the chitosan matrix, and even within the 
scaffold, due to the interconnected porosity which allowed the penetration of the 
heparin solution even to the core of the scaffold (Figure 6.30-A). The change of colour 
in the Toluidine Blue solution was immediate after the immersion of the scaffolds, with 
gradual differences in the shades of blue and purple according to the heparin 
concentration (Figure 6.29). In Figure 6.31 (A to E), it is possible to spot the difference 
among the sample without heparin which presents a completely blue surface, and the 
rest of the samples with heparin, which show purple surfaces with some scattered blue 
spots. However, the purple shade in the heparinized scaffolds did not give much 
information about the concentration of each sample, as no apparent difference among 
scaffolds was notable, regardless of the concentration. 
The loading of heparin onto chitosan is caused by the presence of positive charge 
(amine groups) in the polymer matrix and anionic charge (sulphate and carboxyl 
groups) of heparin. Therefore, the DD of the chitosan plays an important role on 
heparin loading, as mentioned before the scaffold matrix was prepared with a chitosan 
with DD ≥ 90%, thus, presenting enough amino groups for the heparin interaction. 
However, it is important to highlight that during this study most of the heparin was 
released within the first 1.5 hours of immersion in water as shown in Figure 6.33. The 
higher the loading concentration of the scaffold the higher the percentage of heparin 
content released within the first 1.5 hours, with the maximum concentration losing the 
90% of the heparin content within this time. Gümüșderelioǧlu & Aday (2011) reported 
a fast release with their functionalized chitosan scaffold where heparin had been 
bonded electrostatically 78. These authors, however, report a release of at least 50% 
within the first 10 days of exposure to cell culture process. This means that the addition 
of hydroxyapatite, causes the electrostatic interaction between chitosan and heparin to 
Chapter 6: Results and Discussion. Section II 
 
186 
Griselda Valeria Nájera Romero – June 2021 
be weaker, since the distribution of hydroxyapatite throughout all chitosan matrix 
hinders their interaction. Additionally, as explained in section 6.1.1.1 how 
hydroxyapatite exhibits a slightly negative charge due the presence of phosphate and 
hydroxyl groups. This negative charge causes a repulsion of between these two 
components during their interaction in the matrix. This explains the faster release 
when more heparin is presented. This is also why the top surface presented in Figure 
6.30-A presented a deeper purple shade spread all over the surface rather than only in 
one spot of it like in the bottom surface. Covalent bonding of heparin would represent 
an option worth to explore, as well as the response of this bonding and the addition of 
hydroxyapatite. 
Nonetheless, heparin was successfully loaded onto the matrices, creating a 
functionalized scaffold for heparin liberation. Furthermore, a steady release was 
achieved by those scaffolds with less than 1% wt of heparin, giving an important 
indication of the loading limits of a chitosan/hydroxyapatite matrix.  
 
6.3 Biological characterization 
6.3.1 Cell viability determination using Alamar blue 
assay 
Alamar Blue assay was performed to assess cell viability, this characteristic defines the 
ability of the material to maintain the cells alive within the scaffold during a certain 
period. This is achieved by the qualitative measurement of the metabolic activity of the 
cells. While performing metabolism, the organisms decompose different molecules to 
obtain energy and at the same time they produce several nutrients to satisfy their 
needs. Therefore, during Alamar Blue assay the living cells reduce the non-toxic 
reagent resazurin (blue and non-fluorescent) to resorufin (red and fluorescent). It was 
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possible to observe the colour change of this process when the dye goes from blue to 
pink. The lighter the colour obtained, the higher the metabolic activity indicating that 
the cells are able to survive and proliferate in the media they are kept. Figure 6.34 
shows the colour change during the experiment, showing the comparison with the dye 







Figure 6.34. Part of a well-plate after Alamar Blue assay on day 9th. Showing the differences in the 
shades obtained after resazurin reduction. The lighter the colour the higher the metabolic activity. 
 
The metabolic activity of U2OS cells on the scaffolds is presented in Figure 6.35. The 
cells were evaluated for 14 days, with readings taken on the 1st, 4th, 9th and 14th day. It 
can be observed that for the scaffolds without heparin, the proliferation of cells was 
greater over time (higher metabolic activity) when compared to the behaviour 
observed in the scaffolds with different heparin concentrations.  
For the scaffolds with different heparin content, according to these results, cell activity 









Chapter 6: Results and Discussion. Section II 
 
188 













6.3.1.1 Discussion of cell viability results 
The scaffold should provide a suitable environment in terms of attachment and space 
for cell migration. Chitosan and hydroxyapatite scaffolds are already known to offer 
the appropriate biocompatible characteristics for cell survival 155. The evaluation of cell 
viability with of an Alamar Blue assay qualitatively determines the metabolic activity 
of the cells. 
The metabolic activity of U2OS cells on the scaffolds is presented in Figure 6.35. U2OS 
is an osteosarcoma cell line, a well-characterized model frequently used in biomedical 
evaluations due to their fast growth and sharing features with osteoblast and fibroblast 
cells 159,160. The cells were evaluated for 14 days, with readings taken on the 1st, 4th, 9th 
and 14th day. According to these results, regardless of the heparin content, cell activity 
remains constant throughout the entire evaluation. Proving cell attachment, during the 
first day, and cell survival, until the last day of the assay.  
Figure 6.35. Metabolic activity of the U2OS cells on the heparinized scaffolds 
for 14 days. p <0.005 
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Furthermore, it can be observed that for the scaffolds without heparin, the proliferation 
of cells was greater in time (higher metabolic activity) when compared to the behaviour 
observed in the scaffolds with different concentrations of heparin. This is mainly 
because the heparin concentration hinders cells proliferation: the scaffolds present a 
fast desorption of heparin, as mentioned previous sections, which does not allow 
heparin to interact with fibronectin and other attachment factors 78, causing the low 
proliferation profile in these results. Additionally, heparin binds biomolecules such as 
FGF which plays an important role on cell processes such as proliferation and 
differentiation121. Likewise, it has been recently suggested that sulphate groups 
mediate heparin’s interaction with selectins, and they can potentiate their inhibitory 
effect causing the restraint of cell adhesion and migration 122. Similar results are 
presented by Gümüșderelioǧlu & Aday (2011), scaffolds with electrostatically loaded 
heparin reported no particular proliferation during their study 78.   
 
6.3.2 Angiogenic response ex-ovo  
CAM assay allowed to analyse the preliminary performance of the heparin-loaded 
scaffolds. Micrographs of the samples were taken on the third and the sixth day after 
the implantation of the scaffold in the CAM. The following figures show these images 
to assess the changes in the vascularity surrounding the scaffold. These changes can 
help to estimate of the influence of the scaffold in the microvascularity of the CAM. 
The main idea is that if an implant is not angiogenic, there will not be a visible vascular 
response in the surrounding of the sample, i. e. blood vessels will not grow towards or 
into the sample, rather they will not grow at all or they will continue their normal 
growth despite the sample presence. During the experiment, a filter paper was used as 
a negative control sample, assuming vascularization will not grow towards this 
material. Figure 6.36 shows the results for the control sample. It can be observed that 
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by day 6, the microvessels continue to grow below the scaffold regardless of the 
presence of the filter paper, forming a continuity of the vascularization under the 


























Figure 6.37. Micrograph of MMW sample (scaffold of just chitosan, i.e. without hydroxyapatite or 
heparin content)  implanted on the CAM at the 3rd and the 6th day of implantation. 
 
 
3rd day after implantation 6th day after implantation 
3rd day after implantation 6th day after implantation 
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Figure 6.38. Micrograph of M0 sample (scaffold without heparin) implanted on the CAM at the 3rd and 









Figure 6.39. Micrograph of M0.5 sample (scaffold loaded in the 0.5 mg/mL heparin solution) implanted 











Figure 6.40. Micrograph of M1 sample (scaffold loaded in the 1 mg/mL heparin solution) implanted on 
the CAM at the 3rd and the 6th day of implantation. 
 
3rd day after implantation 6th day after implantation 
3rd day after implantation 6th day after implantation 
3rd day after implantation 6th day after implantation 
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Figure 6.41. Micrograph of M2 sample (scaffold loaded in the 2 mg/mL heparin solution) implanted on 











Figure 6.42. Micrograph of M5 sample (scaffold loaded in the 5 mg/mL heparin solution) implanted on 







Figure 6.43. Transversal cut of a M1 sample (scaffold loaded in the 1 mg/mL heparin solution), 
exhibiting vascular ingrowth in the lower part (white arrows). 
 
3rd day after implantation 6th day after implantation 
3rd day after implantation 6th day after implantation 
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Figures 6.37 - 6.42 present the changes observed in the CAM tissue surrounding the 
implanted scaffold. Samples M0, M0.5, M1 and M2 exhibit the growth of ordered 
microvascularization towards the sample, unlike the highest concentration M5, which 
shows less vascular ingrowth towards the sample and the vessels have a disorganized 
appearance. It is also possible to observe how sample MMW presents a lower 
angiogenic response compared to the scaffold with hydroxyapatite.  
On the other hand, Figure 6.38 presents an image of a transversal cut of a M1 scaffold 
(fixed and dried after retrieval). It is possible to observe the presence of vessel inside 
the lower part of the sample, proving the vascular infiltration to the scaffolds.  
The images from Figures 6.36 – 6.42 were used to count the blood vessel growing 
towards the scaffolds, using the method described by Barnhill et al. (1983) for the 
calculation of the vasculogenic index (VIx). The vasculogenic index represents the 
number of blood vessels attached to the scaffold creating a steering wheel pattern 161. 
Figure 6.44-A shows the methodology used for VIx calculation based on Barnhill et al 
(1983), section B of this figure presents an example of VIx calculation in a real image 










Figure 6.44. (A) Pictorial representation of the methodology used for VIx calculation. For this drawing, 
VIx= 4. (B) Determination of VIx based on the methodology represented on the right. For this scaffold, 
VIx = 41. 
A B 
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Vasculogenic indexes were determined on the 6th day after scaffold implantation on 
the CAM. Table 4.5 shows a comparison of the average VIx for the different loading 
concentrations of the heparinized scaffold.  
 
Sample VIx 
MMW 16.33 ± 1.45 
M0 33.5 ± 2.34 
M0.5 36.8 ± 2.33 
M1 32 ± 2.07 
M2 33 ± 3.60 








From the vasculogenic indexes calculation it was observed that for most of the 
concentrations, the results were very close regardless of the amount of loaded heparin, 
with a slightly better performance from the scaffold loaded in the 0.5 mg/mL solution.  
However, visually this is not completely notable, as observed in Figures 6.37 – 6.42.  
It is important to mention that for the highest heparin loading concentration, most of 
the embryos died, (survival rate of 20%). Many of them showed bleeding vessels 
surrounding the scaffold as showed in Figure 4.45. Bleeding in a system is an indication 
of heparin overdose 162. 
Table 6.5. Vascular index results of the scaffolds with increasing heparin content designated 
by: MMW (scaffold of just chitosan, i.e. without hydroxyapatite or heparin content), M0, 
(scaffold without heparin), M0.5 (scaffold of chitosan: hydroxyapatite 50:50 loaded in the 0.5 
mg/mL heparin solution), M1 (scaffold of chitosan: hydroxyapatite 50:50 loaded in the 1 
mg/mL heparin solution), M2 (scaffold of chitosan: hydroxyapatite 50:50 loaded in the 
2mg/mL heparin solution) and M5 (scaffold of chitosan: hydroxyapatite 50:50 loaded in the 5 
mg/mL heparin solution). 
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Figure 6.46 shows the results from the H&E staining after the retrieval of the samples 
of the CAM assay.  
From Figure 6.46 it can be noticed that there is a well define area where CAM’s 
connective tissue can be observed integrating with the scaffold. It is also possible to see 
the appearance of secondary vessels surrounding the CAM tissue (white arrows). No 
anomalies or appearance of inflammatory cells was detectable. 
It is important to highlight cellular infiltration into the scaffolds. It may also be stated 
that for the scaffolds with higher loading concentrations, the integration is not well 








Figure 6.45. Spontaneous bleeding of an embryo implanted with the scaffolds with the highest heparin 
dose (M5 (scaffold of chitosan: hydroxyapatite 50:50 loaded in the 5 mg/mL heparin solution)). 
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6.3.2.2 Discussion of angiogenic response  
The chorioallantoic membrane, CAM, functions as a gas exchanger, and a disposer for 
the chick embryo’s waste. It also plays part in the mineral transport for the bone 
development of the embryo. These activities are mainly due to its location and its 
Figure 6.46. Comparison of the H&E staining of the samples for the different heparin concentrations and 












CAM tissue M0 
M0.5 M1 
M2 M5 
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highly vascularized nature 163. Ribatti (2017) describes CAM assay as an outstanding 
model to assess angiogenic performance of materials and drugs 164, and Mangir et al. 
(2019) and Eke et al. (2017) highlighted the use of the in-ovo technique to improve the 
visual analysis, monitoring, and comparison of the materials under evaluation 130,131.  
CAM assay presents preliminary data regarding the effect of the heparin-loaded 
scaffolds in a living model. Chick embryo’s health and survival, as well as changes in 
the vascularization surrounding or attaching the scaffolds, provide useful information 
on the angiogenic activity of the scaffolds produced in this study.   
The micrographs of the scaffolds taken on the third and the sixth day after the 
implantation were used for the calculation of the vasculogenic index. From these 
results, it was observed that the angiogenic behaviour in all the samples was very 
similar despite the heparin content of the scaffold. There was a slightly better 
performance from the scaffold loaded in the 0.5 mg/mL solution indicating that this 
loading concentration provided better angiogenic response. Comparable results were 
observed from a parallel project within our research group with injectable heparinized-
chitosan hydrogels. From the histology results, it is also notable that the scaffolds did 
not trigger an inflammatory response and they integrated uniformly with the CAM 
tissue (Figure 6.46).  
Angiogenesis is an activity that depends on the constant stimulus to the microvascular 
endothelial cells. As mentioned in section 1.2 hypoxia can prompt the angiogenic 
growth factors (AGF) to trigger angiogenesis (and osteogenesis). To start the 
angiogenic process, tipping cells break down the extracellular matrix, opening the path 
that the capillary sprout should follow. These cells possess several AGF receptors, 
detecting its variations along the surface. The tipping cells align and adjust towards 
the AGF stimulus, followed by the recently proliferated endothelial cells that were 
behind them (Figure 1.1). This creates the elongation of the capillary sprout. With time, 
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the leading cells will join together, creating a continuous tubular structure that will 
allow blood to flow through it. With the oxygen levels returning to normal due to the 
re-established blood flow the AGF levels decrease to their usual values, and the 
angiogenic stimulus disappears. Therefore, it is important to provide an AGF stimulus 
to induce an angiogenic response. 
Heparin binds with angiogenic growth factors such as VEGF and FGF, by an 
electrostatic interaction of the cationic domains of these proteins with the highly 
negatively charged heparin. The heparin release process for lower loading 
concentrations (M0.5 and M1) offered a constant and sustained heparin release, 
providing heparin availability longer than the rest of the concentrations and without 
‘overdosing’ the implanted area and the subject. A longer availability provides enough 
time for heparin to bind with surrounding angiogenic factors, creating a gradient that 
will stimulate an angiogenic response.  
According to the study by Ito & Claesson-Welsh (1999), heparin contributes to present 
VEGF and FGF to their receptors in the cells. Likewise, they concluded that this effect 
can be dependent on the heparin dose, since a reduction of the growth factor affinity 
can be caused by exogenous heparin competing with endogenous heparan sulphates 
for binding VEGF 13. This explains the results for M5 sample, since the high amount of 
heparin being rapidly released caused a decrease on the angiogenesis process, along 
with the overdose of the specimens.  
Visually, however, the slight better angiogenic response of M0.5 was not easily spotted, 
as observed in Figures 6.37 – 6.41. The scaffold without heparin (M0) also presented an 
angiogenic response and vascular ingrowth, suggesting that the material per se also 
generates an angiogenic response in the implanted area. This is also observable in 
Figure 4.45, where scaffolds M0 show a good integration with CAM tissue as well as 
the presence of secondary blood vessels towards the scaffold. Even when chitosan 
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provides an extracellular-matrix-like structure, with interconnected porosity, to 
provide vascular ingrowth and infiltration, this does not seem to be the determining 
factor for our results. In Figure 6.37, though MMW scaffolds induced vascular 
attachment, this is very low as compared with the rest of the samples. As mentioned 
earlier M0 samples reported similar results to the heparinized scaffolds. This is mainly 
due to the presence of hydroxyapatite.  
Meagher M. et al. (2016) report a similar behaviour with scaffolds made from 
collagen/hydroxyapatite combinations. They observe a better angiogenic response 
from scaffolds with hydroxyapatite compared to scaffolds of just collagen. 
Furthermore, this angiogenic behaviour improves with the amount of hydroxyapatite 
added to the scaffolds.  
As mentioned earlier, hydroxyapatite enhances bioactive properties. Bioactivity 
describes the effect a material will have on an organism. The presence of Ca2+, PO3-4 
and OH- ions on hydroxyapatite’s surface provides the ability to interact with several 
molecules from the microvascular cells and their surface, improving and promoting 




The primary aim of the study was to identify suitable materials(s) that promote 
angiogenesis. For this purpose, the material should comply a number of characteristics 
that allow this process to take place such as adequate pore size and pore 
interconnectivity, good bioactive properties, and it also should provide angiogenic 
stimuli. 
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 Within this research, using the freeze-gelation technique, it was possible to obtained 
porous scaffolds able to promote cell infiltration and proliferation. Additionally, these 
scaffolds proved to be bioactive by the apatite layer formed onto them during the 
bioactivity study. It was also possible to confirm that heparin (alone) produces a 
positive angiogenic effect on CAM assay when loaded on to chitosan/hydroxyapatite 
scaffolds. This ability is dependent on the concentration of the glycosaminoglycan; 
therefore, the importance of this study lies on the fact that it defines a starting point of 
the angiogenic effect as well as a point where antiangiogenic results were observed.  
Further conclusions are presented in the next sect 
Chapter 7: Conclusions and Future Work 
 
201 
Griselda Valeria Nájera Romero ― June 2021 
7 
Conclusions and Future Work 
7.1 Conclusions 
The aim of this study was to produce a scaffold able to promote and improve 
angiogenesis during bone regeneration. This study focused on the fabrication of a 
scaffold from materials that have proven to promote osteogenesis, adding heparin that 
binds with angiogenic growth factors with the hypothesis that this mixture will 
produce a composite able to promote angiogenesis.  
During the development process, the main goal was to obtain a scaffold with a 
homogeneous composition, this would provide a constant availability of amino groups 
for heparin to interact and bond with the matrix. At the same time, obtaining a porous 
structure that would provide sufficient surface for bone tissue to grow and develop. 
Stable chitosan/hydroxyapatite scaffolds with controlled porosity were prepared by 
employing freeze-gelation methodology. It was observed that freeze-drying yielded 
porous scaffolds; however, the resultant characteristics of surface skin, closed porosity 
and lack of availability of amino groups were not satisfactory for heparin loading 
purposes. Freeze-gelation, on the other hand, provided a structure with pore size able 
to induce cell growth and proliferation, besides, the interconnectivity of its pores offers 
an ideal surface for vascularization to proliferate. Through SEM characterization it was 
confirmed that the produced scaffolds were bestowed with the necessary organization 
and porosity to enable and promote osteogenesis. Additionally, with FTIR analysis it 
was proven that hydroxyapatite was distributed throughout the chitosan matrix, even 
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creating a hydroxyapatite-rich side, which will provide a highly bioactive surface for 
bone tissue engineering purposes.  
Likewise, this study has demonstrated that 50:50 chitosan: hydroxyapatite ratio and 
freeze-gelation process provide the best combination to produce a porous scaffold for 
the purpose of promoting osteogenesis and angiogenesis. Preliminary in-vitro 
bioactivity performance showed that the scaffolds provide a surface capable to 
promote apatite layer formation, which holds promises for a positive in-vivo 
performance, where osteoblasts can bond with this apatite layer to induce 
osteogenesis.  
Vascularization plays a crucial role in bone development and maintenance as it helps 
to deliver a variety of nutrients, as well as transport a variety of molecules that 
ultimately control its microenvironment. The process of angiogenesis aids to uphold 
vascularization in any tissue. This process depends on the interaction of the tip 
endothelial cells of the blood vessels with the angiogenic growth factors that will 
stimulate the proliferation of more endothelial cell so the vessel can sprout and join to 
form new capillaries. Therefore, maintaining a proper availability of these angiogenic 
factors is critical for the angiogenesis to occur.  
Heparin binds with several angiogenic factors; thus, it can define their availability or 
functionalization. In this study, heparin was successfully loaded to the porous 
scaffolds. The final amount of heparin loaded to the scaffold was defined by the 
electrostatic interaction between the heparin and the chitosan matrix. Scaffolds loaded 
with higher concentrations of heparin resulted on weak interactions providing a fast 
desorption of the heparin. Nonetheless, low concentrations offered a slow release, 
providing a sustained availability of the heparin in the implantation site assuring its 
interaction with the local angiogenic factors. 
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Furthermore, in-vitro degradation study showed that the presence of hydroxyapatite 
and heparin in the scaffold play a major role on its degradation profile. The 
modification of surface charge of the scaffolds resulted in a delay of the chitosan matrix 
degradation due to the interaction of hydroxyapatite and heparin with lysozyme. This 
translates on the scaffold providing a stable framework for bone to regenerate. 
It is important to highlight the biological response to the produced scaffold material, 
since the porous chitosan/hydroxyapatite scaffolds did not exhibit cytotoxic effects. 
The cytotoxicity was evaluated with U2OS osteosarcoma cells, which are widely used 
to evaluate osteoblast-like features. Therefore, their proliferation and survival during 
the evaluation provides a preliminary approach on the expected behaviour of the 
scaffolds when interacting with osteoblasts.  
Additionally, the angiogenic response was evaluated by CAM assay. This 
methodology provides a closer view to the expected performance in-vivo, the 
angiogenic response, i. e. the promotion and attachment of blood vessels to the 
scaffold, was analysed. It was observed that after six day of implantation, the scaffolds 
are able to trigger an angiogenic response without the presence of heparin, providing 
a plus-feature to the material. However, low heparin concentrations exhibited the best 
angiogenic performance during the study, with a higher vasculogenic index (number 
of blood vessels attached to the scaffold), providing an efficiency reference of heparin 
addition. It was also noted that high concentrations of heparin resulted in a non-
angiogenic behaviour, therefore, this research provides information regarding the 
amount of heparin necessary to promote angiogenesis, beyond which a toxic effect can 
be observed.  
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In conclusion, this study demonstrated the feasibility of using heparin alone to 
promote angiogenesis in an in-vivo microenvironment. Other approaches have shown 
it is possible to use heparin to promote bone angiogenesis, however all of them use 
external growth factors or bone proteins. Additionally, the heparin loading procedure 
used during this research is relatively simple and inexpensive technology, which adds 
to the potential of the scaffold for clinical applications. Furthermore, this research has 
also demonstrated that there is a threshold amount for heparin to induce a positive 
angiogenic effect and it is possible to provide bioactive features to the composite by 
including hydroxyapatite. 
 
7.2 Further Work 
During this research, an unprecedented pandemic event took place which hindered 
the possibility of complementing some of the results presented in this thesis, since 
there is the possibility of evaluating the interaction of the scaffolds with VEGF. Based 
on the work performed by Gigliobianco et al. (2015), one approach is to directly 
immerse the scaffolds in a VEGF solution, and subsequently determine the amount of 
VEGF loaded onto the scaffolds by an ELISA assay. Another option consists of 
submerging the scaffolds into VEGF or human blood plasma, after this process the 
scaffolds can be functionalised with fluorescent antibodies and be observed under the 
fluorescence microscope 77. This analysis would help to analyse the distribution of 
VEGF over the scaffold surface. Both experiments provide an overview of the 
interaction of heparinized scaffolds with this crucial angiogenic growth factor.  
Another approach would have been to compare the action of the scaffolds loaded with 
VEGF and the produced heparinized scaffolds; this would provide a useful 
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comparison on the angiogenic action of the heparin alone with the angiogenic effect of 
the growth factor.  
It would have been also interesting to address better and improved loading of heparin 
by exploring the creation of covalent bonding between heparin and the chitosan. The 
process for bonding heparin covalently with chitosan involves a process of incubating 
of the chitosan/hydroxyapatite scaffolds in a solution containing heparin, MES (2-(N-
morpholino) ethanesulfonic acid), EDAC (1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide) and NHS (N-hydroxysuccinimide), followed by extensive washings 
with ultrapure water165, according to Gümüşderelioğlu & Aday (2011) this process 
functionalises the amino groups from chitosan and the carboxyl group from heparin.  
This characterization would show the interaction among the three components, 
providing another insight into the release effect of the heparin from the 
chitosan/hydroxyapatite matrix. Moreover, it offers the possibility of analysing 
different release mechanisms, according to the concentrations of heparin, providing 
more information regarding the effect of heparin in a long-term release. 
Further studies can be focused on the effects of different hydroxyapatite ratios in the 
angiogenic response. Since it was found that the produced scaffolds trigger 
angiogenesis even without the presence of heparin, exploring the effect of 
hydroxyapatite in the angiogenic response would provide deeper understanding on 
the effects of hydroxyapatite and its use in bone tissue engineering constructs. During 
the developing process it was observed that the addition of hydroxyapatite tightened 
the porosity of the scaffold. In additional investigation the amount of hydroxyapatite 
can be decreased to improve porosity and elasticity, hence, the wider interconnected 
porosity would provide a more accessible path for vascular infiltration and retaining 
bioactivity. Likewise, the amount of hydroxyapatite can be increased to compare its 
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effect on the bioactive properties of the composite, as well as to observe differences in 
the porosity and vascular access to the scaffold. 
Similarly, to broaden the scope of the previous suggestion, it is worth exploring the 
effects of different hydroxyapatite substitutions and their effect on the angiogenic 
response. Ionic substitutions may not only have an effect on the osteogenic response, 
but on the angiogenic effect of hydroxyapatite as well, improving its’ bioactivity and 
may enhance biocompatibility as well. For example, incorporation of silica has been 
reported to have positive effects on both osteogenesis and angiogenesis processes 166,167. 
Silica can substitute phosphate groups in hydroxyapatite during hydrothermal 
synthesis168, providing a source to potentiate the pro-angiogenic effect of the system 
proposed in this work.  
There is a latent need for materials to be able to promote and enhance bone 
regeneration. Revascularisation plays an important role in this process, therefore, the 
need to improve this process is extensive. Despite the complementary work that can 
be conducted, this research provides baseline information regarding the angiogenic 





Chapter 8: References  
 
207 
Griselda Valeria Nájera Romero ― June 2021 
8 
References 
1. Bueno, E. M. & Glowacki, J. Biologic Foundations for Skeletal Tissue Engineering. 
Synthesis Lectures on Tissue Engineering 3, (2011). 
2. Doblaré, M., García, J. M. & Gómez, M. J. Modelling bone tissue fracture and 
healing: A review. Eng. Fract. Mech. 71, 1809–1840 (2004). 
3. Park, H. et al. Anionic carbohydrate-containing chitosan scaffolds for bone 
regeneration. Carbohydr. Polym. 97, 587–596 (2013). 
4. Sanjeev, K. & Einhorn, T. A. Tissue Engineering of Bone. in Bone Tissue 
Engineering (eds. Hollinger, J. O., Einhorn, T. A., Doll, B. A. & Sfeir, C.) 277–302 
(CRC Press, 2005). 
5. Dorozhkin, S. Calcium Orthophosphate-Containing Biocomposites and Hybrid 
Biomaterials for Biomedical Applications. J. Funct. Biomater. 6, 708–832 (2015). 
6. Prendergast, P. J. & van der Meulen, M. C. H. Mechanics of Bone Regeneration. 
in Bone Mechanics Handbook (ed. Cowin, S. C.) 32-1-32–13 (CRC Press, 2001). 
7. Hollister, S. J., Gabriel, T.-M., Halloran, J. W. & Feinberg, S. E. Design and 
Manufacture of Bone Replacement Scaffolds. in Bone Mechanics Handbook (ed. 
Cowin, S. C.) 1–14 (CRC Press, 2001). 
8. Pneumaticos, S. G., Triantafyllopoulos, G. K., Basdra, E. K. & Papavassiliou, A. 
G. Segmental bone defects: From cellular and molecular pathways to the 
development of novel biological treatments. J. Cell. Mol. Med. 14, 2561–2569 
(2010). 
9. Hankenson, K. D., Dishowitz, M., Gray, C. & Schenker, M. Angiogenesis in bone 
regeneration. Injury 42, 556–561 (2011). 
10. Saran, U., Gemini Piperni, S. & Chatterjee, S. Role of angiogenesis in bone repair. 
Arch. Biochem. Biophys. 561, 109–117 (2014). 
11. Loi, F. et al. Inflammation, fracture and bone repair. Bone 86, 119–130 (2016). 
12. Bayer, E. A., Gottardi, R., Fedorchak, M. V. & Little, S. R. The scope and sequence 
of growth factor delivery for vascularized bone tissue regeneration. J. Control. 
Release 219, 129–140 (2015). 
Chapter 8: References  
 
208 
Griselda Valeria Nájera Romero ― June 2021 
13. Ito, N. & Claesson-Welsh, L. Dual effects of heparin on VEGF binding to VEGF 
receptor-1 and transduction of biological responses. Angiogenesis 3, 159–166 
(1999). 
14. Rema, R. B., Rajendran, K. & Ragunathan, M. Angiogenic efficacy of Heparin on 
chick chorioallantoic membrane. Vasc. Cell 4, 1–7 (2012). 
15. Chiodelli, P., Bugatti, A., Urbinati, C. & Rusnati, M. Heparin/heparan sulfate 
proteoglycans glycomic interactome in angiogenesis: Biological implications 
and therapeutical use. Molecules 20, 6342–6388 (2015). 
16. Mescher, A. L. Junqueira’s basic histology: text and atlas. (McGraw-Hill Education 
Medical, 2013). 
17. Lowe, J. S. & Anderson, P. G. Steven’s & Lowe’s Human Histology. (Elsevier 
Mosby, 2015). 
18. Bartl, R. & Frisch, B. Biology of Bone. in Osteoporosis. Diagnosis, Prevention, 
Therapy 7–28 (Springer Berlin Heidelberg, 2009). 
19. Boskey, A. L. The Organic and Inorganic Matrices. in Bone Tissue Engineering 
(eds. Hollinger, J. O., Einhorn, T. A., Doll, B. A. & Sfeir, C.) 91–123 (CRC Press, 
2005). 
20. Webster, S. S. J. Integrated Bone Tissue Phisiology: Anatomy and Phisiology. in 
Bone Mechanics Handbook (ed. Cowin, S.) 1-1-1–68 (CRC Press, 2001). 
21. Whiting, W. C. & Zernicke, R. F. Concepts of Injury and Healing. in Biomechanics 
of Musculoskeletal Injury 124–151 (Human Kinetics, 2008). 
22. Liu, Y., Luo, D. & Wang, T. Hierarchical Structures of Bone and Bioinspired 
Bone Tissue Engineering. Small 12, 4611–4632 (2016). 
23. Schenk, R. K., Hofstetter, W. & Felix, R. Morphology and Chemical Composition 
of Connective Tissue: Bone. in Connective tissue and its heritable disorders: 
molecular, genetic and medical aspects (eds. Royce, P. M. & Steinmann, B.) 67–120 
(Wiley-Liss, 2002). 
24. Zanchetta, J. R. & Talbot, J. R. Osteoporosis: Fisiología, diagnóstico, prevención y 
tratamiento. (Editorial Médica Panamericana, 2001). 
25. Kini, U. & Nandeesh, B. N. Physiology of Bone Formation, Remodeling and 
Metabolism. in Radionuclide and Hybrid Bone Imaging (eds. Fogelman, I., 
Gnanasegaran, G. & Van der Wall, H.) 29–57 (Springer Berlin Heidelberg, 2012). 
26. Gelse, K., Pöschl, E. & Aigner, T. Collagens - Structure, function, and 
biosynthesis. Adv. Drug Deliv. Rev. 55, 1531–1546 (2003). 
Chapter 8: References  
 
209 
Griselda Valeria Nájera Romero ― June 2021 
27. Ferreira, A. M., Gentile, P., Chiono, V. & Ciardelli, G. Collagen for bone tissue 
regeneration. Acta Biomater. 8, 3191–3200 (2012). 
28. Olszta, M. J. et al. Bone structure and formation: A new perspective. Mater. Sci. 
Eng. R Reports 58, 77–116 (2007). 
29. Garnero, P. The Role of Collagen Organization on the Properties of Bone. Calcif. 
Tissue Int. 97, 229–240 (2015). 
30. Buck, D. & Dumanian, G. Bone Biology and Physiology:  Part II. Clinical 
Correlates. Plast Reconstr Surg 129, 950e-956e (2012). 
31. Liu, Q., Huang, S., Matinlinna, J. P., Chen, Z. & Pan, H. Insight into biological 
apatite: Physiochemical properties and preparation approaches. Biomed Res. Int. 
2013, (2013). 
32. Liu, Q., Pan, H., Chen, Z. & Matinlinna, J. P. Insight into bone-derived biological 
apatite: Ultrastructure and effect of thermal treatment. Biomed Res. Int. 2015, 
(2015). 
33. Palmer, L. C., Newcomb, C. J., Kaltz, S. R., Spoerke, E. D. & Stupp, S. I. 
Biomimetic systems for hydroxyapatite mineralization inspired by bone and 
enamel. Chem. Rev. 108, 4754–4783 (2008). 
34. Burr, D. B. The contribution of the organic matrix to bone’s material properties. 
Bone 31, 8–11 (2002). 
35. Fernandez-Tresguerres Hernandez-Gil, I., Alobera Gracia, M. A., Del Canto 
Pingarrin, M. & Blanco Jerez, L. Bases fisiologicas de la regeneración osea I. 
Histologia y fisiologia del tejido oseo. Med. Oral Patol. Oral Cir. Bucal 11, 32–36 
(2006). 
36. Rucci, N. & Teti, A. The ‘love-hate’ relationship between osteoclasts and bone 
matrix. Matrix Biol. 52–54, 176–190 (2016). 
37. Florencio-Silva, R., Sasso, G. R. D. S., Sasso-Cerri, E., Simões, M. J. & Cerri, P. S. 
Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone 
Cells. Biomed Res. Int. 2015, (2015). 
38. Ural, A. & Vashishth, D. Hierarchical perspective of bone toughness – from 
molecules to fracture. Int. Mater. Rev. 59, 245–263 (2014). 
39. Rho, J. Y., Kuhn-Spearing, L. & Zioupos, P. Mechanical properties and the 
hierarchical structure of bone. Med. Eng. Phys. 20, 92–102 (1998). 
40. Weinkamer, R. & Fratzl, P. Mechanical adaptation of biological materials - The 
examples of bone and wood. Mater. Sci. Eng. C 31, 1164–1173 (2011). 
Chapter 8: References  
 
210 
Griselda Valeria Nájera Romero ― June 2021 
41. Guo, X. E. Mechanical Properties of Cortical Bone and Cancellous Bone Tissue. 
in Bone Mechanics Handbook (ed. Cowin, S. C.) 10-1-10–23 (CRC Press, 2001). 
42. Gupta, H. S. & Zioupos, P. Fracture of bone tissue: The ‘hows’ and the ‘whys’. 
Med. Eng. Phys. 30, 1209–1226 (2008). 
43. Jepsen, K. J., Davy, D. T. & Akkus, O. Observations of Damage in Bone. in Bone 
Mechanics Handbook (ed. Cowin, S. C.) 17-1-17–18 (CRC Press, 2001). 
44. Maes, C. & Clemens, T. L. Angiogenic–osteogenic coupling: the endothelial 
perspective. Bonekey Rep. 3, 1–4 (2014). 
45. Marsell, R. & Einhorn, T. A. The biology of fracture healing. Injury 42, 551–555 
(2011). 
46. Hu, K. & Olsen, B. R. The roles of vascular endothelial growth factor in bone 
repair and regeneration. Bone 91, 30–38 (2016). 
47. Adair, T. H. & Montani, J.-P. Angiogenesis. (Morgan & Claypool Life Sciences, 
2011). 
48. Kusumbe, A. P., Ramasamy, S. K. & Adams, R. H. Coupling of angiogenesis and 
osteogenesis by a specific vessel subtype in bone. Nature 507, 323–328 (2014). 
49. Lafage-Proust, M. H., Prisby, R., Roche, B. & Vico, L. Bone vascularization and 
remodeling. Jt. Bone Spine 77, 521–524 (2010). 
50. Roseti, L. et al. Scaffolds for Bone Tissue Engineering: State of the art and new 
perspectives. Mater. Sci. Eng. C 78, 1246–1262 (2017). 
51. Yu, X., Suárez-González, D., Khalil, A. S. & Murphy, W. L. How does the 
pathophysiological context influence delivery of bone growth factors? Adv. 
Drug Deliv. Rev. 84, 68–84 (2015). 
52. Stegen, S., van Gastel, N. & Carmeliet, G. Bringing new life to damaged bone: 
The importance of angiogenesis in bone repair and regeneration. Bone 70, 19–27 
(2015). 
53. Geris, L., Gerisch, A., Sloten, J. Vander, Weiner, R. & Oosterwyck, H. Van. 
Angiogenesis in bone fracture healing: A bioregulatory model. J. Theor. Biol. 251, 
137–158 (2008). 
54. Pike, D. B. et al. Heparin-regulated release of growth factors in vitro and 
angiogenic response in vivo to implanted hyaluronan hydrogels containing 
VEGF and bFGF. Biomaterials 27, 5242–5251 (2006). 
55. Yar, M. et al. Production of chitosan PVA PCL hydrogels to bind heparin and 
induce angiogenesis. Int. J. Polym. Mater. Polym. Biomater. 65, 466–476 (2016). 
Chapter 8: References  
 
211 
Griselda Valeria Nájera Romero ― June 2021 
56. Yar, M. et al. Heparin binding chitosan derivatives for production of pro-
angiogenic hydrogels for promoting tissue healing. Mater. Sci. Eng. C 74, 347–
356 (2017). 
57. García, J. R. & García, A. J. Biomaterial-mediated strategies targeting 
vascularization for bone repair. Drug Deliv. Transl. Res. 6, 77–95 (2016). 
58. Blinder, Y. J., Mooney, D. J. & Levenberg, S. Engineering approaches for 
inducing blood vessel formation. Curr. Opin. Chem. Eng. 3, 56–61 (2014). 
59. Sharma, S. et al. Delivery of VEGFA in bone marrow stromal cells seeded in 
copolymer scaffold enhances angiogenesis, but is inadequate for osteogenesis as 
compared with the dual delivery of VEGFA and BMP2 in a subcutaneous mouse 
model. Stem Cell Res. Ther. 9, 1–13 (2018). 
60. Koob, S. et al. Bone Formation and Neovascularization Mediated by 
Mesenchymal Stem Cells and Endothelial Cells in Critical-Sized Calvarial 
Defects. Tissue Eng. Part A 17, 311–321 (2010). 
61. Hankenson, K. D., Dishowitz, M., Gray, C. & Schenker, M. Angiogenesis in bone 
regeneration. Injury 42, 556–561 (2011). 
62. Vo, T. N., Kasper, F. K. & Mikos, A. G. Strategies for controlled delivery of 
growth factors and cells for bone regeneration. Adv. Drug Deliv. Rev. 64, 1292–
1309 (2012). 
63. Bhakuni, T. et al. Role of heparin and non heparin binding serpins in coagulation 
and angiogenesis: A complex interplay. Arch. Biochem. Biophys. 604, 128–142 
(2016). 
64. Rema, R. B., Rajendran, K. & Ragunathan, M. Angiogenic efficacy of Heparin on 
chick chorioallantoic membrane. Vasc Cell 4, 8 (2012). 
65. Collen, A. et al. Unfractionated and Low Molecular Weight Heparin Affect 
Fibrin Structure and Angiogenesis in Vitro Unfractionated and Low Molecular 
Weight Heparin Affect Fibrin Structure and Angiogenesis in vitro. Cancer Res. 
300, 6196–6200 (2000). 
66. Lee, K. W. et al. Sustained release of vascular endothelial growth factor from 
calcium-induced alginate hydrogels reinforced by heparin and chitosan. 
Transplant. Proc. 36, 2464–2465 (2004). 
67. Wu, Q. et al. The effect of heparinized decellularized scaffolds on angiogenic 
capability. J. Biomed. Mater. Res. - Part A 104, 3021–3030 (2016). 
68. Teixeira, S., Yang, L., Dijkstra, P. J., Ferraz, M. P. & Monteiro, F. J. Heparinized 
Chapter 8: References  
 
212 
Griselda Valeria Nájera Romero ― June 2021 
hydroxyapatite/collagen three-dimensional scaffolds for tissue engineering. J. 
Mater. Sci. Mater. Med. 21, 2385–2392 (2010). 
69. Freudenberg, U. et al. Heparin desulfation modulates VEGF release and 
angiogenesis in diabetic wounds. J. Control. Release 220, 79–88 (2015). 
70. Chung, Y. Il et al. Efficient revascularization by VEGF administration via 
heparin-functionalized nanoparticle-fibrin complex. J. Control. Release 143, 282–
289 (2010). 
71. Tan, Q. et al. Controlled release of chitosan/heparin nanoparticle-delivered 
VEGF enhances regeneration of decellularized tissue-engineered scaffolds. Int. 
J. Nanomedicine 6, 929–942 (2011). 
72. Yang, Y. et al. Novel mineralized heparin-gelatin nanoparticles for potential 
application in tissue engineering of bone. J. Mater. Sci. Mater. Med. 25, 669–680 
(2014). 
73. Yar, M. et al. Production of chitosan PVA PCL hydrogels to bind heparin and 
induce angiogenesis. Int. J. Polym. Mater. Polym. Biomater. 65, 466–476 (2016). 
74. Wang, J., Wan, Y. & Huang, Y. Immobilisation of heparin on bacterial cellulose-
chitosan nano-fibres surfaces via the cross-linking technique. IET 
Nanobiotechnology 6, 52 (2012). 
75. Almodóvar, J. et al. Chitosan-heparin polyelectrolyte multilayers on cortical 
bone: Periosteum-mimetic, cytophilic, antibacterial coatings. Biotechnol. Bioeng. 
110, 609–618 (2013). 
76. Shahzadi, L. et al. Triethyl orthoformate covalently cross-linked chitosan-(poly 
vinyl) alcohol based biodegradable scaffolds with heparin-binding ability for 
promoting neovascularisation. J. Biomater. Appl. 31, 582–593 (2016). 
77. Gigliobianco, G., Chong, C. K. & MacNeil, S. Simple surface coating of 
electrospun poly-L-lactic acid scaffolds to induce angiogenesis. J. Biomater. Appl. 
30, 50–60 (2015). 
78. Gümüdereliolu, M. & Aday, S. Heparin-functionalized chitosan scaffolds for 
bone tissue engineering. Carbohydr. Res. 346, 606–613 (2011). 
79. Levengood, S. K. L. et al. Chitosan-based scaffolds for bone tissue engineering. 
J. Mater. Chem. B 2, 3161 (2014). 
80. Croisier, F. & Jérôme, C. Chitosan-based biomaterials for tissue engineering. 
Eur. Polym. J. 49, 780–792 (2013). 
81. Dash, M., Chiellini, F., Ottenbrite, R. M. & Chiellini, E. Chitosan - A versatile 
Chapter 8: References  
 
213 
Griselda Valeria Nájera Romero ― June 2021 
semi-synthetic polymer in biomedical applications. Prog. Polym. Sci. 36, 981–
1014 (2011). 
82. Pillai, C. K. S., Paul, W. & Sharma, C. P. Chitin and chitosan polymers: 
Chemistry, solubility and fiber formation. Prog. Polym. Sci. 34, 641–678 (2009). 
83. Mourya, V. K. & Inamdar, N. N. Chitosan-modifications and applications: 
Opportunities galore. React. Funct. Polym. 68, 1013–1051 (2008). 
84. Usman, A. et al. Chitin and chitosan based polyurethanes: A review of recent 
advances and prospective biomedical applications. Int. J. Biol. Macromol. 86, 630–
645 (2016). 
85. Alves, N. M. & Mano, J. F. Chitosan derivatives obtained by chemical 
modifications for biomedical and environmental applications. Int. J. Biol. 
Macromol. 43, 401–414 (2008). 
86. Domard, A. A perspective on 30 years research on chitin and chitosan. 
Carbohydr. Polym. 84, 696–703 (2011). 
87. Rinaudo, M. Chitin and chitosan: Properties and applications. Prog. Polym. Sci. 
31, 603–632 (2006). 
88. Muzzarelli, R. A. A. Chitins and chitosans for the repair of wounded skin, nerve, 
cartilage and bone. Carbohydr. Polym. 76, 167–182 (2009). 
89. Kim, I.-Y. et al. Chitosan and its derivatives for tissue engineering applications. 
Biotechnol. Adv. 26, 1–21 (2008). 
90. Kurita, K. Chitin and chitosan: Functional biopolymers from marine 
crustaceans. Mar. Biotechnol. 8, 203–226 (2006). 
91. Upadhyaya, L., Singh, J., Agarwal, V. & Tewari, R. P. Biomedical applications 
of carboxymethyl chitosans. Carbohydr. Polym. 91, 452–466 (2013). 
92. Kaya, M., Akata, I., Baran, T. & Menteş, A. Physicochemical Properties of Chitin 
and Chitosan Produced from Medicinal Fungus (Fomitopsis pinicola). Food 
Biophys. 10, 162–168 (2015). 
93. Mesa Ospina, N. et al. Isolation of chitosan from Ganoderma lucidum 
mushroom for biomedical applications. J. Mater. Sci. Mater. Med. 26, 1–9 (2015). 
94. Yaghobi, N. & Hormozi, F. Multistage deacetylation of chitin: Kinetics study. 
Carbohydr. Polym. 81, 892–896 (2010). 
95. Pires, A. L. R. & Moraes, Â. M. Improvement of the mechanical properties of 
chitosan-alginate wound dressings containing silver through the addition of a 
biocompatible silicone rubber. J. Appl. Polym. Sci. 132, 1–9 (2015). 
Chapter 8: References  
 
214 
Griselda Valeria Nájera Romero ― June 2021 
96. Svirshchevskaya, E. V. et al. Analysis of toxicity and biocompatibility of chitosan 
derivatives with different physico-chemical properties. Appl. Biochem. Microbiol. 
52, 483–490 (2016). 
97. Moreno-Vásquez, M. J. et al. Functionalization of chitosan by a free radical 
reaction: Characterization, antioxidant and antibacterial potential. Carbohydr. 
Polym. 155, 117–127 (2017). 
98. Ratner, B. D. Biomaterials Science. an Introduction to Materials in Medicine. 
(Academic Press, 2013). 
99. Hao, R., Wang, D., Yao, A. & Huang, W. Preparation and characterization of ??-
TCP/CS scaffolds by freeze-extraction and freeze-gelation. J. Wuhan Univ. 
Technol. Mater. Sci. Ed. 26, 371–375 (2011). 
100. Gruselle, M. Apatites: A new family of catalysts in organic synthesis. J. 
Organomet. Chem. 793, 93–101 (2015). 
101. Šupová, M. Substituted hydroxyapatites for biomedical applications: A review. 
Ceram. Int. 41, 9203–9231 (2015). 
102. Boanini, E., Gazzano, M. & Bigi, A. Ionic substitutions in calcium phosphates 
synthesized at low temperature. Acta Biomater. 6, 1882–1894 (2010). 
103. Rezwan, K., Chen, Q. Z., Blaker, J. J. & Boccaccini, A. R. Biodegradable and 
bioactive porous polymer/inorganic composite scaffolds for bone tissue 
engineering. Biomaterials 27, 3413–3431 (2006). 
104. Kokubo, T. & Takadama, H. How useful is SBF in predicting in vivo bone 
bioactivity? Biomaterials 27, 2907–2915 (2006). 
105. Kokubo, T. Bioactive glass ceramics: properties and applications. Biomaterials 12, 
155–163 (1991). 
106. Wang, M. Developing bioactive composite materials for tissue replacement. 
Biomaterials 24, 2133–2151 (2003). 
107. Cairns, M. L. et al. Through-thickness control of polymer bioresorption via 
electron beam irradiation. Acta Biomater. 7, 548–557 (2011). 
108. Tsai, C. H., Lin, R. M., Ju, C. P. & Chern Lin, J. H. Bioresorption behavior of 
tetracalcium phosphate-derived calcium phosphate cement implanted in femur 
of rabbits. Biomaterials 29, 984–993 (2008). 
109. Ibrahim, D. et al. Chemical characterization of some substituted 
hydroxyapatites. Chem. Cent. J. 5, 74 (2011). 
110. Roberto J., H. & Committee, P. D. Hydroxyapatite. Safety and Efficacy Report. 
Chapter 8: References  
 
215 
Griselda Valeria Nájera Romero ― June 2021 
Plast. Resconstructive Surg. 110, 1176–1179 (2002). 
111. Sadat-Shojai, M., Khorasani, M. T., Dinpanah-Khoshdargi, E. & Jamshidi, A. 
Synthesis methods for nanosized hydroxyapatite with diverse structures. Acta 
Biomater. 9, 7591–7621 (2013). 
112. Liu, D. M., Troczynski, T. & Tseng, W. J. Water-based sol-gel synthesis of 
hydroxyapatite: Process development. Biomaterials 22, 1721–1730 (2001). 
113. Lakshmi, B. B., Dorhout, P. K. & Martin, C. R. Sol−Gel Template Synthesis of 
Semiconductor Nanostructures. Chem. Mater. 9, 857–862 (1997). 
114. Chen, J. et al. A simple sol-gel technique for synthesis of nanostructured 
hydroxyapatite, tricalcium phosphate and biphasic powders. Mater. Lett. 65, 
1923–1926 (2011). 
115. Chaudhry, A. A. et al. Instant nano-hydroxyapatite: A continuous and rapid 
hydrothermal synthesis. Chem. Commun. 2286–2288 (2006). 
doi:10.1039/b518102j 
116. Kolmas, J., Groszyk, E. & Kwiatkowska-Rózycka, D. Substituted 
hydroxyapatites with antibacterial properties. Biomed Res. Int. 2014, (2014). 
117. Lala, S. et al. Magnesium substitution in carbonated hydroxyapatite: Structural 
and microstructural characterization by Rietveld’s refinement. Mater. Chem. 
Phys. 170, 319–329 (2016). 
118. Tu, Y. et al. Fabrication of nano-hydroxyapatite/chitosan membrane with 
asymmetric structure and its applications in guided bone regeneration. Biomed. 
Mater. Eng. 28, 223–233 (2017). 
119. Ruixin, L. et al. Degradation behavior and compatibility of micro, 
nanoHA/chitosan scaffolds with interconnected spherical macropores. Int. J. 
Biol. Macromol. 103, 385–394 (2017). 
120. Rabenstein, D. L. Heparin and heparan sulfate: Structure and function. Nat. 
Prod. Rep. 19, 312–331 (2002). 
121. Linhardt, R. J. 2003 Claude S. Hudson award address in carbohydrate chemistry. 
Heparin: Structure and activity. J. Med. Chem. 46, 2551–2564 (2003). 
122. Oduah, E. I., Linhardt, R. J. & Sharfstein, S. T. Heparin: Past, present, and future. 
Pharmaceuticals 9, 1–12 (2016). 
123. Casu, B., Naggi, A. & Torri, G. Re-visiting the structure of heparin. Carbohydr. 
Res. 403, 60–68 (2015). 
124. Ho, M. H. et al. Preparation of porous scaffolds by using freeze-extraction and 
Chapter 8: References  
 
216 
Griselda Valeria Nájera Romero ― June 2021 
freeze-gelation methods. Biomaterials 25, 129–138 (2004). 
125. Sawyer, L. C. Polymer Microscopy. (Springer Science & Business Media, 2012). 
126. Qasim, S. B., Delaine-Smith, R. M., Fey, T., Rawlinson, A. & Rehman, I. U. Freeze 
gelated porous membranes for periodontal tissue regeneration. Acta Biomater. 
23, 317–328 (2015). 
127. Reis, R. L. et al. Natural-Based Polymers for Biomedical Applications. (Elsevier 
Science, 2008). 
128. Qasim, S. B. et al. In-vitro and in-vivo degradation studies of freeze gelated 
porous chitosan composite scaffolds for tissue engineering applications. Polym. 
Degrad. Stab. 136, 31–38 (2017). 
129. Smith, P. K. & Mallia,  a K. Colorimetric Method for the Assay of Heparin 
Immobilized Heparin Preparations Content in. Anal. Biochem. 473, 466–473 
(1980). 
130. Eke, G., Mangir, N., Hasirci, N., MacNeil, S. & Hasirci, V. Development of a UV 
crosslinked biodegradable hydrogel containing adipose derived stem cells to 
promote vascularization for skin wounds and tissue engineering. Biomaterials 
129, 188–198 (2017). 
131. Mangir, N., Dikici, S., Claeyssens, F. & Macneil, S. Using ex Ovo Chick 
Chorioallantoic Membrane (CAM) Assay to Evaluate the Biocompatibility and 
Angiogenic Response to Biomaterials. ACS Biomater. Sci. Eng. 5, 3190–3200 
(2019). 
132. Liuyun, J., Yubao, L. & Chengdong, X. Preparation and biological properties of 
a novel composite scaffold of nano-hydroxyapatite/chitosan/carboxymethyl 
cellulose for bone tissue engineering. J. Biomed. Sci. 16, 1–10 (2009). 
133. Jiang, H. et al. A homogenous CS/NaCMC/n-HA polyelectrolyte complex 
membrane prepared by gradual electrostatic assembling. J. Mater. Sci. Mater. 
Med. 22, 289–297 (2011). 
134. Rosca, C., Popa, M. I., Lisa, G. & Chitanu, G. C. Interaction of chitosan with 
natural or synthetic anionic polyelectrolytes. 1. The chitosan-
carboxymethylcellulose complex. Carbohydr. Polym. 62, 35–41 (2005). 
135. Chen, C. et al. Biodegradable composite scaffolds of bioactive 
glass/chitosan/carboxymethyl cellulose for hemostatic and bone regeneration. 
Biotechnol. Lett. 37, 457–465 (2014). 
136. Il’ina, A. V. & Varlamov, V. P. Chitosan-based polyelectrolyte complexes: A 
Chapter 8: References  
 
217 
Griselda Valeria Nájera Romero ― June 2021 
review. Appl. Biochem. Microbiol. 41, 5–11 (2005). 
137. Liuyun, J., Yubao, L. & Chengdong, X. A novel composite membrane of 
chitosan-carboxymethyl cellulose polyelectrolyte complex membrane filled 
with nano-hydroxyapatite I. Preparation and properties. J. Mater. Sci. Mater. 
Med. 20, 1645–1652 (2009). 
138. Dorozhkin, S. V. Dissolution mechanism of calcium apatites in acids: A review 
of literature. World J. Methodol. 2, 1 (2012). 
139. Koç, A., Finkenzeller, G., Elçin, A. E., Stark, G. B. & Elçin, Y. M. Evaluation of 
adenoviral vascular endothelial growth factor-activated 
chitosan/hydroxyapatite scaffold for engineering vascularized bone tissue 
using human osteoblasts: In vitro and in vivo studies. J. Biomater. Appl. 29, 748–
760 (2014). 
140. Harley, B. A. & Gibson, L. J. freeze-dried collagen-GAG scaffolds . 25, (2004). 
141. Zhang, K., Fan, Y., Dunne, N. & Li, X. Effect of microporosity on scaffolds for 
bone tissue engineering. Regen. Biomater. 5, 115–124 (2018). 
142. Guda, T. et al. Hydroxyapatite scaffold pore architecture effects in large bone 
defects in vivo. J. Biomater. Appl. 28, 1016–1027 (2014). 
143. Rosa, A. L., de Oliveira, P. T. & Beloti, M. M. Macroporous scaffolds associated 
with cells to construct a hybrid biomaterial for bone tissue engineering. Expert 
Rev. Med. Devices 5, 719–728 (2008). 
144. Salerno, A., Guarnieri, D., Iannone, M., Zeppetelli, S. & Netti, P. A. Effect of 
micro-and macroporosity of bone tissue three-dimensional- poly(ε-
caprolactone) scaffold on human mesenchymal stem cells invasion, 
proliferation, and differentiation in vitro. Tissue Eng. - Part A 16, 2661–2673 
(2010). 
145. Guaadaoui, A., Benaicha, S., Elmajdoub, N., Bellaoui, M. & Hamal, A. What is a 
bioactive compound? A combined definition for a preliminary consensus. Int. J. 
Food Sci. Nutr. 3, 17–179 (2014). 
146. Ong Yu Min, B. A study on the bioactivity and biodegradation of chitosan / 
hydroxyapatite scaffolds in stimulated body fluid. (University of Sheffield, 
2017). 
147. Pereiro, R. Book review: Acceleration and automation of solid sample treatment. 
Anal. Bioanal. Chem. 377, 1089–1090 (2003). 
148. Choi, W. S. & Kim, K. J. Separation of Acetic Acid from Acetic Acid-Water 
Chapter 8: References  
 
218 
Griselda Valeria Nájera Romero ― June 2021 
Mixture by Crystallization. Sep. Sci. Technol. 48, 1056–1061 (2013). 
149. Christophe Drouet. Apatite formation: why it may not work as planned, and 
how to conclusively identify apatite compounds. Biomed Res. Int. 2013, Article 
ID 490946 (2013). 
150. Sukhorukova, I. V., Sheveyko, A. N., Kiryukhantsev-Korneev, P. V., Levashov, 
E. A. & Shtansky, D. V. In vitro bioactivity study of TiCaPCO(N) and Ag-doped 
TiCaPCO(N) films in simulated body fluid. J. Biomed. Mater. Res. - Part B Appl. 
Biomater. 105, 193–203 (2017). 
151. Hsieh, C. Y. et al. Analysis of freeze-gelation and cross-linking processes for 
preparing porous chitosan scaffolds. Carbohydr. Polym. 67, 124–132 (2007). 
152. Harding, I. S., Rashid, N. & Hing, K. A. Surface charge and the effect of excess 
calcium ions on the hydroxyapatite surface. Biomaterials 26, 6818–6826 (2005). 
153. Online, F. A. & Rogina, A. Journal of Tissue Repair and Regeneration. 23–27 
(1840). doi:10.14302/issn.2640 
154. Lee, W. H., Loo, C. Y., Van, K. L., Zavgorodniy, A. V. & Rohanizadeh, R. 
Modulating protein adsorption onto hydroxyapatite particles using different 
amino acid treatments. J. R. Soc. Interface 9, 918–927 (2012). 
155. Levengood, S. K. L. & Zhang, M. Chitosan-based scaffolds for bone tissue 
engineering. J. Mater. Chem. B 2, 3161–3184 (2014). 
156. Rehman, I. & Bonfield, W. Characterization of hydroxyapatite and carbonated 
apatite by photo acoustic FTIR spectroscopy. J. Mater. Sci. Mater. Med. 8, 1–4 
(1997). 
157. Zaja̧c, A., Hanuza, J., Wandas, M. & Dymińska, L. Determination of N-
acetylation degree in chitosan using Raman spectroscopy. Spectrochim. Acta - 
Part A Mol. Biomol. Spectrosc. 134, 114–120 (2015). 
158. Shahzadi, L. et al. Triethyl orthoformate covalently cross-linked chitosan-(poly 
vinyl) alcohol based biodegradable scaffolds with heparin-binding ability for 
promoting neovascularisation. J. Biomater. Appl. 0, 1–12 (2016). 
159. Burmester, A., Luthringer, B., Willumeit, R. & Feyerabend, F. Comparison of the 
reaction of bone-derived cells to enhanced MgCl2-salt concentrations. Biomatter 
4, e967616 (2014). 
160. Pautke, C. et al. Characterization of osteosarcoma cell lines MG-63, Saos-2 and 
U-2 OS in comparison to human osteoblasts. Anticancer Res. 24, 3743–3748 
(2004). 
Chapter 8: References  
 
219 
Griselda Valeria Nájera Romero ― June 2021 
161. Barnhill, R. L. & Ryan, T. J. Biochemical modulation of angiogenesis in the 
chorioallantoic membrane of the chick embryo. J. Invest. Dermatol. 81, 485–488 
(1983). 
162. Monagle, P., Studdert, D. M. & Newall, F. Infant deaths due to heparin 
overdose: Time for a concerted action on prevention. J. Paediatr. Child Health 48, 
380–381 (2012). 
163. Ribatti, D. The chick embryo chorioallantoic membrane (CAM). A multifaceted 
experimental model. Mech. Dev. 141, 70–77 (2016). 
164. Ribatti, D. The chick embryo chorioallantoic membrane (CAM) assay. Reprod. 
Toxicol. 70, 97–101 (2017). 
165. Gümüdereliolu, M. & Aday, S. Heparin-functionalized chitosan scaffolds for 
bone tissue engineering. Carbohydr. Res. 346, 606–613 (2011). 
166. Götz, W., Tobiasch, E., Witzleben, S. & Schulze, M. Effects of silicon compounds 
on biomineralization, osteogenesis, and hard tissue formation. Pharmaceutics 11, 
1–27 (2019). 
167. Dashnyam, K. et al. A mini review focused on the proangiogenic role of silicate 
ions released from silicon-containing biomaterials. J. Tissue Eng. 8, (2017). 
168. Aminian, A. et al. Synthesis of silicon-substituted hydroxyapatite by a 
hydrothermal method with two different phosphorous sources. Ceram. Int. 37, 
1219–1229 (2011). 
 
 
 
 
 
